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Yeah, the patients shouldn’t have to worry about it [diabetes care at the end of 
life] that’s the only thing I would say that it’s [diabetes] not given as high a 
priority probably as it should be. 
 
 
 
You don’t want to go on with endless care… you’ve got to draw a line 
somewhere but I think I would like to feel comfortable but not be overactive with 
treatment and I feel that’s not done. 
 
 
 
Comments from two people with diabetes receiving palliative care who 
participated in the interviews.  
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EXECUTIVE SUMMARY 
 
The focus of the project was people with diabetes requiring palliative care in the last 
stages of life.  The main goal during these phases is to improve and maintain the 
individual’s quality of life and dignity while positively influencing the course of the life 
limiting illness through appropriately assessing and managing symptoms and contributing 
disease processes to achieve optimal outcomes.  Importantly, palliative care now includes 
managing chronic diseases such as diabetes. In this context, optimal outcomes include 
ensuring the patient is comfortable, alleviating pain and unpleasant symptoms, and 
enabling a peaceful death.  That is, managing the comorbid illness (diabetes) as part of 
caring for people with a progressive life threatening illness where end of life care may be 
required for days or months.  However, diabetes-specific care goals and outcomes at the 
end of life are not well described. 
 
These Guidelines were developed in accordance with the National Health and Medical 
Research Council Guidelines for Developing Clinical Practice Guidelines.  The process 
included: 
 
• Establishing an interdisciplinary advisory committee that provided expert advice 
during the development of the Guidelines. 
• Undertaking a comprehensive review of the best available evidence. 
• Consulting with key stakeholder consumers: people with diabetes, their carers, 
and palliative care and diabetes clinicians. 
• Undertaking formative evaluation of the draft Guidelines and revising the 
Guidelines based on the information key stakeholder consumers provided.   
• Evaluating the final Guidelines for usability and comprehensiveness in a real life 
clinical setting. 
 
Aims and objectives 
The overall aim of the project was to enhance the quality of palliative care delivered to 
people with diabetes in the end stages of life. 
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The specific objectives were to: 
• Develop Guidelines for managing diabetes in patients receiving palliative care 
with a focus on the Palliative Care Outcomes Collaborative (PCOC) end of life 
stages: stable, unstable, deteriorating, and terminal. 
• Implement the Guidelines in a palliative care setting. 
• Assess the effectiveness and acceptability of the Guidelines to palliative care 
clinicians and people with diabetes and their carers and further refine them as 
appropriate. 
 
Ethics approval to undertake the study was obtained from the Barwon Health Human 
Research Ethics Committee and written informed consent was obtained from all 
participants. 
Literature review 
A comprehensive literature review was undertaken but failed to retrieve any randomised 
control trial evidence on which to base the Guidelines.  Ten relevant papers were 
retrieved and initially evaluated by the research team.  Seven of these papers contained 
useful information and were further evaluated by the Advisory Committee and 
subsequently used to develop a set of guiding principles to follow as the Guidelines were 
developed.  
 
The scientific evidence available to inform the development of the proposed Guidelines 
was of low level and no research was identified with an NHMRC level of evidence 
greater than level IV.  The existing literature does not address the PCOC philosophy or 
most of the guiding principles used as the contextual framework to guide the 
development of the current Guidelines. It was largely written by non-diabetes experts, 
and shows little understanding that monitoring and controlling blood glucose is a key 
aspect of identifying the cause of and managing unpleasant symptoms, including pain. 
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Interviews with patients and family members/carers 
Data were collected during individual face-to-face semi-structured interviews with 
fourteen patients with diabetes requiring palliative care and ten family members/carers of 
patients with diabetes requiring palliative care from a large regional palliative care 
facility.  The interviews were audio-recorded and transcribed verbatim after which 
content analysis was undertaken to identify key themes and issues.  
 
Key findings from the interviews that informed the development of the Guidelines were: 
• Continue testing blood glucose until the terminal stage unless otherwise specified in 
an Advanced Care Directive. 
• Continue medicines to control unpleasant hypo/hyperglycaemia until the terminal 
stage but use them in that stage to promote comfort. 
• Medicines may need to changed or adjusted frequently as the person’s condition 
changes and insulin might be indicated.  
• Consider the whole person and individualise their management plan. 
• Health professionals should listen to the person with diabetes because they are 
experts in their disease and recognising symptoms by recognising body cues. 
• Health professionals should acknowledge the role of family members/carers in 
managing the patient’s diabetes as the patient’s health deteriorates, and include 
family members/carers in discussions about the patient’s care plan.  
• Family members/carers may not have previously undertaken tasks such as monitoring 
blood glucose levels and may lack the necessary knowledge and skills to monitor and 
interpret blood glucose levels, manage increasing or decreasing blood glucose levels 
and administer medicines safely and confidently. 
• Family members/carers require more information, education and support in relation to 
managing diabetes in the context of palliative care.  
• Family members/carers may feel anxious about their increasing responsibility 
regarding their care recipient’s diabetes and need support and guidance from health 
professionals. 
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Development of the Guidelines and accompanying document 
The research team developed the Guidelines in consultation with the Advisory 
Committee. The Guiding principles, relevant information from the literature review, and 
the experiences of the Advisory Committee were used to develop the initial draft of the 
Guidelines. The information obtained from the interviews was included in the second 
draft of the Guidelines. 
 
The Guidelines describe appropriate treatment for patients with type 1, type 2 and 
steroid-induced diabetes at the various stages of advanced disease: stable, unstable, 
deteriorating, and terminal.  They are based on the best available evidence at the time 
they were developed. 
 
An explanatory document to accompany the Guidelines was developed simultaneously 
with the Guidelines to help palliative care health professionals understand and implement 
the Guidelines.  The document includes a detailed explanation of the conceptual 
framework and philosophy underlying the Guidelines, an overview of diabetes and the 
complexity of diabetes management in the context of palliative care.   A concise version 
of the accompanying document was prepared for use in clinical practice. 
Evaluation 
Three processes were utilised to obtain feedback from palliative care health professionals 
about the draft Guidelines during the formative and summative evaluation processes: 
• An information and discussion session with 21 palliative care health 
professionals. 
• A questionnaire completed by 20 palliative care health professionals working in 
Barwon Health. 
• A brief interview with seven palliative care health professionals after which the 
draft Guidelines were refined. 
• Palliative care health care professionals were invited to use the revised Guidelines 
to plan care for people with diabetes at the end of life. 
 
The majority of health professionals who responded to the questionnaire (n = 20) found 
the language in the Guidelines consistent with palliative care language and procedures 
and with the PCOC palliative care principles.  Some respondents and interview 
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participants suggested the way the Guidelines were presented could be improved.  No 
health professionals interviewed in the third part of evaluation process specifically 
utilised the Guidelines with a palliative care patient.  However, twelve health 
professionals who completed the questionnaire in the second part of the evaluation 
applied the Guidelines to at least one patient in a specific PCOC phase.  These 
participants found the Guidelines useful and their comments were generally positive.  In 
particular, respondents indicated that the Guidelines were very helpful when managing 
patients with diabetes in the terminal PCOC phase. 
Refining the Guidelines 
The Guidelines were further refined after the evaluation phase.  The key changes were as 
follows: 
• A contents page was added to help health professionals easily locate the section of the 
Guidelines they need. 
• Titles on each page were clarified to describe the content of specific pages more 
clearly. 
• The wording within individual sections was revised to ensure it was consistent 
throughout the Guidelines. For example statements in some text boxes were rewritten 
as active statements. 
• Blood glucose ranges and blood glucose monitoring frequencies were included. 
• A skilled graphic designer was employed to ensure the Guidelines were clear, 
appealing and user-friendly.  
Plan for disseminating the Guidelines 
The final Guidelines will be disseminated in the following manner:   
• They will be officially launched at the Innovations – Updating Professional Practice 
in Palliative Care Conference in Torquay, Victoria in October 2010. 
• Through the CareSearch website, which attracts 100,000 hits per month. 
• Presentations or brief summaries to relevant diabetes and palliative care special 
interest group meetings. 
• In newsletters of diabetes and palliative care professional associations. 
• At local, state, national and international conferences. 
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INTRODUCTION 
 
The focus of the research was people with diabetes requiring palliative care in the last 
stages of life, where the goal is to improve and maintain the individual’s quality of life 
and dignity.  That is, managing the comorbid illness (diabetes) as part of caring for 
people with a progressive life threatening illness where end of life care may be required 
for days or months.  In this context, better patient outcomes include ensuring the patient 
is comfortable, alleviating pain and unpleasant symptoms, and enabling a peaceful death 
(Ellershaw, 2003).  Importantly, palliative care now includes managing non-life-
threatening chronic diseases such as diabetes in the final years (Emanuel, Alexander, 
Arnold et al., 2004).   
 
However, diabetes-specific palliative care goals and outcomes and diabetes management 
at the end of life are not well described. People with cancer may decline in a short period 
of time so that the need for palliative care is obvious.  People with diabetes might 
experience many periods of metabolic instability or deterioration before they enter the 
terminal stage; thus, the need for palliative care may not be so obvious and could involve 
short encounters in many unstable episodes.  
 
Palliative care is defined as:  
An approach that improves the quality of life of patients and their families facing 
the problem associated with life-threatening illness, through the prevention and 
relief of suffering by means of early identification and impeccable assessment and 
treatment of pain and other problems, physical, psychosocial and spiritual. 
(World Health Organisation, 2009) 
 
Diabetes management is complex and becomes increasingly complex in the context of 
palliative care.  For example, several symptoms of advanced cancer are similar to those 
of hyperglycaemia, which complicates care decisions and makes it difficult for health 
professionals to determine and appropriately manage the underlying cause of the 
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symptoms, unless blood glucose is monitored (Quinn, Hudson & Dunning, 2006).  
Likewise, hyperglycaemia causes lethargy and lowered mood, which affects physical 
comfort, quality of life, and relationships.  In addition, some medicines such as 
glucocorticoids, which are often used in palliative care to control symptoms including 
pain and nausea in advanced disease, trigger or aggravate hyperglycaemia (Dunning, 
1996; Plodkowski & Lee, 2008).  
 
Hypoglycaemia can also occur when people are treated with oral hypoglycaemic agents 
(OHA) and/or insulin, especially when food intake is affected by their diseases state, 
fasting for procedures, or as a side effect of medicines.  Altered glucose metabolism 
occurs frequently in the anorexia/cachexia syndrome, which occurs in 40-90% of the 
cancer palliative care population (CareSearch, 2010).  It is difficult to treat 
hypoglycaemia in patients with poor appetite, nausea or vomiting (McCoubrie, Jeffrey, 
Paton & Dawes, 2004; Smyth & Smyth, 2005) and OHA and/or insulin is often stopped 
in these people.  However, stopping the OHA or insulin may not be the best management 
choice because of the resultant hyperglycaemia and its effects.  Likewise, there are 
ethical issues associated with stopping any treatment, even in end of life settings (Ford-
Dunn, Smith & Quin, 2006). The wishes of the patient and their family and Advanced 
Care Directives, if they are available, must be considered (Quinn et al., 2006; Smyth & 
Smyth, 2005). 
 
Few palliative care and diabetes guidelines address managing diabetes in palliative care 
situations at the end of life. For example, palliative care guidelines (e.g. Australian 
Government Department of Health and Ageing, 2006; Qaseem et al., 2008) do not 
address the impact of diabetes on symptoms or quality of life when people with diabetes 
develop a life limiting illness and require palliative care. Existing guidelines adopt a 
broad focus and have not been systematically pilot tested or evaluated (Poulson, 1997; 
McCoubrie et al., 2004; Ford-Dunn et al., 2006).  Anecdotal evidence from consultation 
within the Australian diabetes and palliative care communities and discussion with the 
Advisory Committee appointed for the current research indicates that existing guidelines 
are not well known or used in practice.  The complexity of managing diabetes as well as 
concomitant illnesses requiring palliation and the lack of guidelines make it difficult for 
palliative health professionals to provide optimal diabetes care and enhance the quality of 
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life for individuals with diabetes, and for diabetes experts to provide advice about 
appropriate care (Quinn et al., 2006).  
 
Diabetes is an increasingly common condition and there is good evidence for an 
association among diabetes, obesity and some forms of cancer.  Likewise, people with 
diabetes with long term complications of diabetes such as end stage renal disease and 
cardiovascular disease require palliative care.  Previous research indicates that current 
diabetes management in palliative care situations does not have a robust evidence base.  
However, due to the vulnerable nature of the patients and the ethical issues involved in 
undertaking research in the area it is difficult to conduct robust randomised controlled 
trials in end of life care.  Thus, all forms of evidence need to be considered when 
deciding what constitutes ‘evidence’ including observational and qualitative studies and 
patient and carer wishes.  
 
Aims and objectives 
The overall aim of the project was to enhance the quality of palliative care delivered to 
people with diabetes in the end stages of life. 
 
The specific objectives were to: 
• Develop guidelines for managing people with diabetes receiving palliative care with a 
focus on the Palliative Care Outcomes Collaboration (PCOC) (PCOC, 2008) end of 
life stages: stable, unstable, deteriorating, and terminal. 
• Encompass the Liverpool Integrated Care Pathway for the Dying Patient (Kinder & 
Ellershaw, 2003). 
• Implement the Guidelines in a palliative care setting. 
• Assess the effectiveness and acceptability of the clinical Guidelines to palliative care 
clinicians and people with diabetes and their carers (formative evaluation) and further 
refine them as appropriate. 

A staged approach was used to develop Guidelines for managing diabetes at the end of 
life and the process followed the National Health and Medical Research Council 
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(NHMRC) Guide to the Development, Implementation and Evaluation of Clinical 
Practice Guidelines (NHMRC, 1999) and is described in the following section. 
 
Design  
Consistent with the NHMRC Guidelines, the current Guidelines were developed with the 
assistance of an interdisciplinary Advisory Committee that provided expert advice as the 
Guidelines were developed and evaluated.  The Guidelines were based on a 
comprehensive review of the best available evidence and consultation with people with 
diabetes receiving palliative care, their carers, and palliative care clinicians. Formative 
and content evaluation and revision of the Guidelines occurred during their development 
and the final Guidelines were evaluated in clinical palliative care settings to determine 
their acceptability, usability, and comprehensiveness in a real life clinical setting.  A 
flowchart depicting the method used to develop and evaluation the Guidelines in 
presented in Figure 1 on page 12. 
The project was undertaken in five stages: 
1) Establishing an Expert Advisory Committee.  An Advisory Committee 
comprising experts in the fields of palliative care, medical oncology, radiation 
oncology, nephrology, endocrinology and diabetes management (diabetes educators 
and endocrinologists) provided advice about the content, design and evaluation 
process.  Members of the Advisory Committee critiqued several iterations of the 
Guidelines during the development process and reviewed relevant literature.  This 
process encompassed part of the formative evaluation phase of the study. 
2) Literature review.  A comprehensive, structured literature review was conducted 
to identify whether there were any changes in the management of people with 
diabetes and advanced disease since the principle researcher and two members of 
the Advisory Committee undertook the previous literature review in 2006 (Quinn, 
Hudson & Dunning, 2006).  The grey literature was also searched including books 
written by people who had cared for their relatives in the end stages of life. 
3)  Interviews with patients and carers.  Individual interviews were conducted with 
14 people with diabetes who required palliative care and 10 family members of 
people with diabetes who required palliative care.  The rich data obtained in the 
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
12
interviews informed the development of the Guidelines to ensure that the 
perspectives and preferences of people with diabetes and their family members or 
carers were addressed.  
4) Development of clinical Guidelines.  Draft clinical Guidelines for managing 
people with diabetes at the end of life were developed.  Formative and content 
evaluation occurred in this stage. 
5) Evaluating the draft clinical Guidelines.  The draft clinical Guidelines were 
evaluated in the Palliative Care Service at Barwon Health in Geelong.  Palliative 
care staff commented on the draft Guidelines in the formative evaluation (stage 4) 
and used the Guidelines to manage people with diabetes requiring palliative care in 
the stage 5 evaluation process.  Some staff also participated in individual interviews 
as part of the evaluation process.  The regularly attended Palliative Care Team 
weekly case conference meetings, which enhanced the development and evaluation 
process and aided recruitment into stages 3 and 5. 
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Figure 1.  Flow chart depicting the method used to develop and evaluate the 
Guidelines. 
Advisory Committee established (Sect. 2) 
Guiding principles to serve as the conceptual framework for the 
Guidelines formulated  (Sect. 2) 
Structured literature review undertaken  (Sect. 3) 
First draft of the Guidelines prepared 
Individual semi structured interviews conducted with a) people 
with diabetes receiving palliative care and b) carers of people with 
diabetes receiving palliative care (Sect. 4) 
The revised draft guidelines were presented to palliative care staff 
following a routine staff meeting and case discussion forum. 
Palliative care staff used the revised draft guidelines to plan care 
for people with diabetes in the four PCOC phases and responded 
to an anonymous self-completed questionnaire (Sect. 7) 
Draft Guidelines were revised to include relevant information 
derived from the interviews with people with diabetes and their 
carers. 
The information derived from the questionnaire and discussion 
forum was used to revise the Guidelines again   
Health professionals were asked to use the revised guidelines and 
accompanying document to plan care for people with diabetes 
receiving palliative care (Sect. 7) 
Semi-structured interviews were conducted with health 
professionals who reviewed the revised guidelines  (Sect. 7) 
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Further revisions made to the guidelines. 
A graphic designer was employed to improve the format and 
presentation of the guidelines and brief accompanying document  
(Sect. 9) 
The final guidelines 
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Section 2 
 
 
EXPERT ADVISORY  
COMMITTEE 
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EXPERT ADVISORY COMMITTEE 
Composition of the Advisory Committee 
The researchers invited health professionals with expertise in diabetes management; 
palliative care, endocrinology and nephrology to join the Advisory Committee, which 
was established to help guide the project.  All the people invited accepted the invitation. 
 
Members of the Advisory Committee were: 
 
Ms Karen Quinn RN, MN, Clinical Education Nurse, Caritas Christi Hospice (St. 
Vincent’s Hospital, Melbourne) and Nurse Researcher, Centre for Palliative Care 
Education & Research   
Mr Mark Arnold RN, Nurse Unit Manager Palliative Care Inpatient Unit, Barwon Health, 
Geelong 
Ms Pamela Jones RN, RM, B Nsg, CDE, Grad Cert Diabetes Ed, Dip Management, 
Manager Diabetes Referral Centre, Barwon Health, Geelong 
Associate Professor Peter Hudson RN, PhD, St. Vincent’s Hospital, Melbourne   
Dr Rob MacGinley, MBBS, FRACP, Nephrologist, Barwon Health, Geelong  
Dr Samantha Worboys, MB, BS, FRACP, Endocrinologist, Barwon Health, Geelong 
Ms Sharon Anderson, RN,Assoc Nurse Unit Manager, Palliative Care Inpatient Unit, 
Barwon Health, Geelong 
Role of the Advisory Committee  
The role of the Advisory Committee was to identify and assess relevant literature, 
provide advice about the draft Guidelines as they were developed and about the 
evaluation process and agree on the final Guidelines.  The Advisory Committee met 
regularly throughout the project, usually at eight-week intervals.  Some members of the 
Committee participated in the meetings by telephone.  
 
Initially the Advisory Committee assisted the research team to establish the underlying or 
guiding principles for the Guidelines to ensure they were consistent with palliative care 
principles and diabetes management philosophy.  The palliative care members of the 
Committee offered advice about the logistics of incorporating diabetes management 
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Guidelines into palliative care processes and all members made suggestions about the 
appropriate design and format for the Guidelines.   
 
The Committee reviewed and provided a structured critique of the relevant literature.  
Importantly, the Advisory Committee provided feedback about the many iterations of the 
Guidelines during the formative evaluation phase as the research team developed the 
content and structure of the Guidelines.  The Committee also provided invaluable advice 
about the accuracy and appropriateness of the content and design of the Guidelines. 
 
Guiding principles 
The following guiding principles for managing diabetes at the end of life were 
established in collaboration with the Advisory Committee in the early stages of the 
project.  These guiding principles served as the contextual framework for the Guidelines.  
They are person-centred and holistic and were derived from the limited available 
evidence, palliative care philosophy and information developed from the lived 
experiences of people who cared for their relatives at the end of their lives. Significantly, 
the issues embodied in the guiding principles also emerged in the interviews with the 
participants in the current study (see Section 4).  These guiding principles formed the 
contextual framework for the Guidelines. 
 
• Developing a care plan for managing diabetes at the end of life requires a shared 
understanding about the issues involved and shared, collaborative decision-
making by relevant health professionals and patients and/or their carers. 
• Diabetes and palliative care should be delivered within a Quality Use of 
Medicines (QUM) Framework (Pharmaceutical Health and Rational use of 
Medicines (PHARM) Committee, 2005; National Prescribing Service Limited and 
Palliative Care Australia, 2009). 
• Incorporating diabetes management into the Palliative Care Outcomes 
Collaborative (PCOC) (PCOC, 2008) framework should enhance the applicability 
and acceptability of the Guidelines in palliative care settings. 
• Only people at the end of life truly know the lived experience of dying. 
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• Psycho-social-spiritual distress is as painful as physical symptoms and can have 
just as much impact on the patient and carer’s quality of life. 
• Dying is a part of an individual’s spiritual journey in which the individual may 
search for meaning in their past, present and future lives and utilise hope as part 
of achieving meaning and purpose in the remainder of their life (undertake a 
review of their life). 
• Time is a valuable commodity when a person is dying. 
• Human relationships, including with health professionals, and touch are 
important. 
• Most people require skilled care in the last stages of life.  Dying is a complex 
process that follows a common continuum from stable to unstable, which may be 
remediable or proceed to the dying terminal stage.  
• All carers need to respect the patient’s choices, and where possible, these should 
be documented in Advanced Care Directives and/or other relevant proxy 
decision-making documentation.  
• Most care can be provided in most settings as long as the health professionals and 
family providing care have the necessary resources and are adequately educated 
and supported. 
• Changes in the patient’s condition and the families’ ability to manage the patient 
at home can occur suddenly and strategies and the necessary equipment and 
medicines to manage such changes need to be in place.  Therefore, documented 
and communicated contingency planning to empower patients, carers and health 
professionals is critical. 
• Current diabetes management strategies emphasise interdisciplinary, collaborative 
and holistic care in which the patient plays an active role.  The patient should 
continue to be involved in their care according to their physical and mental 
capabilities during the dying process. 
• Cultural beliefs including those concerning death, dying and grieving should be 
respected. 
• Acute illnesses sometimes superimpose on the individual’s existing illness and 
may require emergency or hospital treatment.  Symptom control and quality of 
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life should still be the focus of care, but relevant treatment of the illness may be 
warranted.  Where relevant, the Liverpool Care Pathway for the Dying Patient 
should be activated. 
• The person’s physical and mental status, projected lifespan, PCOC stage and their 
Advanced Care Directives usually determine care.  
• The last stages of life should be as comfortable and positive as possible to enable 
people to have ‘a good death’. 
• The care provided in the last stages of life can have profound and sometimes 
lasting effects on everybody involved.  Therefore, bereavement support should be 
offered before and after death.  
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Section 3  
 
 
REVIEWING THE 
LITERATURE  
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LITERATURE REVIEW 
 
The literature review involved searching key databases, Pubmed, Medline, CINAHL, and 
CareSearch using the search terms diabetes, palliative care, diabetes/palliative care 
management/guidelines, life limiting illness, end of life, palliative care principles, 
symptom control, caregiver, caregiver expectations, spirituality, hope and bereavement 
and various combinations of these terms.  Articles were excluded from the review if they 
were not published in English.  The content of recent palliative care, diabetes, end of life 
and spirituality publications was examined, unpublished literature was sought from 
people working in palliative care and diabetes and the reference lists of journal articles 
and books were examined.   
 
In addition, Australian and international diabetes and palliative care websites were 
searched for relevant published and unpublished material.  No information about 
diabetes management and palliative care was located.  For example, the following key 
palliative care websites did not mention diabetes management in palliative care settings 
(accessed 06.01.09): www.palliativecare.org; www.caresearch.com.au; 
www.palliativecare.org.au; www.health.gov.au—The National Palliative Care Program, 
Australian Government: Department of Health & Aging; and www.pallcarevic.asn.au. 
 
Although there is a significant body of literature concerning palliative care, mostly 
focusing on symptom management, no detailed guidelines or guiding principles that 
foster an appropriate and evidence-based structure for managing people with diabetes 
requiring palliative care that encompasses quality use of medicines were identified.  Only 
seven papers were identified that specifically addressed diabetes management and 
palliative care.  These publications were subject to a structured critical review, which was 
undertaken by the Advisory Committee. 
 
The critique of the literature included assessing strengths, weaknesses, quality, relevance 
to palliative care and diabetes practice and level of evidence using the NHMRC 
Designation of Levels of Evidence (NHMRC, 1999).  The majority of papers were based 
on expert opinion and clinical experience rather than on research.  Thus, the level of 
evidence of the literature included in the review did not exceed Level IV using the 
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
23
NHMRC criteria.  In addition, several recent relevant papers relied heavily on earlier 
papers for the information presented.  No formal level of evidence is given to expert 
opinion or anecdotal information (NHMRC, 1999).  
 
Literature identified 
Nine published articles that focused on managing diabetes at the end of life and one 
article that focused on various comorbities including diabetes at the end of life were 
identified.  A detailed summary of the ten papers is presented in Table 1 (pages 26–33).  
 
The evidence base of the available literature is weak.  Five papers included one or two 
case studies in addition to expert opinion (Boyd, 1993; Poulson, 1997; Stevenson, 
Abernethy, Miller & Carrow, 2004; Tice, 2006; McPherson, 2008), two papers included 
new data collected from health professionals with diabetes or palliative care experts  
(Ford-Dunn, Smith & Quin, 2006; Quinn, Hudson & Dunning, 2006), two papers 
presented expert opinion only (Ford-Dunn & Quin, 2004; Psarakis, 2006), and one paper 
was a retrospective case note audit of deceased patients with a dual diagnosis of diabetes 
and cancer (McCoubrie, Jeffrey, Paton & Dawes, 2004). 
 
Seven of the ten articles identified included information that was relevant to the current 
Guidelines.  A summary of the relevant information is presented in Table 2 (pages 34–
45) showing general information and information specific to type 1 and type 2 diabetes, 
separately.  
Limitations of the available literature 
• There is a paucity of published literature about managing diabetes when palliative 
care is required; the available literature is rarely based on actual data collected by the 
authors.  Several of the most recent articles cite information provided in earlier 
papers; most relied on the paper published by Poulson (1997). 
• The majority of published papers relied on expert opinion and clinical experience or 
one or two case studies rather than on research data. 
• Very little information about the need to adjust diabetes management strategies, 
sometimes frequently, in the PCOC end of life phases was provided.  Frequently, the 
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only mention of different stages in the dying process was a reference to diabetes 
management when patients only had weeks, months or days to live. 
• Only passing reference was made to steroid-induced diabetes, yet corticosteroids are 
frequently used in palliative care and are known to cause hyperglycaemia, which in 
turn causes uncomfortable symptoms and affects quality of life. 
• People with diabetes’ management preferences are rarely mentioned. 
• Psychosocial dimensions of care are not mentioned. 
• Family members/carers needs were rarely addressed except the general need to 
communicate changes in diabetes management to them.  Although some authors did 
stress the need to consider the wellbeing of family members/carers (McCoubrie et al., 
2004) their education needs and contribution to decisions about care were not 
mentioned. 
• The format of the information provided was not helpful.  Information was typically 
presented in dense text, which makes it difficult to identify information relevant to 
specific situations, and to access ‘at the bedside’.  Only one paper presented a 
summary of information in a format similar to that adopted for the current Guidelines.  
However, the information was very general and did not address the changing care 
needs according to the PCOC stages (Tice, 2006). 
• No authors acknowledged that diabetes could contribute to or even cause remediable 
unpleasant symptoms such as pain and contribute to death. 
• No information about how to distinguish symptoms of hyperglycaemia or 
hypoglycaemia from symptoms associated with other disease/s or palliative care 
treatment was provided. 
 
Themes emerging in the literature 
A number of themes about managing diabetes in palliative care situations emerged from 
the available literature.  It should be noted that the value of the evidence supporting the 
themes is compromised by the limitations of the literature and the poor quality of the 
available literature, as described previously.  
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Type 1 and type 2 diabetes should be managed differently. There was general consensus 
in the literature that managing people with type 1 diabetes is different from managing 
people with type 2 diabetes, particularly in relation to the medicine regimen (e.g., 
Poulson, 1997; Tice, 2006). 
Individualise treatment.  Diabetes management needs to be adjusted according to the 
individual patient’s situation and their preferences and the preferences of their carers 
when relevant (e.g., Smyth & Smyth, 2005; Ford-Dunn et al., 2006). 
The goals of management change when a patient requires palliative care.  Some papers 
specifically mentioned that the goals of diabetes management change from tight 
glycaemic control to maintaining comfort in the end of life (e.g., Poulson, 1997; Smyth & 
Smyth, 2005; Tice, 2006).  However, ‘end of life’ was a blanket term and did not always 
distinguish between terminal care and the other stages of the dying process, and ‘tight 
control’ was not defined. 
The need to alter the patient’s medicine regimen. Changes in nutritional intake, the 
presence of anorexia or nausea and vomiting affect the individual’s medicines regimen 
(e.g., Poulson, 1997; McCoubrie et al., 2004; Smyth & Smyth, 2005).  The amount of 
detail provided about how to manage medicines in these circumstances varied 
considerably among authors; only one author mentioned adopting the Quality Use of 
Medicines framework (Stevenson, Abernethy, Miller & Carrow, 2004). 
Precautions/contraindications to using oral hypoglycaemic agents (OHAs) in the setting 
of renal and liver disease and in combination with palliative care medicines were not 
addressed in significant detail and the safety and benefits of using modern insulin 
analogues was not included. 
Dietary restrictions may be relaxed.  A common suggestion was that diabetes dietary 
restrictions could be relaxed when a person with diabetes has weeks or months to live 
(e.g., Poulson, 1997; Smyth & Smyth, 2005).  However, the suggestion is difficult to 
interpret, given that current dietary guidelines recommend people with diabetes eat a 
healthy diet low in saturated fat and high in complex carbohydrate, the same as the rest of 
the population, rather than ‘a restricted diet.’  Thus, the information the authors used to 
underpin their dietary recommendations was possibly out-of-date. 
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
26
A higher blood glucose level is acceptable.  However, there was little discussion about 
what a ‘higher blood glucose level’ was or what constituted an ‘acceptable’ blood 
glucose level for people with diabetes who were not actively dying  (e.g., Boyd, 1993; 
Poulson, 1997).  The suggested ‘acceptable ranges’ varied among authors but most 
suggested the care focus should change from achieving ‘tight blood glucose control’ to 
achieving comfort.  Some authors indicated that hyperglycaemia causes significant 
discomfort including acerbating pain.  Boyd (1993) suggested a suitable blood glucose 
range for people with type 1 diabetes was 7–17 mmol/L, while Poulson (1997) suggested 
10–15 mmol/L.  No author recommended monitoring ketones in the presence of 
hyperglycaemia in people with type 1 diabetes, yet ketosis causes significant abdominal 
pain, nausea and vomiting.  The criteria authors used to decide on an ‘acceptable blood 
glucose range’ was unclear. 
Blood glucose monitoring.  Only Tice (2006) included clear information about the 
frequency of blood glucose monitoring in different circumstances.  Some authors 
recommended stopping blood glucose monitoring if a patient was unconscious (e.g., 
McCoubrie et al., 2004) but did not indicate whether blood glucose monitoring should 
continue if the unconscious state was due to remediable hypo/hyperglycaemia; others 
suggested discontinuing blood glucose testing when the patient was actively dying 
(McPherson, 2008).  
Prognosis.  Poulson (1997) suggested diabetes management should be changed when a 
patient has only days to live, and this theme emerged in subsequent papers.  Smyth & 
Smyth (2005) and Tice (2006) suggested insulin might be unnecessary when the patient 
is unconscious or death is imminent. Ford-Dunn et al. (2006) and Quinn et al. (2006) 
presented data collected from focus groups with health professionals and showed a lack 
of consensus about blood glucose testing and administering insulin during the last days of 
life. Poulson (1997) argued that insulin could be considered to be life prolonging therapy 
when death is imminent and therefore ceased, which shows little understanding of 
symptom control or insulin action.   However, Poulson (1997) did not indicate how to 
determine when death is ‘imminent’ or the patient is ‘actively dying.’ 
Communication.  Several authors discussed the need to communicate with family 
members, usually about changes in diabetes management.  For example, Smyth and 
Smyth (2005) indicated the family and interdisciplinary team should be consulted about 
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decisions to stop intravenous fluids and insulin.  However, it was not clear whether 
diabetes health professionals were included in the interdisciplinary team.  Quinn et al. 
(2006) found palliative care experts rarely referred to diabetes experts and diabetes 
experts confirmed they were rarely consulted once a patient required palliative care. ) 
Stevenson et al. (2004) provided examples of how to discuss changes in diabetes 
management with patients.  But, none addressed family/carer need for advice, support 
and education when they were caring for the patient at home in the stable and unstable 
phases of the dying process. 
The patient’s wishes.  Some authors referred to the need to consider the patient and/or 
family/carer’s diabetes management preferences (e.g. Boyd, 1993; Tice, 2006) but none 
discussed Advanced Care Directives.  Poulson (1997) did not mention considering the 
patient’s preferences as part of diabetes management, merely the need to ‘inform’ and 
‘reassure’ patients and family members.   
 
Thus, the existing literature does not address most of the guiding principles for managing 
diabetes at the end of life formulated to guide the development of the current Guidelines. 
It was largely written by non-diabetes experts, and shows little understanding that 
monitoring and controlling blood glucose is a key aspect of identifying the cause of and 
managing unpleasant symptoms, including pain, to achieve a ‘good’ death. 
 
Summary 
The scientific evidence available to inform the development of the proposed Guidelines 
was of low level; most was NHMRC level IV, which limited the current researchers’ 
ability to adhere to the NHMRC recommendation to base guidelines on level I evidence  
(NHMRC, 1999).  Thus, the available literature was carefully examined and relevant 
information extracted and discussed with the Advisory Committee and considered in light 
of the guiding principles.   
 
What needs to be included in clinically useful guidelines?  
After considering the literature review, the consensus view of the Advisory Committee 
was that: 
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• The Guidelines should commence with a preamble that explains the underlying 
principles that served as the philosophical and theoretical framework for the 
Guidelines, why the Guidelines are needed, and how to use them.  
• Global statements should be included that stress the importance of:  
- consulting with an interdisciplinary team 
- considering the impact of diabetes on palliative care and vice versa 
- individualising management 
- identifying and incorporating patients’ and family members/carers’ preferences. 
• The Guidelines should be easy to use and prepared in a clear format such as a series 
of flowcharts that include prompts and management options. 
• The Guidelines should include definitions of the different end of life stages and 
information about managing diabetes in each end of life phase, including but not 
limited to the stage when the person with diabetes is unconscious or actively dying. 
• Type 1 and type 2 diabetes should be addressed separately. 
• Information about managing steroid-induced diabetes should be included. 
• Where appropriate, the Guidelines should provide specific details about diabetes 
medicines, blood glucose testing and blood glucose levels. 
• Frequent instructions or reminders to consult patients about their preferences for 
diabetes management should be included in the Guidelines.  Advanced Care 
Directives should be included. 
• Instructions or reminders to consult family members/carers about the patient’s 
preferences if the patient cannot be consulted should be included in the Guidelines. 
• The Guidelines should include instructions or reminders to consult or refer patients to 
other health professionals such as diabetes educators and diabetologists when 
relevant.  
• Psychosocial/spiritual needs should be incorporated into the Guidelines.  
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n
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n
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 st
er
o
id
-
in
du
ce
d 
di
ab
et
es
.
 
Ex
pr
es
se
d 
co
nc
er
n
 
ab
ou
t h
o
w
 
m
u
ch
 
di
sc
o
m
fo
rt
 
fin
ge
r 
pr
ic
ki
n
g 
ca
u
se
s.
 
 
A
 
gr
ea
t d
ea
l o
f p
al
lia
tiv
e 
ca
re
 in
te
rv
en
tio
n
s 
ar
e 
fa
r 
m
o
re
 
u
n
co
m
fo
rt
ab
le
 o
r 
in
v
as
iv
e 
th
an
 
m
o
n
ito
rin
g 
bl
o
o
d 
gl
u
co
se
. 
 
Si
gn
ifi
ca
n
ce
 o
f c
o
m
m
u
n
ic
at
in
g 
w
ith
 
an
d 
ed
uc
at
in
g 
pa
tie
nt
s 
an
d 
fa
m
ili
es
.
 
G
en
er
al
 la
ck
 
o
f r
ef
er
ra
l t
o 
ex
pe
rt 
pr
of
es
sio
n
al
 c
ol
le
ag
u
es
.
 
 
 
C
ro
ss
 s
ec
tio
n
a
l s
ur
v
ey
 
D
es
pi
te
 m
o
st
 
re
sp
o
n
de
nt
s 
in
di
ca
tin
g 
th
ey
 
ha
d 
so
m
e 
ex
pe
rie
n
ce
 
w
ith
 
di
ab
et
es
 
in
 
en
d 
of
 
lif
e 
ca
re
 a
n
d 
th
at
 th
e 
ca
re
 w
as
 
av
er
ag
e 
to
 
go
o
d 
(se
lf-
ra
te
d),
 th
er
e 
ap
pe
ar
ed
 to
 
be
 se
v
er
al
 
in
co
n
sis
te
n
ci
es
 
in
 
di
ab
et
es
 
m
an
ag
em
en
t i
n 
pa
tie
n
ts
 
w
ith
 
ad
va
n
ce
d 
di
se
as
e.
 
Si
gn
ifi
ca
n
tly
 
th
er
e 
w
as
 a
 la
ck
 
o
f c
o
n
fid
en
ce
 to
 
ca
re
 fo
r 
a 
pa
tie
nt
 
w
ith
 
di
ab
et
es
 
w
ith
 
ad
v
an
ce
d 
di
se
as
e,
 
di
ffi
cu
lti
es
 
in
 
di
ag
n
o
si
n
g 
IV
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et
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A
ut
ho
r 
C
ou
n
tr
y 
Pu
rp
o
se
 
M
et
ho
ds
 
D
at
a 
co
lle
ct
ed
 
o
r 
co
n
sid
er
ed
 
R
el
ev
a
n
t f
in
di
n
gs
 
Le
ve
l o
f 
ev
id
en
ce
 
Qu
in
n
 
et
 a
l. 
(20
06
) C
o
n
t. 
40
%
 
re
sp
on
se
 
ra
te
 
    
di
ab
et
es
 
at
 th
e 
en
d 
of
 
lif
e,
 
a 
la
ck
 
o
f r
ef
er
ra
ls 
to
 d
ia
be
te
s e
x
pe
rt
s,
 
la
ck
 
o
f a
w
ar
en
es
s 
o
f h
o
w
 
o
fte
n
 
pa
tie
n
ts
 
o
n
 
co
rt
ic
o
st
er
o
id
s 
ha
d 
ab
no
rm
al
 B
G
 
le
ve
ls 
an
d 
la
ck
 
o
f k
no
w
le
dg
e 
ab
ou
t t
he
 ty
pe
s o
f 
di
ab
et
es
.
 
 
 
R
ec
om
m
en
da
tio
ns
 
fo
r 
fu
tu
re
 
re
se
a
rc
h 
D
ev
el
op
in
g 
gu
id
el
in
es
 
fo
r 
ac
ce
pt
ab
le
 g
ly
ca
em
ic
 r
an
ge
s 
fo
r 
pa
tie
n
ts
 
w
ith
 
di
ab
et
es
 
an
d 
ad
va
n
ce
d 
di
se
as
es
 
m
ay
 
im
pr
ov
e 
th
e 
qu
al
ity
 
o
f l
ife
 
fo
r 
pa
tie
nt
s.
 
 
 
 
Ps
ar
ak
is 
(20
06
) 
U
SA
 
  Cl
in
ic
al
 
ch
al
le
n
ge
s 
in
 
ca
rin
g 
fo
r 
pa
tie
nt
s 
w
ith
 
di
ab
et
es
 
an
d 
ca
n
ce
r 
  
To
 
re
v
ie
w
 
so
m
e 
co
m
m
o
n
 
pr
ob
le
m
s 
en
co
u
n
te
re
d 
by
 
cl
in
ic
ia
n
s 
ca
rin
g 
fo
r 
pe
op
le
 w
ith
 
di
ab
et
es
 
an
d 
ca
nc
er
 
D
isc
u
ss
io
n
 
an
d 
ex
pe
rt 
o
pi
n
io
n
 
Pr
e-
ex
ist
in
g 
re
n
al
, 
ca
rd
ia
c 
or
 n
eu
ro
pa
th
ic
 
co
m
pl
ic
at
io
ns
 
 G
lu
co
co
rt
ic
o
id
s 
 Tu
be
 fe
ed
in
g 
an
d 
to
ta
l 
pa
re
n
te
ra
l n
u
tr
iti
on
 
 N
au
se
a 
an
d 
v
o
m
iti
n
g 
B
G
 
M
an
ag
em
en
t 
du
rin
g 
en
d 
of
 
lif
e 
ca
re
  
Ch
em
o
th
er
ap
eu
tic
 a
ge
n
ts
 
ca
n
 
ex
ac
er
ba
te
 re
na
l, 
ca
rd
ia
c 
or
 
n
eu
ro
pa
th
ic
 c
on
di
tio
n
s;
 tr
ea
tm
en
t m
u
st
 b
e 
ba
se
d 
o
n
 
th
e 
cl
in
ic
al
 
pi
ct
ur
e.
 
 
 Sc
re
en
in
g 
an
d 
ro
u
tin
e 
m
o
n
ito
rin
g 
of
 
di
ab
et
es
 
-
 
tr
ea
tm
en
t o
f 
hy
pe
rg
ly
ca
em
ia
 
de
pe
nd
s 
o
n
 
ty
pe
 o
f d
ia
be
te
s,
 
se
v
er
ity
 
o
f t
he
 
el
ev
at
ed
 B
G
 
le
ve
ls,
 
do
se
 a
n
d 
du
ra
tio
n 
o
f t
he
ra
py
.
 
Co
n
sid
er
 
ch
an
gi
n
g 
fro
m
 
O
H
A
s 
to
 in
su
lin
 
an
d/
o
r 
in
cr
ea
sin
g 
in
su
lin
 
do
se
s.
 
 H
yp
er
gl
yc
ae
m
ia
 is
 a
 fr
eq
u
en
t c
o
m
pl
ic
at
io
n
.
 
Co
n
sid
er
 
in
su
lin
.
 
 
Co
m
m
o
n
 
ad
ve
rs
e 
dr
ug
 
re
ac
tio
n
s—
sc
re
en
,
 
m
o
n
ito
r, 
co
ns
id
er
 
an
tie
m
et
ic
 th
er
ap
y.
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A
ut
ho
r 
C
ou
n
tr
y 
Pu
rp
o
se
 
M
et
ho
ds
 
D
at
a 
co
lle
ct
ed
 
o
r 
co
n
sid
er
ed
 
R
el
ev
a
n
t f
in
di
n
gs
 
Le
ve
l o
f 
ev
id
en
ce
 
Ps
ar
ak
is 
(20
06
) 
Co
n
t. 
Le
ss
 
st
rin
ge
n
t b
ut
 
sh
o
u
ld
 
n
o
t b
e 
ig
n
o
re
d.
 C
o
n
sid
er
 p
at
ie
n
t a
n
d 
fa
m
ily
 
w
ish
es
; r
e-
ev
al
u
at
e 
an
d 
re
v
ise
 
w
ith
 
ea
ch
 c
ha
n
ge
 
in
 
pa
tie
nt
’
s 
cl
in
ic
al
 c
on
di
tio
n
.
 
 
 
M
cP
he
rs
o
n
 
(20
08
) 
U
SA
 
 M
a
n
a
ge
m
en
t o
f 
di
a
be
te
s 
a
t t
he
 
en
d 
of 
life
 
 
To
 
re
v
ie
w
 
th
er
ap
eu
tic
 g
o
al
s 
fo
r 
te
rm
in
al
ly
 
ill
 
pa
tie
nt
s 
w
ith
 
di
ab
et
es
 
 
  
D
isc
u
ss
io
n
 
an
d 
ex
pe
rt 
o
pi
n
io
n
; c
as
e 
st
ud
y 
 n
 =
 
1 
 
 
 
 
N
ee
d 
fo
r 
re
le
v
an
t 
th
er
ap
eu
tic
 g
o
al
s a
t t
he
 
en
d 
of
 
lif
e 
 
Ti
gh
t B
G
 
co
n
tr
o
l i
s a
n 
u
n
re
al
ist
ic
 g
o
al
 fo
r 
pa
tie
nt
s 
w
ith
 
a 
te
rm
in
al
 il
ln
es
s 
an
d 
m
ay
 
ca
u
se
 
u
n
ac
ce
pt
ab
le
 sy
m
pt
om
s 
su
ch
 
as
 
hy
po
gl
yc
ae
m
ia
. 
Fo
r 
te
rm
in
al
ly
 
ill
 p
at
ie
n
ts
 th
e 
gl
yc
o
sy
la
te
d 
ha
em
o
gl
ob
in
 
(H
bA
1c
) 
le
v
el
 
n
o
 
lo
n
ge
r 
pr
ov
id
es
 
u
se
fu
l i
n
fo
rm
at
io
n
.
 
 
Th
e 
m
o
st
 
im
po
rta
nt
 
go
al
 fo
r 
an
 
en
d 
sta
ge
 p
at
ie
nt
 w
ith
 
di
ab
et
es
 
is 
to
 
pr
ev
en
t s
ym
pt
om
s 
re
la
te
d 
to
 
hy
pe
rg
ly
ca
em
ia
 a
nd
/o
r 
hy
po
gl
yc
ae
m
ia
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r 
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co
m
m
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da
tio
n
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fo
r 
m
a
n
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gi
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pe
op
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 d
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be
te
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dv
an
ce
d 
ca
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er
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r 
a
dv
an
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d 
te
rm
in
al
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ln
es
s 
a
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he
 e
n
d 
o
f l
ife
 
pr
es
en
te
d 
in
 
o
rd
er
 o
f t
he
 y
ea
r 
th
ey
 w
er
e 
pu
bl
ish
ed
.
 
(T
he
 
ta
bl
e 
co
n
tin
u
es
 
o
v
er
 1
0 
pa
ge
s) 
 
A
ut
ho
rs
 
R
el
ev
an
t 
fa
ct
o
rs
 
in
cl
u
de
d 
Sp
ec
ifi
c 
gu
id
el
in
es
 
o
r 
re
co
m
m
en
da
tio
n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
B
oy
d 
(19
93
) 
               
B
rie
f g
u
id
el
in
es
 
in
 
te
xt
. 
B
as
ed
 o
n 
tw
o
 
ca
se
 s
tu
di
es
 
an
d 
di
ab
et
es
 
lit
er
at
ur
e.
 
 
B
G
L 
M
ed
ic
in
es
 
En
d 
of
 
lif
e 
st
ag
e 
D
ec
isi
o
n
s 
co
n
ce
rn
in
g 
w
ith
dr
aw
in
g 
of
 
B
G
 
m
o
n
ito
rin
g 
an
d 
re
du
ci
ng
/c
ea
sin
g 
m
ed
ic
in
es
 
m
ay
 
be
 d
iff
ic
u
lt 
 M
od
ifi
ed
 d
ia
be
te
s m
an
ag
em
en
t 
pl
an
s 
ar
e 
ap
pr
op
ria
te
 in
 
ho
sp
ic
e 
pa
tie
n
ts
 
 
 Ti
gh
t g
ly
ca
em
ic
 
co
n
tr
o
l 
u
n
n
ec
es
sa
ry
 
em
ph
as
is 
o
n
 
av
o
id
in
g 
hy
po
gl
yc
ae
m
ic
 a
n
d 
sy
m
pt
o
m
at
ic
 
hy
pe
rg
ly
ca
em
ia
 
 D
et
er
m
in
e 
su
ita
bl
e 
BG
 
ta
rg
et
 
ra
n
ge
 
B
G
L 
tw
ic
e 
pe
r d
ay
 
(B
D)
 
 G
iv
e 
4 
un
its
 
sh
o
rt
 
ac
tin
g 
in
su
lin
 
if 
B
G
L 
>
 
17
m
m
o
l/L
 
  
Su
ita
bl
e 
B
G
 
ra
n
ge
: 
7–
7 
m
m
o
l/L
 
 A
dm
in
ist
er
 
in
su
lin
 w
he
re
 
pa
tie
n
t 
tr
u
ly
 
in
su
lin
 d
ep
en
da
n
t. 
 
  
 In
su
lin
 
ad
m
in
ist
ra
tio
n
 
ap
pr
op
ria
te
 
 
Co
n
sid
er
 
co
n
sc
io
u
s 
le
v
el
,
 
sy
m
pt
om
s,
 
pa
tie
nt
 
an
d 
fa
m
ili
es
’
 
w
ish
es
,
 
pr
ov
id
e 
ad
eq
ua
te
 
ex
pl
an
at
io
n
 
an
d 
su
pp
or
t  
R
el
ax
 
di
et
ar
y 
re
st
ric
tio
ns
 
 R
ev
ie
w
 
O
H
A
 
re
gu
la
rly
 
an
d 
gr
ad
u
al
ly
 w
ith
dr
aw
 
as
 
pa
tie
n
t’
s 
o
ra
l i
n
ta
ke
 
re
du
ce
s,
 
as
 
pa
tie
n
t l
o
o
se
s 
w
ei
gh
t o
r 
as
 
co
n
di
tio
n 
de
te
rio
ra
te
s; 
co
n
sid
er
 O
H
A
 
do
se
 
re
du
ct
io
n
s.
 
 Co
n
sid
er
 sh
o
rt
 a
ct
in
g 
O
H
A
s t
o
 
re
du
ce
 r
isk
 
o
f h
yp
og
ly
ca
em
ia
. 
  M
on
ito
r 
sid
e 
ef
fe
ct
s 
o
f O
H
A
s 
w
ith
 
a 
v
ie
w
 
to
 
do
se
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cl
u
de
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Sp
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o
r 
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co
m
m
en
da
tio
n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
B
oy
d 
(19
93
) 
Co
n
t. 
 
Im
po
rta
n
t –
 
av
o
id
in
g 
hy
po
-
gl
yc
ae
m
ia
  
an
d 
sy
m
pt
om
at
ic
 
hy
pe
rg
ly
ca
em
ia
,
 
re
la
x
in
g 
di
et
ar
y 
re
st
ric
tio
n
s,
 
m
ai
n
ta
in
 
sk
in
/fe
et
 
in
te
gr
ity
,
 
ea
rly
 
id
en
tif
ic
at
io
n 
o
f c
an
di
da
 &
 
o
th
er
 in
fe
ct
io
n
s 
an
d 
m
o
n
ito
rin
g 
ef
fe
ct
s 
o
f c
o
rt
ic
os
te
ro
id
s 
 M
on
ito
r 
sy
m
pt
om
s 
co
n
sid
er
 
co
n
sc
io
u
sn
es
s 
le
v
el
, p
at
ie
nt
 a
n
d 
fa
m
ily
 
w
ish
es
 
 
Pr
o
v
id
e 
su
pp
o
rt
/e
du
ca
tio
n
 
to
 
fa
m
ily
 
m
em
be
rs
/c
ar
er
s 
 
 
 
re
du
ct
io
n/
ce
as
in
g.
 
 R
ec
o
gn
ise
 a
n
d 
ac
ce
pt
 re
la
tiv
es
 
v
ie
w
s 
o
n
 
th
e 
pa
tie
n
ts
 
di
ab
et
es
 
m
an
ag
em
en
t 
  
Po
ul
so
n
 
(19
97
) 
 
In
 
te
x
t a
n
d 
ta
bl
e 
fo
r 
m
o
n
ito
rin
g 
an
d 
m
an
ag
in
g 
Ty
pe
 o
f d
ia
be
te
s 
A
n
tic
ip
at
ed
 
pr
o
gn
os
is 
Tr
ea
tm
en
t n
ee
ds
 
to
 b
e 
in
di
v
id
u
al
ise
d.
 
Ti
gh
t g
ly
ca
em
ic
 c
o
n
tr
o
l n
o
t 
A
bs
o
lu
te
 r
eq
u
ire
m
en
t f
o
r 
in
su
lin
 
to
 
pr
ev
en
t t
he
 d
ev
el
op
m
en
t o
f 
fa
ta
l k
et
oa
ci
do
sis
.  
Su
gg
es
te
d 
BG
 
ra
n
ge
 
8–
15
m
m
o
l/L
 
u
n
le
ss
 
sy
m
pt
o
m
at
ic
.
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R
el
ev
an
t 
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u
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d 
Sp
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c 
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in
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o
r 
re
co
m
m
en
da
tio
n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
Po
ul
so
n
 
(19
97
) C
o
n
t. 
                
di
ab
et
es
.
 
 B
as
ed
 o
n 
cl
in
ic
al
 
ex
pe
rie
nc
e,
 tw
o
 
ca
se
 s
tu
di
es
,
 
an
d 
ca
n
ce
r,
 d
ia
be
te
s 
an
d 
m
ed
ic
al
 
lit
er
at
ur
e.
 
En
d 
of
 
lif
e 
st
ag
e 
 
A
pp
et
ite
/w
ei
gh
t 
B
G
L 
im
po
rt
an
t h
ow
ev
er
 
es
se
n
tia
l t
o
 
av
o
id
 h
yp
o/
hy
pe
rg
ly
ca
em
ia
. 
 
M
ai
nt
ai
n
 
B
G
L 
in
 
an
 
ac
ce
pt
ab
le
 
ra
n
ge
 
w
ith
 
a 
m
in
im
u
m
 o
f 
m
o
n
ito
rin
g.
 
D
ie
ta
ry
 
re
st
ric
tio
n
s 
n
o
 
lo
n
ge
r 
re
qu
ire
d.
 
 Ca
re
fu
l e
xp
la
n
at
io
n
 
to
 
pa
tie
nt
 
an
d 
fa
m
ily
; p
ro
vi
de
 re
as
su
ra
n
ce
 
an
d 
ed
uc
at
io
n.
 
R
ea
ss
u
re
 p
at
ie
nt
s 
an
d 
fa
m
ily
 
th
at
 re
du
ce
d 
di
et
ar
y 
re
st
ric
tio
n
s 
an
d 
m
o
n
ito
rin
g,
 
an
d 
hi
gh
er
 
B
G
L 
re
fle
ct
s 
sh
ift
 
o
f t
he
ra
py
 
to
w
ar
d 
qu
al
ity
 
o
f l
ife
.
 
Su
gg
es
te
d 
sh
o
rt
-
ac
tin
g 
in
su
lin
 
Su
gg
es
te
d 
BG
 
ra
n
ge
 
10
–1
5 
m
m
o
l/L
 
u
n
le
ss
 
sy
m
pt
om
at
ic
.  
If 
st
ab
le
 n
u
tr
iti
on
al
 st
at
u
s,
 
m
ai
nt
ai
n 
pr
ev
io
u
s 
in
su
lin
 
re
gi
m
en
, 
m
o
n
ito
r 
B
G
L 
tw
ic
e 
da
ily
 
be
fo
re
 m
ea
ls 
ev
er
y 
3 
da
ys
.
 
If 
re
du
ce
d 
ap
pe
tit
e,
 
m
o
n
ito
r 
fa
st
in
g 
B
G
 
da
ily
 
fo
r 
3 
da
ys
 
an
d 
re
du
ce
 in
su
lin
 
if 
in
di
ca
te
d.
 
If 
se
v
er
e 
an
o
re
x
ia
 
an
d/
o
r 
v
o
m
iti
n
g,
 
ch
an
ge
 
to
 
sh
or
t-
ac
tin
g 
in
su
lin
.
 
O
nc
e 
st
ab
le
 d
os
e 
es
ta
bl
ish
ed
,
 
in
te
rm
ed
ia
te
-a
ct
in
g 
in
su
lin
.
 
M
on
ito
r 
B
G
 
tw
ic
e 
da
ily
.
 
M
ai
nt
ai
n
 
ad
eq
u
at
e 
in
su
lin
 
to
 
av
o
id
 k
et
o
sis
 
(0.
3-0
.
4 
u
n
its
/k
g/
24
hr
). 
Tr
ea
t h
yp
er
gl
yc
ae
m
ia
 if
 
15
m
m
o
l/L
 
o
r 
ab
ov
e;
 
co
n
sid
er
 
co
m
m
en
ci
n
g 
in
su
lin
 (s
ho
rt
 
ac
tin
g 
do
se
 6
–8
 h
o
u
rly
 
fo
r 
ta
rg
et
 
B
G
 
ra
n
ge
 
10
–
15
m
m
o
l/L
). 
W
ei
gh
t l
os
s 
m
ay
 
sig
n
ifi
ca
n
tly
 
lo
w
er
 
B
G
; c
o
n
sid
er
 
ha
lv
in
g 
O
H
A
s 
(do
se 
re
du
ct
io
n
) p
rio
r 
to
 
di
sc
o
n
tin
u
in
g.
 
 
 
 Ca
re
fu
l m
o
n
ito
rin
g 
o
f c
lin
ic
al
 
st
at
u
s 
is 
re
qu
ire
d;
 
fa
st
in
g 
bl
o
o
ds
 
1/
7 
fo
r 
3 
w
ee
ks
 
th
en
 
bi
 
m
o
n
th
ly
 u
n
le
ss
 s
ym
pt
o
m
at
ic
.
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rm
in
al
—
O
H
A
s 
ra
re
ly
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qu
ire
d 
ex
ce
pt
 w
he
re
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m
m
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n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
Po
ul
so
n
 
(19
97
) C
o
n
t. 
        
do
se
 (u
n
its
) f
o
r 
po
st 
pr
an
di
al
 
B
G
L:
 
B
G
L 
10
–1
5 
   
 
 
 
 
 
 
 
 
 
 
6 
un
its
 
B
G
L 
15
.1
–1
8 
   
   
 
 
 
 
8 
un
its
 
B
G
L 
18
.1
–2
2 
 
 
 
 
 
 
 
 
 
10
 u
n
its
 
B
G
L 
>
22
   
   
   
 
 
 
 
 
 
 
12
 
u
n
its
 
G
lu
co
co
rt
ic
oi
ds
 
ca
n
 
af
fe
ct
 
gl
yc
ae
m
ic
 c
o
n
tr
o
l i
n 
pa
tie
nt
s 
w
ith
 
di
ab
et
es
 
bu
t t
he
 a
ffe
ct
 
v
ar
ie
s 
w
ith
 
th
e 
in
di
v
id
u
al
.
 
Pa
tie
n
ts
 
w
ith
 
Ty
pe
 2
 m
ay
 
de
ve
lo
p 
hy
pe
rg
ly
ca
em
ia
 
an
d 
re
qu
ire
 in
su
lin
.
 
Pa
tie
nt
s 
w
ith
 
ty
pe
 1
 m
ay
 
re
qu
ire
 in
su
lin
 
do
se
 
in
cr
ea
se
s.
 
In
te
ns
iv
e 
B
G
 
m
o
n
ito
rin
g 
is 
w
ar
ra
n
te
d.
 
 
 
 
 
Pa
tie
nt
s 
w
ith
 
n
o
 
o
ra
l i
nt
ak
e 
st
ill
 
re
qu
ire
 b
as
el
in
e 
in
su
lin
 
to
 
pr
ev
en
t 
ke
to
sis
. 
N
ee
d 
to
 
an
tic
ip
at
e 
pa
tie
n
t’
s 
in
su
lin
 
re
qu
ire
m
en
ts
 
an
d 
m
at
ch
 in
su
lin
 d
o
se
 
ac
co
rd
in
gl
y.
 
A
s 
de
at
h 
be
co
m
es
 
im
m
in
en
t 
in
su
lin
 
co
u
ld
 b
e 
co
ns
id
er
ed
 a
s l
ife
 
pr
ol
o
n
gi
n
g 
th
er
ap
y 
em
ph
as
isi
n
g 
th
e 
n
ec
es
sit
y 
o
f d
isc
u
ss
io
n
s 
re
 
w
ith
dr
aw
in
g 
tr
ea
tm
en
ts
 w
ith
 
fa
m
ily
; c
ea
se
 B
G
 
m
o
n
ito
rin
g 
at
 
th
is 
sta
ge
. 
 
 
in
fe
ct
io
n
 o
r 
se
rio
u
s 
st
re
ss
 
fa
ct
o
rs
 
pr
es
en
t. 
M
on
ito
r 
B
G
 
ev
er
y 
tw
o
 d
ay
s 
 
“
an
d 
 
hy
po
gl
yc
la
em
ic
 
tr
ea
tm
en
t i
ni
tia
te
d 
if 
th
e 
cl
in
ic
al
 a
ss
es
sm
en
t s
u
gg
es
ts
 
th
at
 h
yp
er
gl
yc
ae
m
ia
 is
 
co
n
tr
ib
u
tin
g 
sig
n
ifi
ca
n
tly
 to
 
pa
tie
n
t d
ist
re
ss
”
 
(p.
 34
4) 
[N
O
TE
, t
hi
s 
is 
co
n
fu
sin
g 
an
d 
co
u
ld
 
m
ea
n
 
u
se
 
O
H
A
/in
su
lin
 
to
 
co
n
tr
o
l h
yp
er
gl
yc
ae
m
ia
 O
R 
tr
ea
t h
yp
er
gl
yc
ae
m
ia
]. 
R
el
ax
 
di
et
ar
y 
re
st
ric
tio
n
s 
an
d 
ad
jus
t O
H
A
s/i
n
su
lin
 
ac
co
rd
in
gl
y.
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A
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re
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m
m
en
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n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
M
cC
o
u
br
ie
, 
Je
ffr
ey
,
 
Pa
to
n
 
&
 D
aw
es
 
(20
04
) 
M
cC
o
u
br
ie
 e
t 
al
.
 
(20
04
) 
Co
n
t. 
           
B
rie
f g
u
id
el
in
es
 
in
 
te
x
t a
n
d 
ta
bl
e 
o
f g
en
er
al
 
ap
pr
oa
ch
 
to
 
di
ab
et
es
.
 
R
et
ro
sp
ec
tiv
e 
ca
se
 
n
o
te
 a
ud
it 
o
f 4
2 
ca
nc
er
 
pa
tie
n
ts
 
an
d 
di
ab
et
es
,
 
pa
lli
at
iv
e 
an
d 
ca
n
ce
r 
lit
er
at
ur
e.
 
(ci
tes
 
B
oy
d,
 
19
93
 a
nd
 
Po
ul
so
n
,
 
19
97
) 
En
d 
of
 
lif
e 
st
ag
e 
B
G
 
m
o
n
ito
rin
g—
 
fle
x
ib
le
 
ap
pr
oa
ch
 
to
 e
nh
an
ce
 q
ua
lit
y 
o
f 
lif
e 
In
v
o
lv
em
en
t o
f s
pe
ci
al
ist
 
pa
lli
at
iv
e 
ca
re
 te
am
s 
–
 
ea
rly
 
re
fe
rr
al
 to
 
pa
lli
at
iv
e 
an
d 
di
ab
et
es
 
te
am
s 
m
ay
 
fa
ci
lit
at
e 
a 
m
o
re
 
pa
lli
at
iv
e 
ap
pr
o
ac
h 
to
 
ca
re
. 
  
Ea
rly
 
in
v
o
lv
em
en
t a
nd
 
u
pd
at
in
g 
o
f p
at
ie
n
ts
 
an
d 
fa
m
ili
es
 
so
 
th
ey
 
ca
n
 
m
ak
e 
de
ci
sio
n
s 
co
n
ce
rn
in
g 
th
ei
r c
ar
e.
  
 W
ee
ks
/m
o
n
th
s t
o
 
liv
e 
Co
n
sid
er
 
re
fe
rr
al
 to
 
sp
ec
ia
lis
t 
pa
lli
at
iv
e 
ca
re
 a
n
d 
or
 d
ia
be
te
s 
Pa
tie
n
t w
ith
 
w
ee
ks
/m
o
n
th
s 
to
 
liv
e 
In
su
lin
 
re
qu
ire
d 
to
 
pr
ev
en
t 
ke
to
ac
id
o
sis
  
 W
ei
gh
t l
o
ss
 
o
r 
re
du
ce
d 
ca
lo
rie
 
in
ta
ke
 
du
e 
to
 
n
au
se
a 
o
r 
v
o
m
iti
n
g 
m
ay
 
in
di
ca
te
 a
n
 
in
su
lin
 
do
se
 
re
du
ct
io
n
 
 
      Pa
tie
n
t w
ith
 
da
ys
 
to
 li
v
e:
 
If 
co
n
sc
io
u
s 
an
d 
sy
m
pt
om
at
ic
 o
f 
hy
pe
rg
ly
ca
em
ia
, 
u
se
 s
ho
rt
 a
ct
in
g 
Pa
tie
nt
 w
ith
 w
ee
ks
/m
o
n
th
s 
to
 li
v
e 
R
ed
uc
e 
do
se
 o
f O
H
A
s 
as
 
ap
pe
tit
e 
re
du
ce
s 
A
v
o
id
 M
et
fo
rm
in
 
-
 
sid
e-
ef
fe
ct
s 
R
ev
ie
w
 
n
ee
d 
fo
r 
co
rt
ic
o-
st
er
o
id
s a
n
d 
as
k 
ab
ou
t 
sy
m
pt
o
m
s 
o
f h
yp
er
gl
yc
ae
m
ia
 
Ea
rly
 
id
en
tif
ic
at
io
n
 
an
d 
tr
ea
tm
en
t o
f o
ra
l c
an
di
da
 
Ex
pl
ai
n 
th
es
e 
m
ea
su
re
s 
to
 th
e 
pa
tie
n
t a
n
d 
fa
m
ily
 
an
d 
do
cu
m
en
t i
n 
th
e 
m
ed
ic
al
 n
o
te
s 
 Pa
tie
n
ts
 
w
ith
 
da
ys
 
to
 
liv
e:
 
If 
co
n
sc
io
u
s 
an
d 
sy
m
pt
om
at
ic
 
o
f h
yp
er
gl
yc
ae
m
ia
,
 
u
se
 s
ho
rt
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m
m
en
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n
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Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
M
cC
o
u
br
ie
 e
t 
al
.
 
(20
04
) 
Co
n
t. 
 
te
am
 
M
ai
n
ta
in
 
B
G
 
ra
n
ge
 
at
 
10
–2
0 
m
m
o
l/L
 
 
R
ed
uc
ed
 c
al
or
ifi
c 
in
ta
ke
 
an
d 
w
ei
gh
t l
os
s 
sig
n
ifi
ca
n
tly
 
lo
w
er
s 
B
G
 
A
v
o
id
in
g 
hy
po
gl
yc
ae
m
ia
 
pa
ra
m
o
u
n
t 
R
el
ax
 
di
et
ar
y 
re
st
ric
tio
n
s 
M
on
ito
r 
fo
r 
hy
pe
rg
ly
ca
em
ia
 if
 
pa
tie
nt
 
pr
es
cr
ib
ed
 st
er
o
id
s. 
 
Ea
rly
 
id
en
tif
ic
at
io
n
 
an
d 
tr
ea
tm
en
t o
f o
ra
l C
an
di
da
 
 
 
in
su
lin
 
w
he
n
 
B
G
 
>
20
 
m
m
o
l/L
. 
If 
pa
tie
n
t i
s 
u
n
co
n
sc
io
u
s,
 
st
o
p 
al
l 
o
ra
l a
n
d 
hy
po
gl
yc
ae
m
ic
 
m
ed
ic
at
io
n
 
an
d 
BG
 
m
o
n
ito
rin
g.
 
 
D
isc
u
ss
 w
ith
 
re
la
tiv
es
. 
 
ac
tin
g 
in
su
lin
 
w
he
n
 
B
G
 
>
20
 
m
m
o
l/L
.
 
If 
pa
tie
n
t i
s 
u
n
co
n
sc
io
u
s,
 
st
o
p 
al
l o
ra
l a
nd
 h
yp
og
ly
ca
em
ic
 
m
ed
ic
at
io
n
 
an
d 
BG
 
m
o
n
ito
rin
g.
 
 
D
isc
u
ss
 w
ith
 
re
la
tiv
es
. 
 
Sm
yt
h 
&
 
Sm
yt
h 
(20
05
) 
R
ec
o
m
m
en
da
t-
io
n
s 
in
 
te
xt
.
 
Ty
pe
 o
f d
ia
be
te
s 
A
pp
et
ite
/w
ei
gh
t 
Ea
rly
 
st
ag
es
 o
f t
he
 p
al
lia
tiv
e 
ill
ne
ss
 
co
n
v
en
tio
na
l d
ia
be
te
s 
m
an
ag
em
en
ta
n
d
ca
re
ar
e
La
ck
 
o
f a
pp
et
ite
 
a
n
d 
w
ei
gh
t 
lo
ss
, 
n
a
u
se
a
 
a
n
d 
vo
m
iti
n
g:
 
 
La
ck
 
o
f a
pp
et
ite
 a
nd
 
w
ei
gh
t 
lo
ss
: 
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 p
eo
pl
e 
w
ith
 
di
ab
et
es
 a
nd
 a
dv
an
ce
d 
ca
nc
er
 o
r 
 
 
a
dv
an
ce
d 
te
rm
in
al
 il
ln
es
s 
a
t t
he
 e
n
d 
o
f l
ife
 
pr
es
en
te
d 
in
 
o
rd
er
 o
f t
he
 y
ea
r 
th
ey
 w
er
e 
pu
bl
ish
ed
 (C
o
n
tin
u
ed
).  
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
M
a
n
a
gi
ng
 D
ia
be
te
s 
a
t t
he
 E
n
d 
o
f L
ife
   
   
 
 
 
 
 
Co
py
rig
ht
 2
01
0 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
43
A
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rs
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el
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an
t 
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o
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u
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c 
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o
r 
re
co
m
m
en
da
tio
n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
Sm
yt
h 
&
 
Sm
yt
h 
(20
05
) 
Co
n
t. 
               
B
as
ed
 o
n 
pa
lli
at
iv
e 
ca
re
,
 
di
ab
et
es
 
an
d 
ca
n
ce
r 
lit
er
at
ur
e.
 
(C
ite
s 
Po
u
lso
n
, 
19
97
)  
lo
ss
 
N
au
se
a/
v
o
m
it-
in
g 
Pa
lli
at
iv
e 
dr
ug
s 
En
d 
of
 
lif
e 
st
ag
e  
m
an
ag
em
en
t a
n
d 
ca
re
 a
re
 
ac
ce
pt
ab
le
. A
s 
th
e 
pa
lli
at
iv
e 
di
se
as
e 
pr
og
re
ss
es
 
an
d 
pr
og
n
o
sis
 
be
co
m
es
 
w
o
rs
e,
 it
 
be
co
m
es
 
m
o
re
 im
po
rta
n
t t
o
 
m
an
ag
e 
th
e 
ac
u
te
 a
n
d 
di
st
re
ss
in
g 
sh
or
t t
er
m
 
co
m
pl
ic
at
io
n
s 
o
f d
ia
be
te
s 
(hy
po
/ 
hy
pe
rg
ly
ca
em
ia
,
 
D
K
A
,
 
H
O
N
K
) 
ra
th
er
 
th
an
 
th
e 
lo
n
g 
te
rm
 
co
m
pl
ic
at
io
n
s.
 
 
La
te
r s
ta
ge
s 
o
f t
er
m
in
al
 il
ln
es
s 
–
 
it 
is 
re
as
o
n
ab
le
 to
 
re
la
x 
gl
yc
ae
m
ic
 c
o
n
tr
o
l; 
ai
m
in
g 
fo
r 
B
G
 
ra
n
ge
 
o
f 5
 
-
15
m
m
o
l/L
 m
ay
 
he
lp
 
av
o
id
 h
yp
og
ly
ca
em
ia
 
w
ith
o
u
t l
ea
di
ng
 
to
 
hy
pe
rg
ly
ca
em
ia
. 
  
A
 
re
du
ct
io
n
 
in
 
di
et
ar
y 
in
ta
ke
 
m
ay
 
in
cr
ea
se
 
th
e 
ris
k 
o
f a
 h
yp
o,
 in
su
lin
 
m
ay
 
n
ee
d 
to
 
be
 c
ha
n
ge
d 
or
 
re
du
ce
d.
  
Sp
ec
ifi
c 
m
an
ag
em
en
t s
tr
at
eg
ie
s 
m
ay
 
be
 in
tr
od
uc
ed
 in
cl
u
di
ng
 
ad
m
in
ist
er
in
g 
an
tie
m
et
ic
s,
 
en
co
u
ra
gi
ng
 
sm
al
l f
re
qu
en
t m
ea
ls 
an
d 
su
ga
ry
 
dr
in
ks
 
th
at
 
w
ill
 
pr
o
v
id
e 
v
al
ua
bl
e 
ca
lo
ric
 in
ta
ke
 
as
 
w
el
l a
s 
pr
ev
en
tin
g 
hy
po
gl
yc
ae
m
ia
. 
 
Pa
tie
nt
s 
tr
ea
te
d 
w
ith
 
co
rt
ic
o
st
er
o
id
s 
w
ill
 
pr
ob
ab
ly
 
re
qu
ire
 la
rg
er
 
do
se
s 
o
f i
ns
u
lin
 
w
hi
le
 ta
ki
n
g 
co
rt
ic
os
te
ro
id
s.
 
C
ar
e o
f t
he
 d
yi
ng
  
A
 
re
du
ct
io
n
 
in
 
di
et
ar
y 
in
ta
ke
 
m
ay
 
in
cr
ea
se
 
th
e 
ris
k 
o
f h
yp
o-
gl
yc
ae
m
ia
,
 
O
H
A
s/i
n
su
lin
 
m
ay
 
n
ee
d 
to
 b
e 
ch
an
ge
d,
 re
du
ce
d 
o
r 
ce
as
ed
. 
If 
n
au
se
a 
an
d 
v
o
m
iti
n
g 
pr
ev
en
t p
at
ie
n
t f
ro
m
 
ea
tin
g 
an
d 
B
G
L 
co
n
tin
u
e 
to
 
ris
e,
 
in
su
lin
 
an
d 
in
tr
av
en
o
u
s 
flu
id
s 
m
ay
 
be
 re
qu
ire
d.
 
Pa
tie
nt
s 
tr
ea
te
d 
w
ith
 
co
rt
ic
o
st
er
o
id
s 
w
ho
 h
av
e 
ty
pe
 
2 
di
ab
et
es
 
u
su
al
ly
 m
an
ag
ed
 
w
ith
 
di
et
 
an
d/
o
r 
O
H
A
 
m
ay
 
re
qu
ire
 in
su
lin
 
tr
ea
tm
en
t t
o 
co
n
tr
o
l h
yp
er
gl
yc
ae
m
ia
. 
C
a
re
 o
f t
he
 d
yi
n
g 
  Ta
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 o
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 p
ap
er
s t
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m
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 p
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f l
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pr
es
en
te
d 
in
 
o
rd
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 o
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re
co
m
m
en
da
tio
n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
Sm
yt
h 
&
 
Sm
yt
h 
(20
05
) 
Co
n
t. 
              
hy
pe
rg
ly
ca
em
ia
.  
 
M
in
im
ise
 
in
v
es
tig
at
io
n
s.
 
 
Pa
tie
nt
 
co
m
fo
rt
 a
nd
 c
ar
er
 w
el
l-
be
in
g 
sh
o
u
ld
 b
e 
th
e 
ho
lis
tic
 a
n
d 
th
er
ap
eu
tic
 g
o
al
s. 
 
 W
he
n
 
la
ck
 
o
f a
pp
et
ite
 
o
r 
 
an
o
re
x
ia
 p
re
se
n
t, 
al
lo
w
 
pa
tie
n
t 
to
 
ea
t p
re
vi
o
u
sly
 
av
o
id
ed
 fo
o
ds
 
e.
g.
 
 
ic
e 
cr
ea
m
.
 
R
ea
ss
u
re
 
fa
m
ily
 
th
is 
is 
n
o
t 
‘
gi
vi
n
g 
u
p’
.
 
Co
n
su
lt 
a 
di
et
iti
an
 
to
 
de
vi
se
 
a 
su
ita
bl
e 
di
et
 
–
 
pa
tie
n
t m
ay
 
n
ee
d 
su
pp
le
m
en
ts
.
 
Th
e 
ef
fe
ct
 o
f c
o
rt
ic
os
te
ro
id
s o
n
 
gl
yc
ae
m
ic
 
co
n
tr
o
l v
ar
ie
s 
w
ith
 
in
di
v
id
u
al
s 
–
 
im
po
rta
n
t t
o
 
m
o
n
ito
r g
ly
ca
em
ic
 c
o
n
tr
o
l i
n
 
al
l 
In
su
lin
 w
ill
 
u
su
al
ly
 
be
 
n
ee
de
d 
to
 
pr
ev
en
t k
et
os
is 
bu
t t
he
re
 is
 
se
ld
om
 
a 
n
ee
d 
fo
r 
an
 
in
te
n
siv
e 
in
su
lin
 r
eg
im
e 
an
d 
fre
qu
en
t 
m
o
n
ito
rin
g.
 
M
ay
 
ch
an
ge
 
to
 
o
n
ce
-d
ai
ly
 
in
su
lin
 
u
sin
g 
in
te
rm
ed
ia
te
 o
r 
lo
n
g-
ac
tin
g 
in
su
lin
.
 
 W
he
n
 
pa
tie
n
t i
s 
u
n
co
n
sc
io
u
s 
an
d 
n
ea
r 
de
at
h,
 
in
tr
av
en
o
u
s 
flu
id
s a
n
d 
th
e 
ad
m
in
ist
ra
tio
n
 
o
f i
n
su
lin
 
m
ay
 
be
 
u
n
n
ec
es
sa
ry
.
 
 
O
H
A
s w
ill
 
n
o
rm
al
ly
 
be
 
 
st
o
pp
ed
. I
f i
n
su
lin
 
is 
u
se
d 
th
e 
do
es
 
ca
n
 
be
 re
du
ce
d 
or
 
st
o
pp
ed
. 
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f k
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 p
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 p
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f l
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 o
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A
ut
ho
rs
 
R
el
ev
an
t 
fa
ct
o
rs
 
in
cl
u
de
d 
Sp
ec
ifi
c 
gu
id
el
in
es
 
o
r 
re
co
m
m
en
da
tio
n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
pa
tie
nt
s 
re
ce
iv
in
g 
co
rt
ic
os
te
ro
id
s.
 
Fo
rd
-
D
u
n
n
, 
Sm
ith
 
&
 
Qu
in
 
 
(20
06
) 
    Fo
rd
-
D
u
n
n
 e
t 
al
.
 
(20
06
) 
Co
n
t. 
B
rie
f g
u
id
el
in
es
 
in
 
te
xt
.
 
 B
as
ed
 o
n 
ex
pe
rt 
o
pi
n
io
n
 
fro
m
 
21
7 
pa
lli
at
iv
e 
ca
re
 c
o
n
su
lta
n
ts
 
an
d 
11
1 
di
ab
et
es
 
co
n
su
lta
nt
s 
(U
K)
 
Ty
pe
 o
f d
ia
be
te
s 
En
d 
of
 
lif
e 
st
ag
e 
N
ee
d 
fo
r 
in
di
v
id
ua
lis
ed
 
tr
ea
tm
en
t w
ith
 
gu
id
el
in
es
 
ad
jus
te
d 
ac
co
rd
in
g 
to
 
pa
tie
nt
/c
ar
er
 p
re
fe
re
n
ce
 
U
se
 o
n
ce
 d
ai
ly
 
lo
n
g-
ac
tin
g 
o
r 
tw
ic
e 
da
ily
 
in
te
rm
ed
ia
te
-
ac
tin
g 
in
su
lin
 
to
 p
re
ve
n
t h
yp
er
gl
yc
ae
m
ia
 
w
ith
 
m
in
im
u
m
 m
o
n
ito
rin
g 
an
d 
ad
ve
rs
e 
ef
fe
ct
s.
 
 O
n
e-
ha
lf 
to
 
tw
o
-
th
ird
s 
o
f t
he
 
u
su
al
 d
o
se
 o
f i
ns
u
lin
,
 
an
d 
m
o
n
ito
r 
B
G
L 
da
ily
.
 
 
W
he
n
 
pa
tie
nt
 is
 in
 
te
rm
in
al
 
ph
as
e 
an
d 
o
ra
l i
nt
ak
e 
is 
m
in
im
al
, c
ea
se
 O
H
A
 
an
d/
or
 
in
su
lin
 
an
d 
B
G
 
m
o
n
ito
rin
g.
 
It 
m
ay
 
be
 a
pp
ro
pr
ia
te
 
to
 
ch
ec
k 
B
G
L 
an
d 
ac
t a
cc
or
di
ng
ly
 
if 
pa
tie
nt
 h
as
 s
ym
pt
om
s 
o
f 
hy
pe
rg
ly
ca
em
ia
 o
r 
u
n
re
so
lv
ed
 
in
 
cl
in
ic
al
 c
on
di
tio
n
 
ch
an
ge
s.
 
 
IV
 
Ti
ce
 (2
00
6) 
     
Ta
bl
e 
pr
ov
id
es
 
de
ta
ile
d 
gu
id
el
in
es
 fo
r 
dr
ug
 
th
er
ap
y 
an
d 
bl
o
o
d 
gl
u
co
se
 
m
o
n
ito
rin
g.
 
Ty
pe
 o
f d
ia
be
te
s 
St
ab
le
 
n
u
tr
iti
o
n
al
 
st
at
u
s 
W
ei
gh
t l
os
s 
/ 
an
o
re
x
ia
 
Th
e 
go
al
 o
f t
he
ra
py
 
sh
ift
s 
fro
m
 
tig
ht
 
gl
yc
ae
m
ic
 c
o
n
tr
o
l t
o 
m
ai
n
ta
in
in
g 
co
m
fo
rt
 
an
d 
en
ha
n
ci
n
g 
qu
al
ity
 o
f l
ife
.
 
B
eg
in
 d
isc
u
ss
in
g 
an
d 
ed
u
ca
tin
g 
pa
tie
n
t a
n
d 
fa
m
ily
 
m
em
be
rs
 
St
a
bl
e 
n
u
tr
iti
o
n
a
l s
ta
tu
s:
 
m
ai
n
ta
in
 
cu
rr
en
t d
ru
g 
th
er
ap
y;
 
B
G
 
m
o
n
ito
rin
g 
ev
er
y 
3r
d  
da
y,
 
te
st
 
tw
ic
e 
a 
da
y 
pr
e 
m
ea
ls 
an
d 
as
 
re
qu
ire
d 
de
pe
nd
in
g 
o
n
 
sy
m
pt
o
m
s.
 
 
W
ei
gh
t l
o
ss
/a
n
o
re
x
ia
: 
re
du
ce
 
St
a
bl
e 
n
u
tr
iti
o
n
a
l s
ta
tu
s:
 
m
ai
n
ta
in
 
cu
rr
en
t d
ru
g 
th
er
ap
y:
 
B
G
 
m
o
n
ito
rin
g 
—
w
ee
kl
y 
fa
st
in
g 
in
iti
al
ly
,
 
ta
pe
r 
to
 
1-
2/
m
o
n
th
 
u
n
le
ss
 
sy
m
pt
o
m
at
ic
. 
W
ei
gh
t l
os
s/a
n
o
re
x
ia
: 
re
du
ce
 
IV
 
  Ta
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f k
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 p
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 p
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f l
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 o
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er
e 
pu
bl
ish
ed
 (C
o
n
tin
u
ed
).  
 _
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
_
 
M
a
n
a
gi
ng
 D
ia
be
te
s 
a
t t
he
 E
n
d 
o
f L
ife
   
   
 
 
 
 
 
Co
py
rig
ht
 2
01
0 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
46
A
ut
ho
rs
 
R
el
ev
an
t 
fa
ct
o
rs
 
in
cl
u
de
d 
Sp
ec
ifi
c 
gu
id
el
in
es
 
o
r 
re
co
m
m
en
da
tio
n
s 
 
Fo
rm
 
o
f 
gu
id
el
in
es
 
&
 
so
u
rc
e 
 
G
en
er
a
l 
Ty
pe
 
1 
Ty
pe
 
2 
Le
ve
l o
f 
ev
id
en
ce
 
Ti
ce
 (2
00
6) 
Co
n
t. 
 
B
as
ed
 o
n 
di
ab
et
es
,
 
pa
lli
at
iv
e 
ca
re
 
an
d 
ca
nc
er
 
lit
er
at
ur
e,
 
an
d 
1 
ca
se
 
st
u
dy
.
 
(C
ite
d 
Po
u
lso
n
,
 
19
97
) 
N
au
se
a 
an
d 
 
v
o
m
iti
n
g 
B
lo
o
d 
gl
u
co
se
 >
 
25
0 
m
g/
dl
 
(13
.8 
m
m
o
l/L
)  
En
d 
of
 
lif
e 
st
ag
e  
re
ga
rd
in
g 
fu
tu
re
 n
ee
d 
to
 
al
lo
w
 
bl
o
o
d 
gl
u
co
se
 to
 
ru
n
 
hi
gh
er
 
be
fo
re
 n
ee
d 
to
 c
ha
n
ge
 
m
an
ag
em
en
t. 
In
st
ru
ct
io
n
s 
fo
r 
tr
ea
tin
g 
hy
po
gl
yc
ae
m
ia
.  
in
su
lin
 
do
se
 
ba
se
d 
on
 
B
G
L.
 
 
 Co
n
sid
er
 
ch
an
gi
n
g 
to
 
in
te
rm
ed
ia
te
 a
ct
in
g 
fro
m
 
lo
n
g 
ac
tin
g 
in
su
lin
; B
G
 
m
o
n
ito
rin
g—
tw
ic
e 
da
ily
.
 
O
nc
e 
st
ab
le
 re
su
m
e 
ev
er
y 
3r
d  
da
y 
as
 
ab
ov
e.
 
N
au
se
a
 
a
n
d 
vo
m
iti
n
g:
 
ch
an
ge
 to
 
sh
o
rt
 a
ct
in
g 
in
su
lin
.
 
O
nc
e 
st
ab
le
 
ch
an
ge
 
to
 
in
te
rm
ed
ia
te
 a
ct
in
g;
 
B
G
 
m
o
n
ito
rin
g—
tw
ic
e 
da
ily
. O
n
ce
 
st
ab
le
 re
su
m
e 
ev
er
y 
3r
d  
da
y 
as
 
ab
ov
e.
 
BG
 
>
 
13
.8
 m
m
o
l/L
: 
ad
jus
t s
ho
rt 
ac
tin
g 
in
su
lin
.
 
O
n
ce
 s
ta
bl
e,
 
ch
an
ge
 
to
 
in
te
rm
ed
ia
te
 a
ct
in
g.
 
B
G
 
m
o
n
ito
rin
g—
tw
ic
e 
da
ily
. O
n
ce
 
st
ab
le
 re
su
m
e 
ev
er
y 
3r
d  
da
y 
as
 
o
ra
l m
ed
ic
at
io
n
 
do
se
 b
y 
50
%
;  
 B
G
 
m
o
n
ito
rin
g—
w
ee
kl
y 
fa
st
in
g 
x
3,
 
th
en
 
1–
2/
m
o
n
th
 
u
n
le
ss
 s
ym
pt
o
m
at
ic
.
 
 
N
au
se
a
 
a
n
d 
vo
m
iti
n
g:
 
di
sc
o
n
tin
u
e 
o
ra
l a
ge
n
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INTERVIEWS WITH PATIENTS AND CARERS 
 
Ensuring the diabetes management preferences of patients with diabetes requiring 
palliative care and the views of their family members or carers were included in the 
Guidelines was an important component of the Guideline development process.  
Significantly, a consultation report about the quality use of medicines in palliative 
care, published during the later phase of the current project, strongly supported the 
need to ask patients and carers about their expectations and concerns regarding their 
care at the end of life (National Prescribing Service Limited and Palliative Care 
Australia, 2009). However, little information about these issues with respect to 
diabetes care was identified in the literature.  Therefore, a qualitative study was 
undertaken to explore the care preferences of people with diabetes and family 
members or carers when palliative care was required. 
Aims 
The aims of collecting qualitative data from patients and family members/carers were 
to: 
• Explore the past and current experiences of patients requiring palliative care in 
relation to managing their diabetes. 
• Identify the preferences of people with diabetes requiring palliative care regarding 
how they wanted their diabetes managed at the end of life. 
• Identify the views of family members or carers of people with diabetes requiring 
palliative care about managing their loved one’s diabetes at the end of life. 
• Explore the experiences and needs of family members or carers of people with 
diabetes requiring palliative care to assist them to help the individual manage their 
diabetes and/or undertake diabetes management tasks such as managing medicines 
and monitoring blood glucose.  
 
Method 
Data were collected during individual face-to-face semi-structured interviews with 
fourteen people with diabetes requiring palliative care and ten family members/carers 
of people with diabetes requiring palliative care from a large regional palliative care 
facility.  
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Ethics approval was obtained from the Barwon Health Human Research Ethics 
Committee and written informed consent was obtained from all participants. 
The interviews were audio-recorded and transcribed verbatim after which content 
analysis was undertaken to identify key themes and issues.    
Recruitment 
Eligible participants were recruited from a large regional palliative care facility.  The 
inclusion criteria were:  
• aged older than eighteen years 
• people with diabetes requiring palliative care services in stable, unstable, and 
deteriorating PCOC phases 
• family members/carers of people with diabetes receiving palliative care or who 
required  palliative care in the past 
• able to converse in English.  The researchers acknowledge that people who were 
not able to converse in English could have different points of view and needs, but 
felt having an interpreter present was not feasible and could inhibit discussion 
given the sensitivity of the topic and the vulnerability of the participants. 
 
People with diabetes requiring palliative care services and their family 
members/carers were invited to participate in the research project by palliative health 
professionals employed in various clinical palliative care locations within Barwon 
Health.  The research team provided these health professionals with information and 
education about the study and the recruitment procedure at the commencement of the 
study.  Where appropriate, palliative health professionals initiated a conversation with 
the patient and/or family member/carers to determine their interest in participating in 
an individual interview to explore their experiences of and their diabetes management 
preferences at the end of life.  
 
Palliative care staff provided patients and family members or carers who expressed an 
interest in participating with an information package consisting of a participant 
information document, consent form, researcher contact details and a reply paid 
envelope.  The patient and family member/carer were asked to mail the completed 
contact details form to the researchers’ office after which the researcher contacted the 
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patient and/or family members to explain the research project, what participation 
would involve, and schedule a time for the interview.  
 
The initial response to the recruitment procedure was low.  In order to facilitate 
recruitment, the research team submitted an ethics amendment to enable the 
researcher to contact potential participants by telephone after the palliative care health 
professional had given them the information package.  The amendment was approved, 
which enabled the researcher to provide a more comprehensive explanation of the 
research aims and explain what participation involved, which enhanced participation. 
Procedure  
The study was conducted between March and September 2009.  Fourteen patient 
interviews and ten family member/carer interviews were conducted in that six-month 
period.  These people lived in Geelong and surrounding rural areas.  The same 
researcher conducted all the interviews.  Participants were provided with a Participant 
Information and Consent Form prior to the interview and the researcher clarified any 
questions before commencing the interviews.  The interviews were tape recorded with 
participant’s consent and were guided by a series of questions relevant to the Guiding 
Principles and informed by the literature review (see appendices A and B). 
 
Most participants preferred to be interviewed in their homes; however, one interview 
was conducted in a hospice and one in a palliative care unit.  The researcher 
established rapport with the patient and family member/carer and was considerate of 
the participant’s condition and ability to be interviewed.  For example, being 
cognisant of signs of fatigue, pain or emotional distress.  Family member/carer 
interviews were either conducted following the patient’s interview or scheduled for a 
future convenient date/location.  On three occasions, patients rescheduled their 
interviews due to deterioration in their condition, symptom issues or because of an 
unforseen appointment for a medical intervention.  However, all participants who 
needed to reschedule the interview indicated they wanted to participate at another 
time.  The researcher remained in contact with the patient and family member/carer 
and considered the appropriateness of arranging another interview time.    
 
During the interviews the patients were asked about their past and present diabetes  
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management and their diabetes management preferences as their condition changed.  
The family members/carers were asked about their perceptions of the impact diabetes 
had on the patient’s comfort and lifestyle and the role they had played in assisting the 
patient to manage their diabetes in the past and currently, during the patient’s life 
limiting illness.  The researcher referred to the questions throughout the interviews 
(see appendices A and B) when interviewing both patients and family members/carers 
and encouraged the participants to provide as much detail about their diabetes 
management as possible.  The duration of the interviews ranged from 35 to 90 
minutes.  
 
Detailed field notes were compiled during and at the completion of each interview to 
capture non-verbal language and to note the researcher’s assumptions about and 
interpretation of the information presented (reflexivity).  These field notes and the 
interview transcripts were discussed with the other researchers to note emerging 
themes, inform subsequent interviews and to reduce researcher bias. 
Data Analysis  
The interviews were tape-recorded and transcribed verbatim.  Two researchers 
listened to the interviews several times, separately and then met to discuss their 
interpretation of the data and reach consensus about the content.  The interview data 
were collated and presented on a computer disk and in written form.  Content analysis 
of the data was undertaken using the Ritchie and Spencer Framework method (1994) 
to identify key themes.  The framework method comprises five stages: 
- Becoming familiar with the data—the researchers immerse themselves in the 
transcripts and notes from the interviews and list key ideas and emerging 
recurrent themes. 
- Identifying a thematic framework—identifying all the issues, concepts and 
themes by which the data can be examined and referenced. 
- Indexing—applying the index or thematic framework systematically to the 
data by annotating the transcripts with codes. 
- Charting—rearranging the data according to the appropriate part of the 
thematic framework to which they relate, and forming charts. 
- Mapping and interpreting the data—using the charts to define concepts and 
map the range and nature of phenomena and find associations among themes 
(Pope, Ziebland & Mays, 2000). 
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The results of the data analysis from the interviews conducted with patients are 
presented first, followed by the results of the interviews conducted with family 
members or carers. 
 
Results 1:  Interviews with people with diabetes 
Participant Characteristics  
Fourteen people with diabetes requiring palliative care services were interviewed.  As 
Table 3 (page 52) demonstrates, participants were aged between 58 and 84 years.  
Twelve people had type 2 diabetes and two had type 1 diabetes.  The majority had a 
principal diagnosis of cancer and several comorbidities; only one person had a non-
malignant life limiting illness (see Table 3 on the next page).   
 
Table 4 on page 53 presents participant demographic data.  Eleven people were male 
and three were female.  Ten were married and indicated they relied on the help of a 
carer; three patients indicated they were divorced/widowed and had no significant 
carer.  Significantly, twelve people were receiving care at home; only two people   
resided in a health care facility.  
 
Ten of the fourteen people with diabetes requiring palliative care services indicated 
there were no significant issues affecting their ability to continue to manage their 
diabetes independently at the time of the interview; however, four acknowledged their 
ability to self-manage their diabetes was declining: three of the four cited vision 
deficits and one cited dexterity deficits as the main reasons for their declining self-
care ability. 
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Table 3.   Principal diagnosis and comorbidities of people with diabetes receiving 
palliative care who participated in the interviews (n = 14).  
 
Age Diagnosis Type of 
diabetes 
Comorbidities 
 
58 Metastatic 
Neuroendocrine  
Carcinoma 
type 2 Depression 
Hypertension 
Encephalopathy 
58 Advanced oesophageal 
cancer with pulmonary 
metastases. 
type 2 Dysphagia 
Anxiety 
Depression 
60 Pancreatic cancer type 2 Not stated 
60 Metastatic breast cancer type 1 Osteoarthritis 
Asthma 
Eczema 
Cervical spondylosis 
Right mastectomy 
62 Metastatic breast cancer type 2  Non-alcoholic steatohepititis 
Oesophageal varices 
Uterine fibroids 
Large bowel obstruction 
65 Bowel cancer type 2 Hypertension 
67 Squamous cell tongue type 1 Cirrhosis of liver 
Chronic Pancreatitis 
Malnutrition 
Chronic obstructive airways disease 
Nephrolithotomy 
74 Lung cancer type 2 Hypertension 
Chronic obstructive pulmonary disease 
Depression 
78 Lung cancer type 2 
 
Hypertension 
Hyperlipidemia 
78 Pancreatic cancer type 2 Ischaemic heart disease 
Irritable bowel syndrome 
Chronic back pain 
Macular degeneration  
79 Metastatic colo-rectal cancer type 2 Hearing/vision deficits 
81 Malignant thoracic 
mesothelioma 
type 2 Gastro oesophageal reflux disease 
Percutaneous transluminal coronary 
angioplasty     
Ischaemic heart disease 
Obesity  
Gout 
83 End stage congestive cardiac 
failure 
type 2 Gout 
Chronic renal impairment 
84 Adenocarcinoma of the 
lower oesophageus  
 
type 2 Hypertension 
Depression/anxiety 
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Table 4.  Demographic data of people with diabetes requiring palliative care who 
participated in the interviews (n = 14). 
 
Age Gender Marital status Residential location Advanced 
Care 
Directive  
58 Female Married Home Not stated 
58 Male Married Home Yes 
60 Male Divorced/widowed  Home Not stated  
60 Female Divorced/widowed Home No 
62 Female Married Home Yes 
65 Male Married Home No 
67 Male Divorced Hospice  Not stated  
74 Male Married Home  Not stated  
78 Male Married Home  Not stated  
78 Male Married Home No 
79 Male Divorced/widowed Palliative care unit  No 
81 Male Married Home No 
83 Male Married Home No 
84 Male Married Home  No 
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Key Themes 
Five key themes were identified: 
1. living with diabetes 
2. the way health professionals manage diabetes 
3. the interaction between diabetes and other illnesses 
4. managing diabetes when the patient is very ill 
5. plans for the future. 
 
In addition, participants suggested information they felt should be included in the 
Guidelines.  Quotes from participants are presented in italics with the interview 
number in parentheses.  
Living with diabetes 
The main issues emerging from the interviews with people with diabetes about living 
with diabetes at the end of life was ambivalence about how big an impact diabetes 
has, an accepting attitude towards having diabetes, and the substantial impact of 
hypoglycaemia and hyperglycaemia on wellbeing and quality of life, and well being 
and quality of life generally.  These sub-themes are grouped under the headings of: 
- it’s no big deal—or is it?  
- you just have to live with it  
- the impact of hypoglycaemia and hyperglycaemia.  
 
It’s no big deal—or is it?   
Nine of the fourteen participants commented that diabetes did not have a big effect 
when they were first diagnosed; but seven of the nine commented about the changes 
the diagnosis of diabetes caused in their lives, which represented a major impact on 
the lives of some participants.  Not surprisingly, the main changes participants 
described related to what they could eat and drink followed by changes in lifestyle 
and activities.  
 
Three participants who indicated having diabetes did not affect them much in general 
commented:  
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It doesn’t seem to bother me … as long as I keep my [blood glucose] in 
range…it doesn’t bother me  ……  …Oh, I had to go on a diet…a food 
diet…you know…and go on the medication, and everything just seemed to fall 
into place.  (P 5) 
 
Well diabetes itself … it’s never been a big problem for me.  (P 6) 
 
[Effect of diabetes] Not a terrible lot … no … not a terrible lot … no … not 
much at all.  (P 13) 
 
In contrast, participants who indicated diabetes had a big impact on their lives 
commented: 
 
…and it [diabetes] certainly has a lot to do with the pain in my feet … I get 
very painful feet and ankles … really painful … if they [nurses] lift my feet up 
…awww I go through the roof … but if they handle me by the heel I’m alright 
… if they grab me but the ankles ohhhh, … talk about hurt.  (P 8) 
 
…buggered me up actually … I had to be at a certain place at a certain time 
… I had to know where my needle was … in the end I had one in the car and 
one where I sit at night times … evenings … amongst the table in other words 
… yeah its stuck in my head trying to think of this other bloody needle.  (P 4) 
 
Two other participants, who initially indicated that diabetes did not affect them much, 
later commented on the significant ways it had affected them.  Pairs of quotes from 
some of these participants included: 
 
It obviously still affects what I eat … what I can and can’t eat … but I don’t 
feel that it affects me in any way.  (P 3) 
 
Well it does it affects what you eat … obviously you can’t drink [alcohol] … 
well you can, but it’s wiser not too … yeah it affects a lot of your life … it 
would be easier if I didn’t have it.  (P 3) 
And 
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Basically … I did the exercise I took the pills … I tried to restrain the diet … 
otherwise it didn’t really affect my life at all … (P 11) 
 
…there was a constant battle to get the hyper down or the actual blood 
readings below 10 … I mean you really had to be very strict to get it down 
below 8.  (P 11) 
 
You just have to live with it 
Participants generally accepted the diagnosis of diabetes and the self-care tasks they 
needed to undertake to manage it.  Only one participant commented about how much 
he disliked pricking his finger to check his blood glucose and that he also hated ‘the 
needle’ (insulin).  For example, participants who accepted the diabetes self-care tasks 
commented:  
 
Well its just something I have to do … I think you’ve got to be pragmatic about 
these things and its something you have to do … its just what you do.  (P 3) 
 
No, I might be one of them queer buggers but I never worry about things…you 
know…if it’s there it’s there…so you accept it.  (P 5) 
 
Well you’ve just got to wear it … not much you can do about it … as I say if 
the researchers come up with something brilliant … I’d be the first to applaud 
and use their new system …but until that happy day, we’re stuck with the 
finger prick and the pills.  (P 12) 
 
Get it [blood glucose testing, insulin] over and done with and that’s it.  (P 14) 
 
The impact of hypoglycaemia and hyperglycaemia 
The effects of hypoglycaemia and hyperglycaemia emerged as an important theme 
from the interview data.  The sub-themes identified were that both states are very 
unpleasant but the symptoms and effects varied among individuals: that is, 
participants tried to avoid blood glucose levels in the high or low ranges; and with 
time, participants believed they knew when a hypoglycaemic or hyperglycaemic event 
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was imminent or had started because of the symptoms they experienced (listened to 
body cues).  
 
How it feels.  Ten participants vividly described what it feels like to ‘have a hypo’      
(hypoglycaemia) or hyperglycaemia and stressed how unpleasant these states and the 
accompanying symptoms and emotional effects were.  The symptoms of hypo/ 
hyperglycaemia participants experienced varied among individuals, but, by listening 
to their body cues and testing their blood glucose, they were able to accurately 
recognise high or low blood glucose levels, as the following quotes illustrate:  
 
The lips went numb and … I got the shakes … that was before … I’d realised 
what I’d got [hypoglycaemia] …. And I went back to bed again and the next 
minute I found myself on the floor and I don’t know … I wouldn’t have a clue 
how I got there … on the floor.  (P 5) 
 
[Hypoglycaemia] I would go to put my foot to the floor and it would be 
jumping and shaking and my son would be saying ‘mum, test your sugars 
[glucose]’. (P 9) 
 
[When the blood glucose is high]  Yes it makes you feel terrible, to me if its 
above 12 you start to feel itchy, ants crawl all over your face … and a little bit 
dizzy … and the vision gets a little bit impaired, its terrible. (P 6) 
 
 
Participants dreaded hypoglycaemia or hyperglycaemia and the symptoms and 
described them as something to avoid.  Participants described how frightening 
hypoglycaemia and hyperglycaemia were and were keen to avoid further episodes: 
 
Well it did frighten me, I’ll admit it [hypoglycaemia]. I never want to feel that 
way.  (P 5) 
 
Yeah …  two tests a day … yeah … I didn’t want that [hypo] to happen again. 
(P 12) 
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Warning signs.    Participants did not always recognise the cause of hypo/ 
hyperglycaemia symptoms the first time they experienced them, but with time, by 
listening to body cues and experiencing these states, most were able to recognise the 
warning signs.  Listening to body cues and blood glucose testing enabled participants 
to appropriately manage the episode.  For example: 
 
… and then with the years going by through those things [symptoms] I 
managed to discover that if I feel that sensation of ants crawling and that, I 
knew that the blood sugar level is high and if I felt faint that it is too low.  (P 
6) 
 
Whenever I have a low I get dizzy I act quickly, and take something … sweet 
biscuit, a glass of coke ….  (P 8) 
 
She’ll [wife]  be able to tell if I’m about to have a hypo ’cause she said I get 
this vacant look in my eyes .  (P 9) 
 
Now I understand them [ hypos] I can keep them off before they get serious… I 
can feel my sugars getting low … I’ll get shaky if I get below 4 … or if I get 
above 12 then … I start to sweat … so it’s a matter of learning which way 
you’re going, I think.  (P 13) 
 
The way health professionals manage diabetes 
Participants had mixed views about health professionals’ approach to diabetes 
management.  The sub-themes emerging from the data reflected negative experiences 
with health professionals particularly in acute care settings, but experiences with 
specialist health care professionals were more positive. Many also felt health 
professionals did not treat the whole person by acknowledging the importance of 
diabetes and did not listen to the patient.  These sub-themes are grouped under the 
headings of: 
- they bugger it up 
- positive experiences 
- listen to the patient. 
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They bugger it up 
A number of participants described negative experiences with health professionals 
whilst in an acute care setting, and suggested diabetes was not given enough attention 
when they were admitted for other illnesses.  Problems managing medicines and 
appropriate food for people with diabetes were discussed: 
 
You sort of find you keep stable and it’s good, stable [blood glucose] but when 
you go into hospital its erratic cause they bugger it up…  It’s really 
frustrating; I joke with [husband] and say oh well here we go back into 
hospital bloody sugars will be up the tree.  (P 1)  
 
…that’s the only thing I would say that it’s [diabetes] not given as high a 
priority probably as it should be … I think they should be made very aware of 
the diabetes … … we all should be confident knowing that you come into 
hospital and that you’re unwell but that the diabetes will not be forgotten and 
that you don’t have to worry about it … that the kitchen is aware, the staff are 
aware …. (P 3) 
 
But they messed me up [blood glucose] in hospital … they had me taking little 
bits of this and little bits of that [insulin ‘top up’ doses].  (P 8) 
 
They treated the diabetes like it wasn’t a part of me…but then that’s what they 
do … they’re looking at the illness [cancer], not the person … and it’s 
[diabetes] a big part of me.  (P 9) 
 
Positive experiences    
However, participants also described more positive experiences with health 
professionals in acute care, most of which occurred when specialists, particularly 
diabetes specialists, were involved in their care:  
 
 
… and the endocrinologist was a great help, he was very good indeed … so it 
didn’t take me [long] … it took me about a month I suppose to get stabilised 
again.  (P 3) 
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They had a diabetes educator in there who helped me a lot and I stayed in 
hospital for a week because I went through the thing of having the big fluid 
drop [intravenous infusion] or whatever it is … … and I was right then.  (P 9) 
 
… because we came to an agreement that while I was outside, doing my 
lifestyle stuff he’d [specialist] knew I’d play up [not adhere to advice] but when 
I go to hospital that’s when he [diabetes specialist] I had to put up with …[I 
had to] take his line … and we’ve been together for about 13 years … a happy 
little couple. [P 10] 
 
Other specialists also received praise, for example: 
 
Once it [blood glucose] was up and [Palliative care nurse] was on the 
ball….she said ‘you need to be seen’….you know ‘we need to do something 
about this’… she’s on the ball [palliative care nurse]. (P 1)  
 
  
Listen to the patient    
Seven participants stated that health professionals should listen to what the person 
with diabetes tells them and consider the person as a whole.  Many participants were 
frustrated that most health professionals did not seem to listen or acknowledge their 
diabetes expertise: 
 
Well I would like to think that people would listen to what I’m saying from my, 
from what my body’s experiencing….I think that’s important… my body tells 
me that I, I don’t need to take that much insulin or I need more insulin and I 
adjust accordingly.  (P 2) 
 
Well I would expect the nurse to come in and see me … to see the person, to 
see what they’ve [the patient] been doing such and such at home and to listen 
to them …. (P 7) 
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What happened to me at the [hospital] was they treated the diabetes like it 
wasn’t a part of me … but then that’s what they do … they’re looking at the 
illness, not the person.  (P 9) 
 
One participant commented that there should be more communication among 
different health professional disciplines.  The participant was particularly referring to 
communication between health professionals treating cancer and those managing 
diabetes. 
 
…there should be a little bit of communication between the diabetes side and the 
cancer side … about what is the best diet to have …  that actually joins the two 
together … the diabetes and the cancer side should get together to actually talk to the 
dietician … and come up with a menu or a diet they see suits both sides … (P 11) 
 
The interaction between diabetes and other illnesses 
An important theme emerging from the data was people with diabetes were aware of 
the effect other illnesses had on their blood glucose and consequently, their diabetes 
management.  Twelve of the fourteen patients interviewed commented that their other 
illness or illnesses affected their blood glucose levels and required changes to their 
usual diabetes management regimens.  They noted it was more difficult to keep the 
blood glucose levels in an acceptable range when they were ill. 
 
Participants described how treatments and medicines prescribed for their other illness 
caused ‘problems with their diabetes’, and how the symptoms associated with their 
other illness complicated their diabetes management.  For example, chemotherapy 
caused problems such as nausea, vomiting and hyperglycaemia; and diminished 
appetite could cause hypoglycaemia and affect their diabetes medicines regimen. 
  
Chemotherapy.   Four participants described the problems they experienced managing 
their diabetes as a result of having chemotherapy for their other illness.  
 
When I first had chemotherapy … they put me in hospital two days before I 
would have normally would have gone in so that they could set themselves up 
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and … gauge how the effect would be on my blood sugars.  So that cost me 
about three days in hospital.  (P 10) 
 
After chemo the blood sugar levels go out of sight … I mean out of control … 
we had levels at one stage up to 27 … I was still alive and lucid … that was in 
the evening and the next morning it was down to 2.4 … so … in that period 
initially after chemo … say for four days it’s irregular … but then it’s alright. 
(P 11) 
 
Medicines required to treat their other illnesses also caused problems. 
 
Other medicines and diabetes.   Participants described how some medicines 
prescribed for their other illness affected their blood glucose levels and diabetes 
management, in particular, some participants mentioned corticosteroids such as 
prednisolone: 
 
Some of the drugs they give you for palliative care, they interfere with the 
blood sugar.  It’s a complicated subject isn’t it?  (P 8)  
 
Diabetics can’t take prednisolone, that’s all there is to it.  (P 9) 
 
Symptoms of the other illness.   Some participants said the symptoms associated with 
their other illness affected their blood glucose levels and their ability to manage their 
diabetes.  Most notably vomiting, nausea and a reduced appetite affected their blood 
glucose levels: 
 
But because of the location of the stent umm [patient had a gastrointestinal 
stent], until such time as, umm I can get my eating regiment together umm, 
I’ve been vomiting on a regular basis … I’ve therefore desisted from injecting  
[insulin].  (P 2) 
 
Diabetes management was affected by the medicines and interventions required for 
the person’s life limiting illness and diabetes management required significant 
alterations.    
 
 _______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
66 
Changes in diabetes management.   Changes in diabetes medicines were usually 
needed, sometimes frequently, because of the impact of other illnesses and their 
management, on blood glucose levels.  Participants described complex adjustments to 
their medicine regimens.  It should be noted that people with diabetes using insulin 
often adjust their own insulin doses.  The first and third of the following three 
comments represent health professional participants who had diabetes and were 
receiving palliative care:  
 
When I was having chemo…the three days I was having chemo they [doctors] 
wanted me to have 20 units in the morning and 10 units at night because of the 
dexamethasone.  But obviously I won’t be doing that now because with this 
oral chemo I’m not having steroids so I assume that’s right - I don’t take the 
evening insulin its alright my sugars are alright. It was three yesterday in the 
morning and five today.  (P 1) 
 
…  umm, initially It was via oral medication, umm, but its advanced now to the 
stage that I’m on two different types of insulin, but that’s only been the 
occasion, ahh well first of all, only I would say 12 months ago, I was 
introduced to Lantus, which is, from my understanding a long – sorry a 24 
hour acting, has a 24 hour action and recently, since my last hospitalisation, 
I’ve been put on novorapid, which is a quick acting, umm insulin. (P 2)  
 
Well six or seven [blood glucose level] I think if I can, when I was having the 
chemotherapy [specialist] said he wasn’t concerned about it if it went into the 
low teens … I used a bit more Novorapid then … I tried to keep up with it but 
it is a bit hard to do … the Novorapid worked quite well ... When you needed it 
… so I’d bump the Lantus up … to a total of 28 to 30 [units].  (P 7)  
 
These comments also demonstrate that people with diabetes acquire considerable 
expertise in managing their diabetes and insight into their disease.  Significantly, the 
relationship between diabetes and their other illness was extremely complex for some 
participants, including those participants accustomed to adjusting their medicines. 
 
What’s what?   Four participants described the inter-relatedness between diabetes and  
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other illnesses, three of these participants discussed their experiences and one 
suggested some health professionals may have difficulty understanding the cause of 
the symptoms if they do not test blood glucose levels regularly.  For example: 
 
But they think I am an unusual case because the tumour began on my pancreas 
… so they think …what came first the diabetes or the tumour, we don’t know 
and I was diagnosed straight away as a type 1. (P 3) 
 
… but when I started with the cancer [treatment] and just before my cancer 
[diagnosis], because we thought [why isn’t the medicine working] … 
autonomic nerve disorder or something else but [the doctors] found out it was 
the cancer … 
 
One participant found it difficult to distinguish the symptoms of hyperglycaemia from 
cancer-related symptoms: 
 
It’s hard to say what causes all the symptoms I’ve got.  I don’t know what’s 
what. I don’t know which is diabetes and which is this cancer or what. I don’t 
know.   (P 14) 
 
Most participants found the effects of their other illness made managing diabetes 
more difficult, but two participants found their blood glucose levels were lower 
because they lost weight as a result of the other illness and their diabetes was, in fact, 
better controlled.  
 
Managing diabetes when the patient is very ill 
Participants were clear about how they would like their diabetes managed, whether 
they wanted active management, and who should provide diabetes care if they were 
too unwell to undertake self-care.  Responses about diabetes management were coded 
according to how active participants wanted their diabetes management to be.  The 
sub-themes identified were not mutually exclusive, although the majority of 
participants were generally aligned with either an active or a less active approach to 
managing their diabetes.  The sub-themes identified were: 
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- actively managing diabetes  
- the middle ground 
- no active management  
- who should decide? 
 
Actively managing diabetes  
Ten of the 14 participants indicated diabetes should be actively managed at the end of 
life: two of these mentioned the need to consider diabetes as a cause of symptoms, 
four indicated it was important to continue managing diabetes to make the person 
comfortable, and four indicated their existing diabetes management should be 
continued.  
 
Consider diabetes as a cause of symptoms.  Two participants indicated health 
professionals should be aware that symptoms could be related to the patient’s 
diabetes, which suggests an active approach to managing diabetes that includes blood 
glucose monitoring to assess the impact of illness on metabolic control whenever the 
patient is unwell.   
  
Yes they [health professional’s] should be aware [of the impact of diabetes] 
because it can easily get confused with other symptoms so whether people 
could have a hypo … be prepared to do a [blood glucose] test whenever … you 
know if the person’s not feeling well …to diagnose what’s gone wrong.  (P 3) 
 
Maintain comfort.  Participants stressed the importance of identifying and 
preventing/managing the unpleasant symptoms associated with hypoglycaemia and 
hyperglycaemia.  For example:  
 
I can’t imagine if you are dying and you’ve got a blood sugar of 30 and no 
one’s treating it, I can’t sort of accept that, I mean you don’t want to go on 
with endless care … but I think I would like to feel comfortable.  (P 1) 
 
Oh, yeah, I would prefer to be monitored just to make sure. I don’t want 
another of them hypos again.   (P 5) 
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Leave everything alone.  Four participants wanted to continue their existing diabetes 
management regimen in the last palliative care phases (active management).  One 
person said:  
 
And provided …the monitoring stays reasonable … leave everything alone … 
like I said before if it ain’t broke don’t fix it.  (P 11) 
 
I don’t know how you could improve it any.  The present set up is pretty good.  
(P 13) 
 
The middle ground 
Five of the 14 participants took the ‘middle ground’.  They wanted their diabetes 
managed when they were very ill, but suggested management could be less rigorous, 
for example accept a wider blood glucose range, and perform blood glucose 
monitoring less frequently.  Two other participants suggested they wanted active 
management, two participants did not want active management, and one participant 
wanted both active and no active management depending on the likely outcome of the 
episode.  Comments included: 
 
… and they want me to eat and then they send you that other gruel to eat cause 
you’re diabetic … it’s not worth it … what’s more important, eating [and] 
putting four to five kilos on, maybe having a little more adjustment to the 
insulin and that will affect my eyes … neuropathy and all this type of thing but 
who cares …. (P 10) 
 
Yes, and if his [blood glucose level] is 24 well that’s a different story … well 
he needs insulin … if it’s in the low teens just don’t get too excited about it.  (P 
7) 
 
No active management  
Three participants explicitly stated that, in certain circumstances, they would not want 
their diabetes management to continue.  The circumstances included if they were 
unconscious and when death was imminent. 
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If I am unconscious.  Three participants indicated that they would not want anything 
done to manage their diabetes if they are unconscious or ‘non-compos’ for example: 
 
I would see no point to tight glycaemic control … the focus should be on 
making life as comfortable as possible… no I couldn’t see the point [of tight 
control]… maybe because I’m almost 70 I feel like that but, and maybe 
because I’ve had the experiences I’ve had … I wouldn’t see the point to it 
really … and then if I’m unconscious, well don’t do anything ….  (P 9)  
 
... but when you get to the non-compos stage I don’t think it matters.  (P 7) 
 
If I am on the way out.  Two participants also suggested when they are in the process 
of dying they would not care whether their diabetes was managed or not: 
 
I would just think ‘if you have to give me some insulin, give me eight units’.  I 
don’t know what … but why bother and go through all that … even though it’s 
[diabetes] a large part of me ... I wouldn’t want it to be the dominating factor 
if I’m heading out the door.  (P 9) 
 
Who should decide? 
Eleven participants indicated either health professionals or family members/carers 
could make the management decisions if they were very ill and dying. 
 
Health professionals and family/carers.   Most of these eleven participants suggested 
health professionals and family members or carers could jointly make decisions for 
them.   
 
I’ll just leave that with [specialist] and X, my wife. (P 10) 
 
Only three participants suggested only health professionals should decide, for 
example: 
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Well I say you’ve got to trust the doctors and that. Well, … I haven’t been to 
bloody university or anything like that to know exactly what’s going on …so 
let’s go with the professionals.  (P 4) 
 
Other participants wanted to be involved in decision-making. 
 
Listen to me.   Seven participants explicitly stated they wanted to have a say in how 
their diabetes was managed when they are very ill, or at least to have their wishes 
respected.  Some explained why they should be listened to, but acknowledged the 
important role of health professionals: 
 
Well I’d like them [health professionals] to respect ummm, my thoughts. I’m 
obviously guided by professionals but umm, I think that given that I’ve been a 
diabetic for three and a half years, and …  I’ve experienced the progression of 
the diabetes that, I’d like to think that …my thoughts would be respected. (P 2) 
 
I would like to have a say (P 6) 
 
Planning for the future 
All participants were asked about their plans for diabetes management when their 
condition deteriorated; nine were specifically asked about Advanced Care Directives 
and they all said they had not thought about these issues or completed Advanced Care 
Plans regarding their diabetes management.  For example: 
 
I’ve never really thought about it … (P 11) 
 
Only one participant indicated she had prepared an Advanced Care Directive that 
included her diabetes management preferences for the future: 
 
You would put it in your Advanced Care Plan, we’ve done that, umm and let 
everyone know your feelings...you know so your doctors that are all looking 
after your [husband] know what you want… (P 1) 
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This participant elaborated on why she felt it was s important to ensure her diabetes 
management preferences are known: 
 
And with the diabetes perhaps the health care professional has not had 
diabetes so doesn’t know what the feeling of hyperglycaemia is like.  (P 1) 
 
One other participant said he was thinking about ‘something like an advanced plan’ 
and one was interested in the idea and indicated she would like to ‘do something like 
that’ and asked the researcher where to find out more about Advanced Care 
Directives. 
Patient participants’ suggestions for the Guidelines 
Participants were asked whether they had any had suggestions about what to include 
in the Guidelines for managing diabetes at the end of life.  Three participants 
suggested health professionals need to be more aware of diabetes when developing 
palliative care management plans, two participants suggested people’s needs should 
be considered individually, and two suggested health professionals need to listen to 
the patient. One participant suggested including diabetes management preferences in 
Advanced Care Directives.   
 
Participants indicated information about food and new advances in diabetes 
management should be included in the Guidelines and they welcomed the idea of 
Guidelines for managing diabetes at the end of life ‘it is a good idea to get the 
knowledge together.’ 
 
Participants who suggested that health professionals should be ‘more aware of 
diabetes’ commented:  
 
I mean I think they [health professionals] should be made very aware of the 
diabetes … I don’t think that sometimes they’re aware enough and they should 
be.  (P 3)  
 
The ordinary nursing staff, who are very good, are given a little bit more 
familiarity with what’s in those tubes [intravenous tubes] and what/how 
they[the person with diabetes]  react … if the patient’s asleep he might be 
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hypo … or the other, … so I think a little bit broader education … on the 
diabetes side, the patient might not be well enough to have his insulin or eat 
his meal….  (P 7) 
 
Participants also stressed the need to consider each person individually: 
 
Umm, not really, I’m quite happy that each case has got to be considered on 
its individual merits having regard to whatever the diagnosis or the prognosis 
is.    (P 2) 
 
Other participants wanted to make sure health professionals using the Guidelines 
would listen to what the patient with diabetes said: 
 
Well see, one of the things I was going crook about was how the team at the 
hospital didn’t take any notice of what I [said] … (P 9) 
 
The participant who already had prepared an Advanced Care Directive suggested the 
diabetes management Guidelines could be included in the Directive.  It appeared that 
this participant was prompted to include diabetes in her Advanced Care Directive by 
the invitation to take part in the current research: 
 
I would like to see it as the Advanced Care Directive, possibly it could be 
included because I don’t think you would routinely include that [diabetes 
management preferences] it’s only that I have diabetes and I knew about your 
research otherwise that would never have come up (P 1) 
 
The following comment from one participant who liked the idea of putting all the 
information together concludes this section: 
 
I think it’s a good idea to get something like that [the Guidelines] organised … 
because I think before [there] hadn’t been enough knowledge of what care you 
can get and what is available … I think it is a great idea …  (P 13) 
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Results 2:  Interviews with family members/carers 
Participant Characteristics 
Ten family members of people with diabetes receiving palliative care were 
interviewed.  As Table 5 on the next page demonstrates, eight participants were 
female and two were male.  All were spouses of a person with diabetes receiving 
palliative care.  Two participants’ spouses had died: one died prior to the study and 
one patient had participated in an interview and died before the study was completed.  
Eight participants were caring for their ill spouse at home at the time of the interview.  
In order to reduce the stress and keep the interviews focused on the topic (caring for a 
dying family member) the interviewer did not ask personal details such as age but all 
participants were of a similar age to their spouses whose ages ranged between 58 and 
84 years.  
 
The duration of the semi-structured interviews ranged from approximately thirty 
minutes to one and a half hours.  As with the patient interviews, the same researcher 
conducted all family member/carer interviews.  On nine occasions the researcher had 
met the family members/carers prior to the patient’s interview, which provided a 
valuable opportunity to build rapport and discuss the family member’s/carer’s 
involvement in the project, and for the researcher to respond to any questions about 
the study from family members/carers. 
 
All the family member/carers were willing to participate in the research and were 
eager to describe their experiences and their perceptions of the effect diabetes has or 
had on their spouse and the subsequent effects on themselves.  Family members/carers 
described their spouse’s diabetes management before the diagnosis of their life 
limiting illness and the subsequent changes to their spouse’s diabetes management as 
a result of the life limiting illness including medicines, functional decline, loss of 
motivation, and depression. 
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Table 5.  Relevant information about family members/carers of people with 
diabetes receiving palliative care who participated in the interviews  
(n = 10).   
 
Gender Relationship to 
patient 
Duration of patient’s 
diabetes 
Patient’s  
residence 
Female Wife (married 55 
years) 
25 years Home 
Female Wife 19 years Home 
Female Wife 19 years Palliative care unit 
Female Wife  2–3 years  Deceased 
(Patient not interviewed) 
Male  Husband 20 years Deceased  
(Patient interviewed)  
Male Husband 2 years  Palliative care unit 
Female Wife 11 years Home 
Female Wife 40 years Home 
Female Wife 20 years Home 
Female Wife 3 years  Home 
 
 
 
 
However, some family members/carers indicated they were uncertain and confused 
about their spouse’s future diabetes management when death was days away.  Their 
concerns were related to the care their spouse received from health professionals, for 
example the possibility that medicines and blood glucose monitoring would be 
ceased, or their spouse would commence insulin.  Family members/carers also 
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expressed concerns about how they would manage their spouses’ diabetes, for 
example managing hypoglycaemia and hyperglycaemia and performing ‘technical’ 
tasks such as ‘finger pricking’ and administering insulin they had not previously 
performed.  
 
Family members/carers described very personal experiences at an extremely 
emotional time as their loved one neared death.  Significantly, five key themes 
emerged from the interviews.   
       
Key Themes 
The five key themes that emerged from the interviews with family members/carers 
were:  
1. the effects of diabetes on partner and self  
2. witnessing distress/being distressed (distress caused by hypo/hyper/medicines) 
3. increasing burden of care  
4. recognising ‘I’m out of my depth—I need help’ 
5. being uncertain about diabetes management when spouse neared the end of life. 
 
These themes are discussed in the following section and illustrated using quotes from 
participants, which are presented in italics with the interview number in parentheses.  
In addition, family members/carers suggested some information they would like 
included in the guidelines.   
 
Effects of diabetes on partner and self  
Family members/carers of people with diabetes described varying effects of diabetes 
on their spouse and themselves.  Participants explained the effects of diabetes on their 
spouses and themselves at the time diabetes was first of diagnosed, the processes 
involved in adjusting to diabetes, and the escalating effects of diabetes in light of the 
life limiting illness.  These sub-themes are grouped under the headings of: 
- diabetes at diagnosis 
- adjusting to life with diabetes. 
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Diabetes at diagnosis  
Seven of the ten family members/carers described the effect of diabetes on their 
spouse and themselves at diagnosis as being minimal; however, five of the seven 
described some significant issues that suggested otherwise.  For example, the 
difficulty of managing ‘dietary restrictions’: 
 
Nothing really … the only thing is … for a start off he … I couldn’t get him to 
understand that dieting would have helped …(C 9) 
  
Well it’s [diabetes] made him think a lot more about what he eats … that’s the 
main thing …(C 10) 
 
For another participant, the complexity of managing a spouse’s diabetes who was a 
shift worker was an issue: 
 
The major impact would be …taking adequate food at the appropriate time … 
having access to the proper food. (C 5) 
    
Two participants described significant behaviour changes and physical effects on their 
spouse resulting from the diagnosis of diabetes. 
 
Well when he found out he had diabetes, he was very aggressive … and he 
couldn’t adjust to the eating habits, and … It’s hard to explain … because he 
really didn’t, couldn’t realise how serious diabetes is …(C 2) 
 
He had a lot of intercurrent infections, and was often very tired and so when 
he was diagnosed it sort of all fitted into place … he was just having these 
ongoing sort of colds and cold sores and he was overweight and he was 
feeling tired and … passing all the urine …  (C 7) 
 
Two family members/carers described positive effects on their spouse and themselves 
following the diagnosis of diabetes.  One participant said she was more mindful about 
her health and lifestyle and the health and lifestyle of her spouse.  
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It’s more a positive effect in the sense that … we were probably both a bit 
overweight … we probably thought we ate quite well but … when you sat 
down and looked at it we needed to make some modifications to our diet … it 
encouraged us to exercise more regularly … so they were good things that 
came about as a result from it … [C 7] 
 
I think it probably had a positive effect … we became more aware of the need 
to monitor what we ate …[C 5] 
 
Adjusting to life with diabetes   
The family members/carers indicated they adopted a supportive role helping their 
spouse to adjust to life with diabetes when initially diagnosed.  Their comments 
related to taking on an active and supportive role and working together as a team are 
grouped together.  Comments relating to assisting their spouse to integrate diabetes 
management strategies into a daily routine are grouped together; and comments from 
two participants who were anxious about adjusting to life with diabetes are grouped 
together.   
 
Working together—working as a team.  Five participants described ‘working together’ 
and ‘teamwork’ as central to supporting their spouse to manage his or her diabetes.  
The participants described being in the background, providing active support, 
encouragement and incorporating lifestyle changes.  One participant said working as a 
team was the usual way the participant and their spouse worked, thus they worked as 
a team to manage diabetes:  
 
We always worked as a team looking after each other … it just became a 
reflex just like caring for anyone else …[C 5] 
 
Teamwork was described as making joint decisions and altering their own diet and 
lifestyle to demonstrate understanding.  Examples of comments concerning working  
together include:  
 
I would watch what we were cooking and how much fat and oil and whatever 
we were using and … just keep an eye on what he was having because he did 
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love lots of butter, lots of cream, lots of ‘wrong things’ … so I managed to 
gradually change all that and it did help with his … he became stabilized … 
quite stable with his blood sugars … took a while though …[C 4] 
 
 
I suppose in thinking about managing the diabetes it’s part of the whole 
helping B care for himself of which I have taken on quite a bit of that role in a 
supportive way … I haven’t just tried to take over … I’ve tried to, him and I do 
it together … so he does his blood sugars quite regularly and then we’ll talk 
about adjusting his medication depending on what his blood sugars are. [C 7] 
 
A sense of routine.  Three participants described helping to integrate their spouse’s 
diabetes management activities into regular, everyday tasks.  These participants 
indicated that, once their spouse had a routine, the demands of managing their 
diabetes seemed more achievable.      
 
Comments included:  
 
… Cause I got … the insulin that I organise for him night and morning … it’s 
a regular thing that as soon as I get up and have my shower … I produce the 
… his blood machine and the insulin and … then about 5 pm each night it’s 
just a regular thing that I do… it’s part of the routine now … I think we’re 
such creatures of habit that things … once things … get into a routine I 
haven’t got any problems … [C 10] 
 
… So I’ve always paid attention to that … I’ve encouraged us to exercise 
regularly but he does that as well … so yeah, I’ve tried to encourage him as 
much as possible to take control of it …[C 7] 
 
When discussing routine diabetes management support strategies, one participant 
described reminding, prompting and encouraging her spouse to undertake diabetes 
self-management tasks including blood glucose testing and remembering to take his 
medicines.  When asked how she felt about the role she replied:    
 
It doesn’t worry me doing it [reminding, prompting and encouraging him to 
undertake diabetes self-management tasks including blood glucose testing and 
 _______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
80 
taking medicines] … he’s been part of my life for so long now … we’re sort of 
more or less like one …[C 8] 
 
However, one participant indicated it was challenging for her spouse to develop a 
diabetes self-management routine. 
 
But I think for him its been difficult because it’s meant quite a lot more of a 
routine and for someone like him who travels for 5 weeks … goes away for 5 
weeks and comes home for 5 weeks … his life is very much … I shouldn’t say 
unstructured but … Yeah … and so to have to take blood sugars and do all of 
those things … so in some ways some people might say he’s been a bit non – 
compliant but he’s been as compliant as he possibly can given the person that 
he is …[C 7] 
 
Anxiety about adjusting.  Two participants described heightened levels of anxiety 
about their ability to adjust to their spouse’s diabetes management routine.  Both 
participants described complicating factors that affected their spouse’s ability to cope 
with the diagnosis of diabetes and the requisite self-care management strategies.   
 
The first participant said her husband had significant mental health issues when he 
was diagnosed with diabetes and commented:  
 
Well …  he had a mental illness as well … he had paranoid schizophrenia … 
and he’d had that for about ten – fifteen years so he had episodes of delusional 
disorders … and so because of that … he was unable to see reality in a 
situation and … he couldn’t see the importance of following a strict diet and 
regularly checking his blood sugars … and he’d get a bit aggressive if I tried 
to encourage him or force him into taking his blood sugars so … that was a bit 
difficult for a while …[C 4] 
 
The second participant’s wife was diagnosed with diabetes and cancer at the same 
time, which created stress, anxiety and uncertainty for both partners.  The participant 
was not concerned about managing diabetes at diagnosis or later.  He said:  
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We found out on the same day that she had diabetes, that she had a tumour on 
the pancreas and one on the liver … so … that was such a shock … the 
diabetes did sort of become secondary …[C 6] 
 
Witnessing distress/being distressed—effects of diabetes during life 
limiting illness  
The effects of diabetes on their spouse overwhelmed participants during their spouse’s 
life limiting illness.  Seven of the ten participants reported their stress levels escalated 
and their anxiety and worry increased as their spouse’s illness progressed and they 
undertook more of the diabetes self-care tasks such as blood glucose monitoring and 
managing medicines.  Participants felt distressed when their spouse experienced 
diabetes-related symptoms such as hypo/hyperglycaemia and did not know how to 
help their spouse.  These sub-themes are grouped under the headings of: 
- it’s a worry 
- hypoglycaemia/hyperglycaemia. 
 
It’s a worry 
A sub-theme emerging from the interview data was the constant worry 
family/members endured due to the effects of diabetes on their spouse’s life limiting 
illness.  
Comments included: 
  
Well it’s … it’s a worry … you know when I go shopping or I sort of go out 
somewhere and I think ‘oh, did he take his insulin or did he help himself to a 
cuppa’ … that worries me … when I go out because many time I get very 
angry and I come home and I see the cup is still standing there.  [C 2] 
 
Yeah, I mean I was always … I guess you are always aware of … you know I 
used to check his book to see what his blood sugars were cause I was always 
anxious that … and to see what he’d eat … what effect it would have on his 
blood sugars … just in case he was hypo or hyper … whatever … because he 
didn’t experience it so he didn’t realise how bad it could be … [C 4] 
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A lack of knowledge about the impact of the life limiting illness and its treatment on 
their spouse’s diabetes added to the negative affect the family member/carer 
experienced: 
 
So at the moment it’s confusing for us … we don’t know what’s causing what 
symptom … [C 3] 
 
Hypoglycaemia/hyperglycaemia  
Negative emotions.  Four participants described their distress at witnessing their 
spouse having a ‘hypo’ or ‘hyper’.  In many instances the family member/carer had no 
previous experience managing hypoglycaemia and felt isolated because most 
hypoglycaemic episodes occurred at home.  Four participants said they were 
‘frightened’ and ‘scared’ their spouse would have a ‘hypo’ or ‘hyper.’  
 
Comments included: 
 
Well it scares me, and then I get very angry with him…[seeing her husband 
having a hypo]  …[C 2] 
 
 
He doesn’t demonstrate clearly that he’s hypo or hyper … it’s the blood sugar 
machine [blood glucose meter] that tells you that … it doesn’t have such a 
huge impact but it … it does worry me that he’ll have a whopping hypo. [C 7] 
 
Not knowing what is happening.   One participant gave a vivid account of her husband 
experiencing a hypo and the participant did not know what was happening. 
 
Well, it happened in the night and I just think … he went like … like a dream 
and he was probably talking in his dream and … then I thought ‘oh, he fell out 
of bed’ and I got out of bed and went to him … and I thought no, he’s not right 
there’s something wrong here … and that’s when I panicked … and I couldn’t 
lift him up … so I thought well, I’ll call my friends and … they came … and I 
said ‘I’ll phone for the ambulance’ and they came … I didn’t know what it was 
… to be honest and it never dawned on me that it was his sugar … [C 1] 
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Two participants described instances where they were concerned about their spouse’s 
health and thought their spouse was having a hypo so they tested their spouse’s blood 
glucose.  Comments were: 
 
There were occasions when her blood sugars were low … we just used to do 
that by checking with the glucometer [blood glucose meter] and if it was a 3 or 
so when she woke up I’d make sure she got something to eat pretty quickly … 
[C 5] 
 
 
He did have a lot of light headed episodes … and … then … this was after he 
was diagnosed with cancer … he had a few episodes like that when I insisted 
that I take his blood sugars … [C 4] 
 
Increase in hypoglycaemia and hyperglycaemia.   Two participants commented on the 
effects of diabetes and the life limiting illness on their spouse’s blood glucose levels.  
They indicated that the blood glucose was more erratic and unpredictable and 
episodes of hypoglycaemic or hyperglycaemia occurred frequently . 
 
I suppose that is what we’re still trying to get our head around … it would 
appear that his … with cancer he’s having more hypoglycaemic episodes … 
well he’s started having more hypoglycaemic episodes because it’s affected 
his eating … the cancer affected his eating … and as he ate less and couldn’t 
deal with as much food … and he was still taking the same sorts of 
medications because they didn’t know he had cancer … he was having 
hypoglycaemic episodes and we don’t know whether he was hypoglycaemic or 
hypotensive … at times it’s hard to tell … [C 3]  
 
One participant (a nurse) specifically mentioned her distress seeing her spouse 
develop hyperglycaemia due to diabetogenic medicines prescribed to manage his life 
limiting illness.   
 
One of the most challenging things has been … with having chemotherapy is the 
prednisolone and what that does to his blood sugars … and I don’t know if he 
told you about a night that his blood sugar was 27 and … I was actually going 
 _______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
84 
to take him to the hospital … cause I was really worried about him … going into 
a coma … [C 7] 
 
Increasing burden of care/stress 
A significant issue emerging from the interview data concerned the increasing burden 
of care on family members/carers as their spouse’s life limiting illness progressed.  
Seven of the ten participants described how they had assumed increasing 
responsibility for managing their spouse’s diabetes and other illnesses and discussed 
their concerns about the increasing responsibility of the ‘new role’ for which they 
were unprepared.  Participants’ comments are grouped together as:  
- care tasks 
- being housebound 
- emotional response to new role 
- what will happen if I get sick? 
 
Participants provided details about their new care tasks. 
 
Care tasks 
The family members/carers described the many care tasks they performed as their 
spouse’s condition deteriorated.  These tasks included attending to personal hygiene 
needs, assisting with meals and nutrition, administering medicines including diabetes 
medicines and pain relief, attending medical appointments with their spouse and 
generally being present for their spouse.  
 
Comments included: 
 
Oh, yeah, yeah … yeah I have too … because there are many thing he can’t do 
now …like I help him … he puts his pants and that on himself …  but the socks 
is a struggle … cause when he bends down … you know to put the socks on … 
he gets out of breath straight away … and I help him in the shower … what I 
never did before … it’s just little things … you know but I’m … well I thinks 
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it’s important for him that I help him in that way … but I do everything I can 
… [C 2]  
 
The time taken to perform these tasks was substantial and affected the time the carer 
was able to spend on their own interests and responsibilities: 
 
Well I just put it down to … by the time I’ve got up and I help him have a wash 
… cause when he’s having a wash I have to hold him cause he said when he 
puts his head down he goes dizzy … so he has a wash … I help him to have a 
wash … wash his body and back … and then … put his shirt on … have to 
button his shirt for him … cause he’s a bit shaky … then I give him his 
breakfast … then I clean up and maybe I have to go to the shops … come back 
… then it’s lunch time … I give him his lunch … and before I know it … you 
know the day’s gone … and there’s things I can see wanting doing in the 
house and I think ‘ gee I’ll have to do that’ but I don’t get time … cause I’m  
with him … all the time… [C 4] 
 
The repercussions of their spouse’s increasing care needs included restrictions on the 
participants’ activity. 
 
Being housebound 
Two of the ten participants briefly alluded to experiencing isolation due to a 
combination of their spouse’s health decline and their own increasing anxiety to leave 
their spouse alone.  Comments included: 
  
 Well if he doesn’t go out, I don’t go out … [C 2] 
 
 
One participant elaborated on why she did not leave her spouse alone: 
 
He was in terrible pain and I didn’t like to leave the house and leave him 
alone I wanted someone he with him … worried when I wasn’t here … 
because at the time I didn’t know what was going on and I didn’t know what 
was likely to happen when I was out the door … [C 9] 
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Emotional response to new role  
The emotional response of individual family members/carers to the increased needs of 
their spouse varied greatly.  Negative emotions were related to feeling inadequate and  
wishing they could perform their new role differently: 
 
Yeah … so … so sometimes I feel angry and inadequate and … and sometimes 
I feel like I’m chasing my own tail trying to look after him in that I’m forever 
picking up the pieces rather than being proactive … I’m being reactive … [C 
3] 
 
Negative emotional responses also reflected a carer’s reaction to the loss of freedom 
imposed on the family member/carer by their new role:  
 
I felt trapped a lot of the time … you know, because I found towards the last 
few weeks I had to stay home all the time, I didn’t like to leave him because he 
… was getting a little bit disorientated, at times not a lot but he tried to do 
things for himself and he was very fragile and unsteady on his feet and I was 
worried … what’s going to happen if he falls … so someone had to be here all 
the time … so that … does limit the time that I could go out ………[C 4] 
 
Another family member/carer acknowledged the difficulty they experienced 
undertaking their new role, but also indicated that they felt privileged to be doing it: 
 
It’s about the time that it takes to deal with that [diabetes management] … and 
I’m not complaining I actually feel fairly privileged that I can care for him, 
that’s something that I can do for us … so in some ways it’s a privilege to do 
that it’s just juggling all the hats that you have to wear and the time, the 
nature of the time. [C 7] 
  
It was apparent from one participant’s comments (a health care worker) that role 
conflict affected her emotional response to the new care tasks she was taking on.  This 
participant was apprehensive about taking over her spouse’s diabetes self-
management tasks including blood glucose monitoring.  She indicated she wanted her 
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role to remain as his wife; yet she understood she needed to know about and 
undertake blood glucose monitoring.   
 
Umm … how do I feel … not exactly thrilled … because …. Because I do work 
in the medical system … for me part of the juggle is … being his wife and not 
predominately his nurse … so I have to be careful that I don’t … that, that sort 
of medical background that I have doesn’t dominate our relationship … so for 
me taking that on would be fine I can do it … it’s not that I can’t do it, I can 
do it… but it would just be one thing that I would do which would be sort of 
more part of that medical care of him … I mean I’ll do it … that’s why I asked 
him to show me how to do it … with the machine … in case I ever need to 
know how to do it … [C 7] 
 
What will happen if I get sick?    
Family members/carers were concerned about what would happen to their spouse if 
they were unable to look after them. They worried about who would undertake the 
diabetes management task they now performed for their spouse.  For example: 
 
The only thing is if I’m too sick to do it or something like that … like I keep 
pretty well but I run on a pace maker and I have an artificial valve in my heart 
…  and they’ve sort of given me 8 more years of life … 9 more years now but 
… coming up to 9 … since they did my heart operation … but … and I had 
cancer at the same time … so … he’s sort of been more my … looking after me 
more than I’ve been looking after him until the last 12 months or so … [C 9] 
 
Another participant discussed what would happen if she was not able to be there for 
her husband, and was more specific about who would be appropriate to assist him 
manage his diabetes: 
 
… I think if need be I could get the support … I wouldn’t be happy about just 
getting a friend to pop in and do it because … I’d like someone who’s done it 
before because I know the first day I started pricking the finger I was rather 
hopeless. [C 10] 
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Recognising ‘I’m out of my depth—I need help’ 
Several family members/carers indicated they would need advice and education when 
their spouse was nearing death.  Comments included:  
 
I think I’d need a bit of assistance … yes I would … yes I would need 
assistance from someone … but as I say it would have to be a professional … 
[C 1]  
 
Well like I said how long I can manage it myself, I don’t need any help but 
when it comes to the stage that I really need somebody well I would like that 
somebody is there for me … you know … [C 4] 
 
One family member/carer explained why they needed education and advice help: 
 
Because the other day when he needed me to be able to do it, I didn’t really 
know what to do … [C 3] 
 
Another participant mentioned he or she might need help as their spouse approached 
the terminal stage but did not really know until he or she was in that situation: 
 
Well, maybe I need some help … I don’t know … until it gets to the stage … 
 [C 2]   
 
Uncertainty concerning diabetes management when spouse approached 
the end of life 
The language family members/carers used when they were asked about managing 
diabetes when their spouse approached the end of their life suggested many were 
uncertainty about the issue.  Some family members/carers indicated they preferred to 
continue diabetes management.  Comments were grouped as: 
- wanting diabetes management to continue 
- being guided by others 
- letting go. 
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Wanting diabetes management to continue   
Three family members/carers indicated they thought diabetes management should 
continue, typically to increase their spouse’s comfort and reduce the risk of diabetes-
related symptoms and illnesses: 
 
I would think to continue with it … I wouldn’t like to think he was stopped and 
take sick … again and go through all that trauma … [C 1] 
 
 
Nearer toward the end of life … I’m trying to think of the way to say this … I 
want him to be comfortable … and if it means continuing with the monitoring 
to keep him comfortable then I think that’s really important … [C 7] 
 
One participant gave contradicting responses to the question about continuing 
diabetes management when her spouse was close to death revealing a level of 
uncertainty about what would be best for his/her spouse.  Initially the participant 
responded: 
 
Oh … it wouldn’t worry me [to cease diabetes management]… so long as he 
was being looked after and was well … so long as he’s not suffering in any way 
from it … [C 9] 
 
Only minutes later she stressed the importance of actively managing her spouse’s 
diabetes to maintain his comfort: 
 
No I don’t think I’d like them [BG testing and medicines] to be stopped 
because I think that would only make him feel worse … [C 9] 
  
Two participants believed blood glucose monitoring should be continued because it 
provides important information about their spouse’s condition: 
 
’Cause I feel it’s a guide … you know too … at least if you can test … his 
sugar you know what it’s … what’s happening … I guess if you didn’t do it 
you’d just have to guess and I think it’s much better to keep on doing the 
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testing … and you know where you are … I mean it’s showing you isn’t it in a 
tangible way … what’s happening ……… [C 10] 
 
Oh well I would tell them [health professionals] that it is necessary [insulin 
and blood glucose monitoring] … because otherwise they’ve got no idea … if 
his sugar level is high or if its too low or whatever I mean you have to do that 
…  [C 2] 
 
The latter participant indicated she would be guided by other people when making the 
decision to continue or cease her spouse’s diabetes management. 
 
Being guided by others  
Two participants said they would rely on other people to tell them what to do and 
when to cease blood glucose monitoring if their spouse was near the end of life.  
Comments included: 
 
Well I don’t know … I really don’t know but I think it would help him and its 
necessary … I would do it [blood glucose monitoring] until somebody tells me 
otherwise … [C 2]  
 
Another participant stated: 
 
So if … that was what the palliative care people recommended I would trust 
them because they’re the experts and I would say ok, that’s fine lets give it a go 
and see how it goes but if they said to me that they think it’s really important for 
his comfort that we continue with that then I’d be guided by them … [C 7] 
 
Letting go     
Two family members/carers spoke about stopping active diabetes management as 
‘letting go’.  One suggested letting go would be difficult: 
 
… and I suppose it’s that letting go of something that’s become part of your 
life … that’s become routine … seeing that the first thing that B does when he 
wakes up is do a blood sugar and we talk about what that is and … then work 
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out what we’ll have for breakfast from that … it’s habitual I suppose … it 
would be hard to get out of that habit … [C 7] 
 
Another participant described feeling that her spouse wanted to let go: 
 
I think he wants to just let go of the diabetes control even though he might feel 
lousy … and I don’t know whether doing that is exacerbating the cancer or the 
cancer’s exacerbating the feelings of just wanting to let go of the control … 
but he’s certainly … for quite some time now he hasn’t wanted to test himself 
or take his insulin …[C 3] 
 
The participant continued to prepare the self care equipment for her husband but left 
the decision about blood glucose testing/taking medicines to him.  It was not clear 
from her comments whether the she accepted the situation, was resigned to it, or 
passively resisted the situation.  Nor was it clear whether she had discussed ‘letting 
go’ with her husband. 
 
So now I just put everything in front of him and if he chooses to use it he uses 
it, if he doesn’t he doesn’t … [C 3] 
 
Suggestions family members/carers made about the type of information 
they would like included in the guidelines 
Significantly, all family members/carer offered valuable suggestions about the type of 
information they would like included in the Guidelines.  Many felt they were 
inexperienced to take on diabetes self-care tasks and/or to support their spouse with 
their diabetes management in the context of a life limiting illness.  They were 
concerned about performing technical tasks such as blood glucose testing and 
administering insulin, which many had never performed before.   
 
They also worried about being able to interpret/respond to blood glucose readings and 
appropriately manage symptoms of hypoglycaemia and hyperglycaemia.  They 
described feeling anxious, overwhelmed and initially incapable of taking in vast 
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quantities of information about diabetes management because they were coping with 
the emotional and physical impact of knowing their spouse was dying.  
 
The three major themes identified from the interview data were: 
- education, guidance and support 
- individualised, inclusive approach with carer 
- meeting patient care needs if carer unavailable. 
 
A need to know more about how to care for their spouse and support to do so was an 
important theme emerging from the data. 
 
Education, guidance and support 
Primarily, family members/carers suggested health professionals needed to provide 
clear and concise explanations about how to manage diabetes in the presence of a life 
limiting illness.  The sentiment was exemplified by the following comment: 
 
That’s the most important thing I think in explaining things properly  (C 2) 
 
Family members/carers discussed their escalating frustration about not being able to 
manage or cope with their spouse’s diabetes management in the presence of a life 
limiting illness when they had not previously undertaken many diabetes management 
tasks.  They wanted specific education, guidance and support for carers to be a 
leading consideration in the Guidelines. 
 
Comments included:  
 
I almost need a list of things to go through, so yes a bit of education, a bit of 
guidance is probably what the carer needs  … I’m not a health care 
professional so I really don’t know what to do when things go wrong … I 
almost need a checklist of … you know what to do next … (C 3) 
 
Education and counselling …  (C 4) 
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Another family member/carer suggested: 
 
Some written guidelines for the carer … would be really helpful.  (C 7) 
 
This statement echoes an earlier comment from the same participant: 
 
 
If there was a suggested treatment plan that would be really helpful because 
one of the … one of the scary things about … it’s that sort of watching and 
waiting approach … is that you might not have it right … [C 7] 
 
Individualised, inclusive approach with carer 
Four of the ten family members/carers discussed the need for the Guidelines to 
encourage an individualised and inclusive approach to the patient and family 
member/carer when managing diabetes at the end of life. 
 
Consider individual needs.   Family members/carers discussed the importance of 
identifying the most appropriate care for each individual patient.  Comments included: 
 
You just have to take the approach of each individual client … (C 5) 
 
… It is a good idea to talk to the carer as well … and say … ‘what can we do 
for you’ … ’cause I assume there are some people that are quite frightened … 
because it all came in a rush for us  … (C 6) 
 
 
The importance of including both the patient and the carer in discussions about care 
plans was also articulated. 
 
A shared responsibility.   One family member/carer reiterated that the patient’s 
diabetes management at the end of life as a shared responsibility that incorporated the 
family member/carer as active participants in the care.  This sentiment echoes the 
discussion about ‘team work’ discussed earlier.  Significantly, the participant’s 
responses suggested that although she wanted to share responsibility for care 
decisions, she also wanted to defer to health professionals advice to avoid self-blame 
and distress if her decisions ‘don’t work.’:  
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 …  through communication and consultation and that I’m not left with the 
responsibility of it … that’s what … I don’t want the responsibility of it … I 
think that’s what it is … yes … because if something doesn’t work then I don’t 
want to be left blaming myself because of that … (C 7) 
 
And,   
That the care plan is negotiated with the carer and the patient … I suppose 
that the guidelines are based on what evidence there is … yeah and I just think 
having guidelines would be a really good thing to have … and that it’s done  
… when those guidelines are being considered in regards to a patient that, 
that’s communicated to the patient and their carer … (C 7) 
 
Participants suggested the Guidelines should encompass the need to assess the 
individual patient’s and carer’s diabetes management capabilities when care plans are 
prepared for patients being managed at home. 
 
Mirroring care to reflect patient’s capability and willingness.   One family 
member/carer suggested the Guidelines should reflect care that is consistent and 
achievable in all settings, to enable an easier transition from home to health facility 
and vice versa.  The participant described the need to focus on the patient’s ‘best 
possible outcomes,’ indicating the importance of developing patient-centred care 
goals to enhance quality of life, as opposed to prescriptive medical/nursing goals.  
 
Her comments included: 
 
I think it really important that in care it has to mirror what s been happening 
at home… and some … strategies devised to get it as good as it can be 
knowing that that’s what’s going to happen at home rather than have the ideal 
situation because the person’s compliant and the nursing staff are good at 
their job and you have really good control and then you go home and to a 
disaster … (C 3) 
 
And, 
To work out ‘what is this person willing to do’ once they leave the hospital 
setting … and then as I said before … once that’s established they you can 
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develop the prescription level according to his best possible outcome, even 
though it’s not medically the soundest … (C 3) 
 
Meeting patient care needs if carer unavailable  
Two of the ten family members/carers suggested including ‘contingency planning’ in 
the Guidelines; for example, information about what to do if the family member/carer 
becomes unwell or is no longer able to care for the patient.  This suggestion is 
consistent with the participants’ concerns about what would happen if they could not 
care for their spouse.  One participant said: 
 
I think to be able to have some sort of help if I’m not there to do it (C 9) 
 
When asked what would help to support the carer, another participant responded:  
 
Just that … I guess we’d have help if I happened to … not be available 
[inferring significant illness or death] … you know Mr M would need some 
help.  [C 10] 
 
 
Discussion   
The participants 
The participants with diabetes were willing to discuss their diabetes and palliative 
care despite having a limited life expectancy and being unwell.  Similarly, family 
members/carers were willing to be interviewed for the project despite the many 
demands on their time and the difficulties they were experiencing.  Participants 
provided moving and useful information about the complexity of managing diabetes 
in the presence of a life limiting illness.  The recruitment process was complex and 
time consuming due to the vulnerability of the target participants and the intricacies of 
involving busy palliative care health professionals in the recruitment process.  The 
researcher had prior experience with palliative patients and used flexible and 
innovative skills to involve palliative care heath professionals by establishing 
relationships, attending bi-weekly palliative care meetings and maintaining contact by 
email and telephone. 
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Participants were from different backgrounds and age groups and some had sensory 
disabilities.  In addition, the palliative care phase they were in, as defined by Palliative 
Care Outcomes Collaboration (PCOC, 2008), at the time of the interview varied; all 
four PCOC phases were represented.  Some participants were undergoing treatment 
for cancer and were reasonably well at the time of the interview.  Others were very 
unwell and were interviewed while they were in hospital.  Sadly, four people who 
participated in the interviews and contributed important information, passed away 
before the Guidelines were completed. 
 
The interviews 
Interviewing people receiving palliative care presented an unusual situation for one of 
the researchers.  Palliative patients and their family members/carers live with the 
diagnosis of a life limiting illness and often have complex needs and symptom 
management requirements.  Most patient interviews were conducted in the patient’s 
homes and many were in a very poor health and in bed when they were interviewed, 
thus, they were extremely vulnerable (Koffman et al., 2009).  Nevertheless, they were 
keen to ‘be heard’; therefore, it was particularly important that the interviews were 
conducted sensitively and with compassion.  It was also important that the researcher 
was able to debrief with the rest of the research team and to balance discussing her 
concerns about the patient or carer that emerged during the interview with the treating 
palliative care staff when relevant, with respecting the individual’s confidentiality. 
 
The tapes and transcripts of the interviews demonstrate that the researcher quickly 
established a good rapport with each individual and was extremely mindful of their 
particular situations.  It is clear that the patients were very happy to discuss their 
health and quite sensitive topics.  The field notes the researcher recorded 
contemporaneously with each interview indicate that several interviews were very 
difficult for her due to the patient’s sensory deficits or because the patient was in pain 
during the interview but wanted to continue the interview despite their obvious 
discomfort.  
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Participants’ diabetes management preferences 
While patient participants’ specific diabetes management preferences varied, there 
were common views about how diabetes should be managed.  Significantly, the 
patient participants in the current study wanted an individualised, collaborative, 
consistent approach to managing their diabetes.  They wanted relief from distressing 
symptoms, including hypoglycaemia and hyperglycaemia, and flexible approaches to 
managing their medicines and blood glucose monitoring.  Some participants were 
happy to leave decisions to health professionals, but some specified that health 
professionals should be competent and ‘know what they are doing’ with regards to 
managing diabetes.   
 
Participants indicated health professionals should listen to the patient because they are 
‘experts in their bodies and their diabetes.’   Interestingly, people with diabetes 
interviewed for the current project experienced a variety of symptoms of 
hypoglycaemia and hyperglycaemia.  The symptoms varied among participants and in 
some cases were different from common ‘textbook’ symptom lists that health 
professionals rely on to detect blood glucose levels in the high and low ranges.  
People with diabetes learn to recognise body cues associated with hypo/hyper-
glycaemia; these cues/symptoms often change over time with increasing duration of 
diabetes or be masked by other diseases or medicines.  For example, people with type 
1 diabetes can experience hypoglycaemic unawareness due to autonomic neuropathy 
and other causes including frequent episodes of hypogycaemia (Schwab, Menche, 
Schmeisl & Lohse, 2004).  Frequent episodes of hypoglycaemia also reduce the 
individual’s ability to detect hypoglycaemia symptoms (brain desensitisation).  The 
brain no longer signals for adrenaline release and the upregulation of brain glucose 
transporters, which lowers the glycaemic threshold at which people recognise 
hypoglycaemic symptoms (Cryer, 1997).   
 
Significantly, people with diabetes and their family members/carers are afraid of 
hypoglycaemia and the threat to their safety, which includes death (Egi, Bellomo, 
Stachowski et al., 2010).  The unpleasant effects of hypoglycaemia often persist after 
the blood glucose is corrected, but can recur if treatment is inadequate and in some 
cases become chronic (Dunning, 2009).   
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OHA-induced hypoglycaemia is hard to detect and usually occurs more slowly and 
produces different symptoms from insulin-induced hypoglycaemia.  Likewise, it often 
takes longer to resolve, especially if renal disease is present.  Hyperglycaemia also 
causes unpleasant symptoms such as lethargy, low mood, nausea and vomiting and 
exacerbates pain that may not be adequately relieved if the underlying cause is not 
identified (Campbell, 2007).  Blood glucose monitoring is necessary to detect 
hypoglycaemia if the individual has hypoglycaemic unawareness or is cognitively 
impaired and cannot respond to or indicate they are hypoglycaemic.   
 
Most participants accepted blood glucose monitoring as part of their life with diabetes 
and indicated it helped them manage symptoms and medicines.  Health professionals 
in Quinn et al’s (2006) study indicated that finger pricking in the last days of life 
might be distressing for the patient.  However, only one patient participant in the 
current study expressed a strong dislike of finger pricking, which was present 
regardless of his palliative care status.  Health professionals need to reflect on their 
own concerns about blood glucose monitoring and discuss the issue with patients with 
diabetes or family members/carers before making a decision to stop testing.  The 
notion that blood glucose testing is an unnecessary and painful intervention needs to 
be reassessed in light of other more invasive and unpleasant palliative care 
interventions.   
 
Only one patient participant in the current study had formulated an Advanced Care 
Directive.  She had not included her diabetes management preferences until she 
agreed to participate in the study.  Health professionals are in an ideal position play an 
active role advising palliative care patients to formulate an Advanced Care Directive 
early in the course of their patient’s disease.  Health professionals could counsel 
palliative care patients to include their diabetes management preferences in their 
Advanced Care Directives.  For example, the patient’s views on continuing blood 
glucose monitoring could be specified in the Advanced Care Directives. 
 
The perspective of family members/carers 
The family members/carers interviewed in the current study discussed the impact of 
the new diabetes management tasks they undertook when their care recipient’s health 
deteriorated.  They articulated a need for more education and support to help them in 
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their new role, and some described feeling ‘out of their depth’ and expressed 
uncertainty about how the patient’s diabetes should be managed in the context of 
other life limiting illnesses.  Family members/carers also wanted to be included in 
decision-making and discussions about the care of the patient with diabetes.   
 
Health professionals and diabetes management in palliative care 
Some participants felt health professionals did not give diabetes enough attention once 
the patient required palliative care.  Quinn et al. (2006) conducted focus groups with 
diabetes and palliative care specialists to discuss end of life issues.  The diabetes 
health professionals indicated they did not receive referrals from palliative care health 
professionals and the latter indicated they did not often refer palliative care diabetes 
patients to diabetes specialists.  Significantly, rural palliative care participants in 
Quinn et al’s study indicated they did not know how to access diabetes experts or 
information. 
 
Diabetes experts may not have a good understanding of palliative care.  Collaborative 
health professional education programs could foster collaborative relationships and 
improve knowledge and understanding regarding managing people at the end of life 
and result in improved patient outcomes.  
 
In summary, the following conclusions were drawn from the interview data about 
study participants’ preferences about managing diabetes when palliative care is 
required. 
Conclusions 
 
• Each person with diabetes needs to be treated individually.  There was a wide 
variation in how patient participants responded to having diabetes, the extent to 
which diabetes and their other illness/es were inter-related, and how actively they 
preferred to have their diabetes managed when they are very ill.  
• Patient participants described a variety of symptoms of hypoglycaemia and 
hyperglycaemia that were not always consistent with textbook lists, which could 
make it very difficult for health professionals to recognise hypoglycaemia or 
hyperglycaemia in patients with diabetes requiring palliative care.   
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• Patient participants found hypoglycaemia and hyperglycaemia very uncomfortable 
and they wanted to avoid these events.  Similarly, family members/carers 
commented on their concern about their spouse experiencing these events. 
• Significantly, the majority of patients indicated change was needed in their 
diabetes management as a result of their other life limiting illness/es.  They were 
aware of the complexity of the interaction between the treatment/medicines they 
needed to manage their other illness and their diabetes medicines.  Likewise they 
were aware of the impact of medicines such as glucocorticoids on their blood 
glucose levels and wanted their blood glucose monitored and controlled to prevent 
hypo/hyperglycaemia. 
• Patient participants accepted the tasks involved in managing their diabetes, for 
example, testing their blood glucose levels.  Only one of the 14 patients 
interviewed indicated he disliked pricking his finger to test his blood glucose.  
This finding suggests health professionals need not be concerned about blood 
glucose monitoring causing pain or distressing patients. 
• Some patients felt health professionals do not pay sufficient attention to their 
diabetes and do not know enough about diabetes management.  They described 
inconsistencies in how health professionals managed diabetes in different health 
care settings. 
• Patients were frustrated when health care professionals did not pay attention to the 
patient’s views about how to manage their diabetes.  Seven of the 14 patient 
participants specifically indicated that they wanted health professionals to listen to 
them.  
• Patient participant’s preferences for diabetes management when they are very ill 
varied.  Some wanted very active management; some wanted less active 
management, and some thought diabetes management could be stopped when they 
were no longer conscious.  Some patients stressed the need to be kept comfortable, 
especially when they were close to death.  Identifying and acknowledging the 
patient’s diabetes management preferences is extremely important. 
• Generally, the patients interviewed were unaware of Advanced Care Directives, 
which suggests they need information from health professionals about the option 
of preparing Advanced Care Directives that could include diabetes management. 
 _______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
101 
• Family members/carers took on an increasing role regarding diabetes management 
for the person with diabetes requiring palliative care as the patient’s life limiting 
illness progressed.   
• While family members/carers responded differently to the demands of their new 
role, it was apparent that it had a substantial impact on them.  Many experienced 
difficulties and were anxious about performing specific diabetes care tasks.  Some 
were also concerned about leaving their care recipient alone. 
• Most family members/carers interviewed indicated they needed more information 
and education about managing diabetes and also wanted health professionals to 
include them in discussions about care plans with the patient.  
 
These data provided very useful information to include in the Guidelines.  
Significantly, they are consistent with the guiding principals developed as the 
conceptual framework for the Guidelines. 
Key findings that informed the development of the Guidelines  
• Continue testing blood glucose until the terminal stage unless otherwise specified 
in an Advanced Care Directive. 
• Continue medicines to control unpleasant hypo/hyperglycaemia until the terminal 
stage but use them in that stage to promote comfort. 
• Medicines may need to changed or adjusted frequently as the person’s condition 
changes and insulin might be indicated.  
• Consider the whole person and individualise their management plan. 
• Health professionals should listen to the person with diabetes because they are 
experts in their disease and recognising symptoms by recognising body cues. 
• Health professionals should acknowledge the role of family members/carers in 
managing the patient’s diabetes as the patient’s health deteriorates, and include 
family members/carers in discussions about the patient’s care plan.  
• Family members/carers may not have previously undertaken tasks such as 
monitoring blood glucose levels and may lack the necessary knowledge and skills 
to monitor and interpret blood glucose levels, manage increasing or decreasing 
blood glucose levels and administer medicines safely and confidently. 
• Family members/carers require more information, education and support in 
relation to managing diabetes in the context of palliative care.  
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• Family members/carers may feel anxious about their increasing responsibility 
regarding their care recipient’s diabetes and need support and guidance from 
health professionals. 
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ACCOMPANY THE 
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INTRODUCTION 
 
In the course of the formative evaluation of the Guidelines it became apparent that a 
detailed explanation of the framework and philosophy underlying the Guidelines, an 
overview of diabetes, and an explanation about the complexities of managing diabetes 
in the context of palliative care was needed to help palliative care and diabetes health 
professionals understand and implement the Guidelines.  Therefore, a document to 
accompany the Guidelines was developed simultaneously with the Guidelines—the 
accompanying document.  The accompanying document is presented in the following 
section.  A shorter version of the accompanying document that could easily be used in 
clinical situations was also prepared and is described in a later section of the report 
and presented in Appendix C. 
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DOCUMENT TO ACCOMPANY THE GUIDELINES FOR 
MANAGING DIABETES AT THE END OF LIFE 
Background 
The project to develop guidelines for managing diabetes at the end of life originated 
from collaboration between diabetes and palliative care clinicians.  The project was 
designed to address the critical need for clear guidelines for managing people with 
diabetes requiring palliative care.  
Palliative care is defined as:  
An approach that improves the quality of life of patients and their families 
facing the problem associated with life-threatening illness, through the 
prevention and relief of suffering by means of early identification and 
impeccable assessment and treatment of pain and other problems, physical, 
psychosocial and spiritual. 
 (World Health Organisation, 2009)  
The goal of palliative care is to achieve the best quality of life for patients and their 
families.  Most people gradually deteriorate towards the active dying phase after a 
period of illness: less than 10% die suddenly or unexpectedly (Emanuel et al. 2008).  
However, people with chronic diseases such as diabetes may have many episodes of 
the unstable Palliative Care Outcomes Collaboration (PCOC, 2008) phase before they 
enter the final end of life stage. 
 
A detailed report about the development of the Guidelines, including a literature and 
interviews with people with diabetes requiring palliative care and their carers, was 
prepared.  The following sections provide information about the philosophical and 
theoretical frameworks used to underpin the Guidelines and detailed background 
information about managing diabetes in people requiring palliative care.   
The Palliative Care Outcomes Collaboration framework 
The Palliative Care Outcomes Collaboration (PCOC, 2008) palliative care phases and 
the Quality Use of Medicines (QUM) Framework (PHARM Committee, 2005) were 
used as the underlying conceptual framework for the Guidelines.  
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The five palliative care phases are:  
1. stable 
2. unstable 
3. deteriorating 
4. terminal  
5. bereaved. 
 
The phases are not necessarily sequential and an individual patient can move between 
the phases (PCOC, 2008).  There is no defined duration of the phases or for the entire 
dying entire process.  
 
Separate Guidelines for managing diabetes are provided for each PCOC phase with 
the exception of the bereaved phase.  In addition, guidelines for managing people, 
with and without diabetes, who are prescribed corticosteroid medicines are included.  
 
A definition of each phase is presented in the following section based on the PCOC 
definitions (PCOC, 2008). 
 
Phase 1:  STABLE  
All people not classified as unstable, deteriorating or terminal. 
 
The person’s symptoms are adequately controlled using their established management 
plan but interventions to maintain symptom control and quality of life have been 
planned. 
 
The family/carers’ situation is relatively stable and no new issues are apparent. Any 
needs are addressed in the established plan of care. 
 
 
Phase 2:  UNSTABLE 
The person develops a new unexpected problem or a rapid increase in the severity 
of existing problems, either of which requires an urgent change in current 
management or emergency treatment. The person could restabilise or deteriorate. 
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The family/carers experience a sudden change in their situation requiring urgent 
intervention by members of the multidisciplinary team. 
 
Phase 3:  DETERIORATING  
The person’s existing symptoms gradually worsen or they develop new but 
unexpected problems. These require specific plans of care and regular review but 
not urgent or emergency treatment. 
 
The family/carers experience gradually worsening distress and other difficulties, 
including social and practical difficulties, as a result of the illness of the person they 
are caring for. This requires a planned support program and counselling as necessary. 
 
Phase 4:  TERMINAL  
Death is likely in a matter of days and no acute intervention is planned or required. 
However, frequent, usually daily, interventions aimed at physical, emotional and 
spiritual comfort is required. 
 
The typical features of a person in the terminal phase include some or all of the 
following: 
• profound weakness 
• essentially bed bound 
• drowsy for extended periods 
• disoriented for time and has a severely limited attention span 
• increasingly disinterested in food and drink 
• finding it difficult to swallow medicines. 
 
The family/carers recognise that death is imminent and care is focussed on ensuring 
comfort and emotional and spiritual care as a prelude to bereavement.  
 
Phase 5:  BEREAVED 
The individual died and the carers are grieving.  A planned bereavement support 
program is available in many palliative care services including referral for counselling 
as necessary.  
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Diabetes and palliative care 
Diabetes is a complex multifaceted disease of disturbed glucose homeostasis. Normal 
glucose metabolism is finely balanced among glucose uptake and glucose utilisation, 
production and storage (Table 6 on the next page).  However, glucose enters cancer 
cells down a concentration gradient rather than being insulin-mediated and the 
metabolism favours lactate production, which is used in the liver for gluconeogenesis, 
which increases blood glucose levels.  Lactate production may also increase the risk 
of lactic acidosis especially in people with type 2 diabetes taking Metformin.  There is 
an association between some forms of cancer such as breast, pancreas, liver and 
kidney, and diabetes and obesity.  Weight loss associated with cancer often leads to 
malnutrition, reduced immunity and affects normal cell functioning.  
 
In addition, renal disease is a significant complication of diabetes and influences the 
choice of medicines, many of which are excreted via the kidney, and care must be 
taken to protect the kidney if radio-contrast media are used.  People with a long 
duration of diabetes may have autonomic neuropathy, which can lead to unrecognised 
hypoglycaemia and gastric stasis.  The latter can complicate medicine-induced 
constipation, and nausea and lead to unstable blood glucose levels and nutrient 
malabsorption, which complicates the nutritional status and contributes to falls. 
  
Hypoglycaemia produces unpleasant symptoms and affects cognitive functioning. 
People with liver disease and limited nutritional reserves are not able to mount an 
effective counter-regulatory response to hypoglycaemia and glucagon injections may 
not be effective in these people.  In addition, the counter-regulatory response to 
hypoglycaemia decrease in type 1 diabetes: glucagon and adrenaline secretion 
diminishes; thus, the early warning signs are lost (Cryer, 1997).  Hypoglycaemia can 
occur when people are on glucose lowering medicines, have renal or liver disease and 
inadequate carbohydrate intake. 
 
Hyperglycaemia produces unpleasant symptoms, which can be mistaken for other 
causes. It affects mood, quality of life and cognitive functioning.  Significantly, type 2 
diabetes is a progressive disease of beta cell decline and insulin is needed in 75% of 
people to control blood glucose, and thus symptoms. 
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Table 6.  Normal glucose metabolism: a fine balance among glucose uptake, 
glucose utilisation, production and storage.   
 
Circulating blood glucose 
(Available fuel) 
Hepatic glycogen stores 
(Stored fuel) 
 
After food—the 
post prandial state 
Fasting state and 
between meals 
Longer term 
Glucose enters the 
bloodstream after food is 
digested in the GIT and 
stimulates the pancreas to 
secrete insulin (glucose-
mediated insulin release). 
The intestinal incretin 
hormones also play a role in 
insulin release when the BG 
rises after food. 
Insulin attaches to the insulin 
receptors on the cell 
membranes (insulin binding). 
Insulin initiates a cascade of 
intracellular events that 
enables glucose to enter the 
cells. 
Inside the cell the glucose is 
used for immediate energy 
production or stored for 
longer term use. 
Counter-regulatory 
hormones e.g. glucagon, 
adrenaline, cortisol, and 
growth hormone release 
glucose stores from the 
liver and muscle between 
meals, overnight and when 
fasting. 
Insulin is required for the 
glucose to enter the cells. 
It attaches to the insulin 
receptors on the cell 
membranes (insulin 
binding). 
Insulin initiates a cascade 
of intracellular events that 
enables glucose to enter 
the cells. 
Inside the cell the glucose 
is used for immediate 
energy production or 
stored for longer term use 
 
In the longer term glucose is 
manufactured in the liver 
from protein and fat stores 
(gluconeogenesis and 
glycogenolysis). Thus, 
protein and fat are important 
fuel substrates. 
Insulin is needed for the 
new glucose to enter the 
cells. If insulin is lacking or 
the individual has insulin 
resistance the glucose does 
not enter the cells and 
hyperglycaemia and 
hyperlipidaemia occur. 
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A summary of the short and long term complications of diabetes is provided in Table 
7.  Many of these are present before diabetes is diagnosed thus non-diabetics at risk of 
type 2 diabetes are likely to have impaired glucose intolerance and complications such 
as cardiovascular disease. 
 
Table 7.   The short term and long term complications of diabetes. 
 
   Short term complications    Long term complications 
Hypoglycaemia 
Hyperglycaemia, if not corrected  
can lead to: 
- ketoacidosis 
- hyperosomolar states 
Active infection 
 
 (1)  Microvascular disease  
- retinopathy  
- nephropathy (eGFR < 60ml/min)  
(2)  Macrovascular disease  
- cardiovascular disease  
- cerebrovascular disease 
- intermittent claudication 
(3)  Neuropathy 
- peripheral 
- autonomic 
- responsible for gastroparesis and 
hypoglycaemia unawareness 
(4) Periodontal disease 
(5)  Anxiety and depression and burnout 
 
 
 
People may already have diabetes when they enter palliative care or may develop 
diabetes during palliative care, often as a consequence of treatment with diabotegenic 
medicines. A number of factors are known to increase the risk of people developing 
diabetes. 
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Risk factors for type 1 and type 2 diabetes 
People most at risk of developing type 2 diabetes: 
• family history of diabetes 
• have the metabolic syndrome (a cluster of risk factors for cardiovascular 
disease and type 2 diabetes) 
• are aged over 50 years (but prevalence is increasing in younger people) 
• have close relatives with type 1 or type 2 diabetes 
• are overweight 
• are women who had gestational diabetes or gave birth to large babies 
• belong to Asian, Pacific Islander or Australian Aboriginal ethic groups  
• have hepatitis C  
• have schizophrenia 
• have pancreatic cancer 
• are using immunosuppressive therapy and/or  
• take diabetogenic medicines (Diabetes Australia, 2009b; Dunning, 2009). 
 
People most at risk of developing type 1 diabetes: 
• genetic predisposition 
• pancreatectomy or other significant pancreatic disease or trauma. 
 
Diagnostic criteria   
The criteria for diagnosing diabetes are presented in Figure 2 (next page).  Fasting 
plasma glucose is the preferred diagnostic test, but any of the three tests are 
acceptable. 
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Figure 2.   Criteria for diagnosing diabetes (venous plasma glucose levels in 
mmol/L) (Based on Diabetes Australia, 2009b).  The OGTT is rarely 
required and is contraindicated if the blood glucose is already high.   
 
Overview of diabetes management  
In general, diabetes management involves an appropriate diet and activity for both 
type 1 and type 2 diabetes even when medicines are needed. Managing diabetes  
 
involves: 
• Lifestyle changes particularly for type 2 diabetes. 
Diabetes not likely Diagnosis not clear Diabetes probable 
Oral glucose 
tolerance test 
Fasting or Random 
< 5.5 
Fasting   5.5–6.9  
Random 5.5–11.0  
Fasting  7.0 
Random   11.1 
< 7.8 
 7.8–11.0 
  11.1 
Diabetes not likely Impaired glucose tolerance Diabetes probable 
Re-test yearly 
if high risk 
 
Re-test 3 yearly if 
increased risk 
2 hr glucose levels 
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• Medicines:   
o Type 1 diabetes – insulin 
o Type 2 diabetes oral hypoglycaemic agents, incretin mimetics and/or 
insulin. 
Note: beta cell function declines over time in type 2 diabetes and 
approximately 75% eventually need insulin. 
• Managing blood glucose, lipids and blood pressure. 
• Regular medicines review. 
• Regular monitoring by health professionals to identify and manage the short 
and long term complications of diabetes. 
• Diabetes education including educating significant others. 
• Self-care by the patient, with support from family/carer. 
 
Hyperglycaemia and hypoglycaemia 
Two conditions commonly associated with diabetes are hyperglycaemia, a symptom 
of uncontrolled diabetes, and hypoglycaemia, a side effect of glucose lowering 
medicines, especially sulphonylureas and insulin.  
Hyperglycaemia 
Under usual circumstances, many people with type 2 diabetes do not experience the 
symptoms of hyperglycaemia until their blood glucose levels are extremely high.  
Common symptoms of hyperglycaemia include: 
 
• feeling excessively thirsty 
• frequently passing large volumes of urine  
• feeling tired 
• blurred vision  
• infections e.g. thrush, cystitis, wound infections 
• lowered mood 
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• weight loss in the longer term (Diabetes Australia, 2009a). 
Hypoglycaemia  
Hypoglycaemia, also called a ‘hypo’, low blood glucose, or insulin reaction, occurs 
when the blood glucose level falls below 3.5 mmol/L. Symptoms of hypoglycaemia 
vary from person-to-person, however, common feelings are: 
• weakness, trembling or shaking 
• sweating 
• light headedness 
• headache 
• dizziness 
• difficulty concentrating 
• tearful/crying 
• behaviour change 
• irritability 
• hunger 
• numbness around the lips and fingers (Diabetes Australia, 2009a). 
 
Hypoglycaemia unawareness may be present especially in people with long-standing 
type 1 diabetes.  This means they may not recognise the early adrenergic symptoms of 
hypoglycaemia. In addition, symptoms may be masked by analgesia, delirium and 
other cognitive changes and cancer-related autonomic neuropathy.  Significantly, 
people with diabetes and their family members/carers are often very fearful of 
hypoglycaemia and the consequences, which includes death. 
The Quality Use of Medicines framework 
The Quality Use of Medicines (QUM) Framework (PHARM Committee, 2005) is the 
recommended Australian framework for making medicines-related decisions and was 
used when formulating these Guidelines (see Figure 3, page 114).  The safe and 
effective use of medicines is extremely important at the end of life (National 
Prescribing Service Limited and Palliative Care Australia, 2009). 
 _______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
115 
 
The factors to consider when determining a diabetes medicine regimen for people 
with diabetes receiving palliative care, if medicines are indicated, are: 
 
• Insulin doses may need to be adjusted frequently. 
• Patients on metformin who develop nausea and vomiting especially the elderly, 
those on diabetogenic medicines, and those with reduced renal function, liver, 
cardiac and respiratory disease, and people who are not eating, may be at risk of 
lactic acidosis, a relatively rare but serious adverse event.  Significantly, most 
reported cases of lactic acidosis associated with metformin occurred in people 
with known contraindications (Australian Adverse Drug Reactions Advisory 
Committee, 2001). Therefore, metformin may not be the best choice. 
• Insulin mimetics can induce weight loss and nausea, therefore, they may be 
contraindicated. 
• Thiazolidinediones contribute to weight gain due to fluid retention and may be 
contraindicated.  
• Diuretics can exacerbate dehydration and increase blood glucose levels. 
• Corticosteroids, and atypical antipsychotics are frequently used in palliative care 
and other disease processes and increase blood glucose levels. 
• Glucagon used to treat severe hypoglycaemia usually increases blood glucose 
quickly.  A second dose can induce nausea but may be ineffective in emaciated 
people with reduced glycogen stores.  This means if oral glucose treatment of 
hypoglycaemia and intramuscular (IM) glucagon are ineffective or 
contraindicated, intravenous (IV) dextrose may be required. 
• Some oral nutrition supplements affect blood glucose levels, often leading to 
hyperglycaemia. 
• The patient may be using complementary medicines (CAM) and other CAM 
therapies.  If so, determine why the person is using CAM, what they are using, and 
whether CAM is appropriate i.e. the benefits outweigh the risks and there is 
evidence for its use.  
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• CAM medicines may interact with conventional medicines.  However, some non-
medicine CAM therapies can relieve symptoms such as stress and pain and may 
be safer than medicines. 
• CAM use should be included in the management plan and monitored. 
• Opioids and other psychoactive medicines can mask hypoglycaemia. 
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Figure 3.  Quality Use of Medicines Framework for managing diabetes at the end 
of life.  
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Corticosteroid medicines 
Corticosteroid medicines are an essential part of the management of several disease 
processes such as haematological malignancies, inflammatory diseases, allergies and 
shock.  However, long term use and high doses predispose people to insulin resistance 
(IRS), glucose intolerance (IGT) and steroid-induced diabetes; and causes 
hyperglycaemia and the resultant symptoms in people with diagnosed diabetes.  IRS 
and IGT can occur within 48 hours of commencing steroids, especially in at-risk 
individuals and those with diabetes.  People should be informed they could develop 
diabetes when diabetogenic medicines are prescribed. 
 
Several mechanisms have been proposed for the diabetogenic effects of steroids. 
These include: 
 
• Enhancing gluconeogenesis by upregulating key regulatory hormones that 
contribute to hyperglycaemia such as glucose-6-phoshatase and 
phosphoenolpyruvate carboxylase. 
• Suppressing insulin release from the beta cells. 
• Inducing peripheral insulin resistance by inhibiting production of glucose 
transporters in adipose and skeletal muscle cells. 
Both fasting and post prandial blood glucose levels are affected. 
 
These proposed mechanisms of action suggest the key areas to target when 
developing strategies to manage IGT, IRS, and steroid-induced diabetes.  However,  
the effect on blood glucose depends on the biological action of the specific 
corticosteroid medicine and the period of time it is used for as well as the individual’s 
personal risk of developing diabetes.  Hyperglycaemia usually occurs when doses of 
Prednisolone or equivalent medicines exceeds 7.5 mg/day.  In contrast, short courses 
may not cause hyperglycaemia or only have a short term effect on the blood glucose. 
 
Corticosteroids can also mask the signs and symptoms of infections, which often do 
not present in the usual way in people with diabetes and can be difficult to detect.  
The skin can become thin and fragile and prone to tears. If not managed, these effects 
can cause considerable discomfort and distress. Corticosteroids also have variable 
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effects on bone formation and reduce calcium absorption from the intestine, which 
predisposes susceptible individuals to osteoporotic fractures and pain.  
Mental changes can also occur ranging from mild psychosis to significant pathology.  
These effects can be distressing for the individual and carers. 
 
Managing medicine-induced diabetes in palliative care patients 
Balancing the need for corticosteroid medicines with their effects on glucose 
homeostasis is multifactorial and challenging and is affected by individual 
susceptibility, meal schedules, whether dosing is intermittent or continuous and the 
diabetogenic effects of the individual medicines. Table 8 (next page) outlines an 
appropriate diabetes management strategy for people with medicine-induced diabetes.  
 
 
Palliative care symptoms and diabetes 
Sub-optimal symptom control can be due to the diabetes or the life-threatening 
primary illness or both.  Distinguishing between cause and effect can be difficult. 
Symptoms not caused by diabetes can have significant effects on diabetes 
management.  Table 9 (pages 118–121) outlines the relationships between common 
palliative care symptoms and diabetes.
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Table 8.  Managing medicine-induced diabetes.  
 
1.  Pre-prescription evaluation • Screen for diabetes risk factors. 
• Complete assessment and medical history. 
• Undertake a comprehensive medicine review 
including self-prescribed and complementary 
medicines. 
• Provide education and counselling about 
weight, diet and activity. 
• Select the most appropriate medicine and use 
the least diabetogenic medicine for shortest 
duration, if possible (Quality Use of 
Medicines principles). 
• Monitor blood glucose regularly. 
 
2.  Individualise therapy • Choose an appropriate medicine (as above). 
• Reduce diabetogenic medicine doses as soon 
as possible. 
• Set blood glucose target and commence 
relevant oral hypoglycaemic agents (OHAs) 
or insulin, if indicated e.g. blood glucose 
consistently > 7 mmol/L. 
• Target post-prandial blood glucose levels, use 
long acting insulin analogue. Add prandial 
insulin (meal time) use rapid acting analogue 
if indicated. 
 
 
3.  Monitor • Self-blood glucose testing regularly. 
• Test ketones if person has type 1 and blood   
glucose is high. 
• The need to continue corticosteroids. 
• Reduce OHA/insulin doses as steroid doses 
are reduced. 
• Monitor physical and mental status. 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
121 
Table 9.   The relationship between common palliative care symptoms and 
diabetes.  (Table continues over 4 pages) 
 
Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
Pain 
(acute/chronic) 
 
Increased:  
- somnolence or confusion/cognitive 
impairment due to pain/analgesia 
- risk of hyperventilation 
- hyperglycaemia 
Reduced: 
- intake 
- mobility 
- sleep 
- self-care ability  
- quality of life 
- Peripheral vascular 
disease 
- Amyotrophy 
- Peripheral neuropathy 
- Myocardial Infarction 
(MI) 
- Tissue glycosylation 
(e.g. carpel tunnel 
syndrome) 
- Ketoacidosis 
(abdominal pain) 
 
Depression/ 
anxiety 
 
Increased:  
- fatigue 
- lethargy, change in performance status 
- risk of DKA, HONK 
- social isolation 
Reduced: 
- self-care ability, disinterest increased 
risk of hyperglycaemia 
- confidence 
- inadequate nutrition increased risk of 
hypoglycaemia 
- effects on communication and self-care 
 
- Associated with 
diabetes especially 
hyperglycaemia 
- Renal disease 
- Corticosteroid 
medicines 
- Hypoglycaemia 
symptoms can be 
mistaken for anxiety 
Oral Pathology 
(oral and 
maxillofacial 
pathology)  
Increased: 
- pain 
- dry mouth 
- inadequate nutrition, inappropriate 
- Diabetic ketoacidosis 
(DKA), hyperosmolar 
states (HONK) may 
lead to dry mouth, 
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Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
pathology)  
Mucositis, 
ulcers, dry 
mouth 
weight loss, cachexia, hypoglycaemia 
if on OHA/insulin 
 
Reduced: 
- intake 
- self-care deficits 
- mood 
lead to dry mouth, 
thirst and clinical 
dehydration 
- Risk of dental caries 
and oral pathology 
- Risk of hypoglycaemia 
if on OHAs or insulin 
Nausea/vomiting 
 
Increased: 
- confusion 
- lethargy 
- disinterest  
- pain/discomfort 
- inadequate nutrition → weight loss, 
cachexia, hyperglycaemia 
- hypoglycaemia if on OHA/insulin 
- dehydration and electrolyte imbalance 
- risk of ketoacidosis 
Reduced: 
- intake  
- energy, depleted energy stores 
- May be due to gastric 
autonomic neuropathy 
- Renal disease 
- Hyperglycaemia – 
DKA, HONK 
- Medicines: 
- Metformin 
- Byetta 
Delirium 
 
Increased: 
- cognitive impairment 
 
Reduced: 
- ability to communicate and detect 
signs/symptoms of 
hypo/hyperglycaemia  
- self-care ability  
- May be due to many 
factors including hyper 
and hypoglycaemia 
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Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
Sepsis 
 
 - May be silent in 
diabetes (urinary tract 
infection (UTI), MI) 
- May precipitate DKA, 
HONK 
Acute Dyspnoea 
 
Increased: 
- hypoxia contributing to confusion  
Reduced: 
-     self-management capacity 
 
Note: MI often silent in diabetes 
Increased: 
- confusion 
- energy requirements 
- pain 
- difficulty interpreting 
elevated white cell 
count, which could be 
caused by  
hyperglycaemia, 
sepsis, or other factors 
-     bone marrow failure 
Reduced: 
- intake increased  DKA, 
HONK risk 
- quality of life 
- wound healing 
Diabetes 
Emergencies 
Examples: 
- Hypoglycaemia 
- Hyperglycaemia 
- MI 
- Hypoglycaemia 
- DKA, HONK, Lactic 
acidosis 
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Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
Oncology 
Emergencies 
 
 
Examples: 
- Spinal Cord Compression 
(corticosteroids) and acute immobility 
- Superior vena clava (SVC) obstruction 
(acute dyspnoea and delirium) – high 
dose of corticosteroids 
- Febrile neutropenia 
- Major bronchial obstruction (dyspnoea 
and use of corticosteroids) 
- Hypoglycaemia 
-     DKA, HONK, Lactic 
acidosis 
 
Considerations when using the Guidelines   
The key themes that emerged from the interviews with patients and their family 
members/carers that were conducted to ensure the guideline development process was 
consistent with NHMRC recommendations and people with diabetes and their 
relatives’ voices were heard, follow.  Importantly, these themes are consistent with the 
guiding principles developed as the conceptual framework for the Guidelines 
development project. 
 
• Care should be individualised for each patient because the situation, diagnosis and 
responses of each individual are unique. 
• Patients want a consistent approach to their diabetes management.  When they are 
cared for by health professionals they want their diabetes management to be 
consistent with their usual self-management practices, and they want different 
health professionals to be consistent in how they manage the patient’s diabetes. 
• Comfort is very important to patients and interview participants stressed that they 
want their diabetes managed to prevent unpleasant symptoms of hypoglycaemia 
and hyperglycaemia. 
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• Most patients want some say in how their diabetes is managed, but are happy for 
experienced health professionals to work with their family/carers to make 
decisions when they are no longer able to do so, if they have not communicated 
their wishes in an Advanced Care Directive. 
• Family members/carers need education about managing diabetes as the patient’s 
health deteriorates and the family member/carer takes on new responsibilities. 
 
 
General considerations—diabetes and all palliative care phases 
Goal of care  
• Symptom management and support for the patient. Manage diabetes using the 
Guidelines for each PCOC phase in people diagnosed with diabetes.  Identify 
diabetes or impaired glucose tolerance in non-diabetics for example, those on 
corticosteroids to enable appropriate timely care and symptom control. 
• Consider the patient’s wishes and choices when making decisions about diabetes 
management. 
• Discuss changes in diabetes management with other relevant health professionals, 
the patient and family members/carers. 
• Include diabetes management in care plans and advanced care planning 
directives. 
• Provide education to the patient and their family members or carers concerning 
the focus of care, which focuses on preventing symptoms of 
hypo/hyperglycaemia and their consequences and enhancing quality of life.  
However, long term diabetes complications may be present and affect palliation, 
general care plan, medicine choice, and contribute to or be the cause of 
symptoms.  Therefore, they must be identified and managed. 
• Involve an interdisciplinary health team to foster inclusive, collaborative goals of 
care (endocrinologist, diabetes educator, palliative care specialists—
medical/nursing; psychologist; social worker; occupational therapist; 
physiotherapist; pastoral care worker) and communication. 
• In addition to the tools already used to assess patients, assess whether the patient 
has diabetes and/or the signs and symptoms of diabetes.  
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• Blood glucose monitoring is an important decision-making tool rather than an 
unnecessary intervention. 
• Admissions may be needed for acute illnesses. 
 
Stable phase 
General considerations  
• The goals of care are symptom management and support for the patient and 
carers to maintain independence and self-care capacity as long as possible. 
 
• Determine the cause of the symptoms and whether diabetes is causing or 
exacerbating symptoms. 
 
• The stable phase represents a ‘window of opportunity’ to identify, 
acknowledge and document patient’s wishes for current and future diabetes 
management.  Initiate Advanced Care Planning including preferences for 
future diabetes management 
 
• Assess carer’s capacity to provide care and their need for diabetes education. 
 
• Management begins with a thorough clinical assessment and medicines review 
during which the patient’s and carer’s level of understanding and current 
treatment regimen is evaluated.  
 
• If the patient’s blood glucose pattern is stable and in an acceptable range (4-8 
mmol/L) continue current treatment regimen.  The assessment should include 
documenting the presence of long term complications and a medication 
review.  Liver/renal disease may mean OHAs and some other medicines are 
contraindicated.  Determine whether the patient is using complementary 
medicines (CAM) or other CAM therapies and their safety and efficacy and 
potential interactions with conventional medicines. 
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• The patient’s diet may need to be revised and supplements may be needed 
particularly if anorexia or cachexia is present.  The patient and carers may 
need significant explanation and education if the diet changes significantly 
from the diet they have been familiar with for many years. 
 
• Glucocorticoids induce glucose intolerance and insulin resistance and may 
cause blood glucose levels to rise.  People prescribed these medicines often 
need insulin to control blood glucose levels and diabetes symptoms.  The 
effect of corticosteroids on glycaemic control varies with individual 
corticosteroid medicines and among individuals.   
  
• Other medications can cause hyperglycaemia, for example, atypical 
antipscychotics, thiazide diuretics and octreotide (a somastatin analogue). 
 
• Blood glucose monitoring is advisable to identify hyperglycaemia early and 
manage it to reduce the impact of diabetes-related symptoms on pain, mood 
and quality of life and prevent consequences such as DKA, HONK and lactic 
acidosis. 
 
• Blood glucose testing for patients who are not on corticosteroids could be once 
to twice a day.  Increase the frequency of blood glucose monitoring if 
symptoms develop or the patient becomes ill.  In the stable phase this might be 
every 2–4 hours depending on the type of diabetes.  Patients with type 1 
diabetes should also be tested for ketones. 
 
• If the patient is on corticosteroids refer to Part 3 of the Guidelines. 
  
Case study 
“A” is a 78-year-old woman with severe dementia and type 2 diabetes.  She lives in a 
residential aged care facility and requires full nursing care including continence 
management.  She has no Advanced Care Plan.  She previously had very limited 
intake, which became much worse in the last three months, and her family have 
requested a palliative approach. 
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• Ascertain whether there is an Enduring Medical Power of Attorney (EMPOA) 
or limitation of treatment order.  An Advanced Care Plan is vital to establish 
the boundaries of care and help health professionals respect the individual’s 
wishes.  
•  “A” may need insulin to prevent hyperglycaemia if oral medicines are 
stopped.  Insulin should be considered with the other ‘core’ out-of-hours 
emergency medicines to ensure it is available as part of the contingency plan 
as part of the discussion with other health professionals, in particular with her 
General Practitioner.  Including insulin in the ‘core’ medicines list should 
minimise the risk of an inappropriate/unwanted out-of-hours admission to 
hospital. 
Unstable phase 
General considerations  
• The goal of care is to rapidly identify the cause/causes of the instability, treat 
the cause/s if possible, manage symptoms and support the patient and his or 
her carers. 
 
• Consider whether the phase is likely to revert to stable or continue to the 
deteriorating or terminal phases. 
 
• Determine the cause of symptoms and whether hypo/hyperglycaemia could be 
causing or exacerbating symptoms.  Monitor BGLs regularly for example 
every four hours while her condition is unstable.   
 
• Provide education to the patient and his or her family members or carers about 
the focus of care, which should be on preventing symptoms of 
hypo/hyperglycaemia and their consequences and enhancing quality of life.  
However, short and/or long term complications may be present and affect 
palliative care, medicine choice and contribute to or be the cause of symptoms.  
Therefore, ideally, they should be identified and managed. 
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• Review her medicines regimen, including any CAM treatments and self-
prescribed medicines she might be using, considering her complication status 
and BGL pattern, and potential medicine interactions. 
 
• Several symptoms of advanced cancer are similar to those of hyperglycaemia. 
It is important to consider diabetes as a possible cause of symptoms.  Blood 
glucose monitoring is important to determine whether diabetes is involved. 
 
• If changes in symptoms are due to intercurrent illness, treat the cause and/or 
consider whether an emergency department or hospital admission is needed.  
Consider the possibility that DKA could occur in type 1 diabetes and test for 
ketones.  Blood ketone testing is preferred over urine ketone testing. 
 
•  The patient’s diet may need to be revised and supplements may be needed 
particularly if anorexia or cachexia is present.  The patient and carers may 
need significant explanation and education if this is a radical change from the 
diet they have been familiar with for many years. 
 
• Ascertaining the patient’s and family’s wishes is vital to determine the 
boundaries of investigating the primary disease and progressive co-
morbidities.  Using disease-specific prognostic tools when they are available, 
these tools can also assist health professionals obtain informed consent from 
the patient or carers.  General prognostication such as functional status prior to 
the period of instability might help determine the appropriate approach. 
Case study 
“B” is a 60-year-old woman with renal failure, cardiovascular disease (NYHA stage 
IV) and type 1 diabetes.  Her weight has decreased from 80 kg to 65 kg over the last 
six months.  B is unstable due to increasing dyspnoea at rest, a prolonged episode of 
chest pain, and delirium. She has been taking regular long acting opioids (morphine).  
B has an Advanced Care Plan (ACP).  
 
• Consider what symptoms represent and what can and cannot be controlled or 
reversed.  There are many causes of delirium. 
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• Determine whether the ACP covers her diabetes management preferences or the 
contingency that this may represent acute on chronic renal impairment? 
• B’s symptoms, including delirium, may be due to hyperglycaemia leading to 
dehydration, or hypoglycaemia including nocturnal hypoglycaemia, and she may 
need acute complex management. 
• B’s dose or choice of opioid may change depending on the degree and rapidity of 
her renal function decline and further renal impairment. 
• Her 19% recent weight loss is a very significant prognostic factor and needs to be 
considered when formulating a management plan as well as considering her pre-
existing diabetes and renal impairment. 
• If renal and diabetic causes are excluded, a host of other factors that could cause 
or contribute to the presenting picture including opioid toxicity, hypoxia, stroke, 
thromboembolism and ketoacidosis need to be considered. 
• Determining the venue of immediate care and the degree of intervention is 
complex and may require a senior clinician’s guidance. 
 
Deteriorating phase 
General considerations  
 
• The goal of the deteriorating phase is to support and comfort the patient and 
carers, maintain comfort, dignity and autonomy as long as possible and 
maximum comfort. 
 
• Generally, do not cease insulin for patients with type 1 diabetes in this phase 
but dose reductions may be indicated. 
 
• Check the patient’s Advance Care Plan if they have one.  If not, ascertain their 
wishes as a matter of urgency. 
 
• Provide education for the patient and their family members or carers about the 
focus of care, which should be on preventing symptoms of 
hypo/hyperglycaemia and their consequences and enhancing quality of life. 
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However, short and long term diabetes complications may be present and 
affect palliative care and medicine choice and contribute to or be the cause of 
symptoms. Therefore, ideally they should be identified and managed. 
 
• Weight loss, lack of appetite and decreasing performance status are the main 
expected issues in this phase. Maximising and maintaining as much function 
as possible may require a multimodality approach including nutritional 
supplements, exercise including resistance training and orexigenic medications 
that can alter glucose metabolism and diabetes management.  Examples 
include glucocorticoids and agents such as megestrol acetate.  The diabetes 
management plan will need to be revised if these interventions are used. 
 
• The patient’s diet may need to be revised and supplements may be needed 
particularly if anorexia or cachexia is present.  The patient and carers may 
need significant explanation and education if this is a radical change from the 
diet they have been familiar with for many years. 
 
• Several symptoms of advanced cancer such as dry mouth and polydipsia are 
similar to the symptoms of hyperglycaemia.  It is important to consider 
diabetes as a possible cause of symptoms, which, if corrected will enhance 
comfort.  Blood glucose monitoring is important to determine whether 
diabetes is involved.  
 
• If changes in symptoms are due to intercurrent illness, consider whether 
treatment and/or an emergency department or hospital admission is needed. 
 
• A patient with diabetic ketoacidosis (DKA) or hyperosmolar non-ketotic 
(HONK) coma may not actually be in a coma.  If these conditions are present 
insulin is generally needed. 
 
• Ketone testing is important in type 1 diabetes during illness and 
hyperglycaemia to detect DKA early.  DKA can contribute to pain and 
cognitive changes.  Insulin doses may need to be increased to manage ketosis. 
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Case study 
“C” is a 65-year-old male with metastatic non-small cell lung cancer.  He has 
cachexia and is taking dexamethasone.  He has steroid-induced diabetes.  C has no 
Advanced Care Plan. 
 
• Determine the patient’s wishes and suggest he develops an ACP. 
• C may need insulin when on high dose Dexamethasone.  Note the syndrome of 
cancer cachexia may increase insulin resistance. 
• C’s insulin doses and dose frequency will need to be carefully titrated when his 
Dexamethasone dose is weaned or increased. 
• Regular blood glucose monitoring will provide important information on which to 
base insulin dose adjustments. 
• The patient and carers may need diabetes education because Mr C’s diabetes is a 
very ‘new’ diagnosis.  Education should include blood glucose testing and 
medicines management.  They may be distressed at dealing with a new illness in 
addition to the primary lung cancer.  It may all feel ‘too much;’ support and 
counselling may be needed. 
 
Terminal phase 
General considerations  
  
• The goal of the terminal phase is to maximise comfort and ensure a peaceful 
transition to death. 
• Very limited or no oral intake is often a sign that death may be close. 
Providing mouth care may be the major comfort measure. 
 
• Decisions should be made about which medicines can be stopped and whether 
blood glucose testing should be continued or stopped, explored.  Check the 
patient’s Advance Care Plan if they have one.  If not, ascertain their wishes as 
soon as possible. 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
133 
 
• A patient with diabetic ketoacidosis (DKA) or hyperosmolar non-ketotic 
(HONK) coma may have an impaired conscious state.  These states should be 
excluded as the cause of ‘the terminal phase’ and treated to manage symptoms. 
 
• Glucocorticoids may no longer confer any symptom or quality of life benefit 
and could be ceased. 
 
Case study 
“D” is a 40-year-old woman with breast cancer and depression.  D has type 1 diabetes 
and no Advanced Care Plan. 
 
• Determining D’s judgement regarding the boundaries of care may be difficult due 
to her depression and no pre-morbid ACP. 
• The duration of the terminal phase may influence the approach to managing her 
diabetes care.  If she dies in a matter of a few hours the issue may not arise, but 
some people can remain in the terminal phase for days and insulin or other 
interventions may be needed to promote comfort.  The ethical considerations may 
be complex and need a multi-disciplinary approach and senior clinicians 
discussing the issues with her family so they can make a substituted judgement. 
• Consider whether D’s depression can be treated in the timeframes indicated by 
your prognostication, or whether it is caused or affected by her blood glucose 
levels. 
• Her insulin requirements may change dramatically and she may need a more 
flexible dose regimen. 
• Blood glucose and ketones monitoring will help plan care to prevent short-term 
symptoms and ease her discomfort. 
• All oral medicines may need to be rationalised with a view to stopping them. 
Full case study 
“E” is a 55-year-old male with colorectal cancer and long standing type 2 diabetes 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
134 
E lives alone with his dog.  He is Italian and has limited English.  He presented with 
rectal bleeding and was diagnosed with metastatic colorectal cancer (bulky liver 
metastases) following palliative bypass surgery during which widespread peritoneal 
seeding was noted.  He often experiences nausea and vomiting, he has had peripheral 
diabetic neuropathy (PDN) for over 20 years.  He has episodes of angina and erectile 
dysfunction. 
E has not told his health care professionals that he takes some complementary 
medicines (CAM). He consumes 10–20 standard units of alcohol per day and 
probably drank more in the past. 
 
Shortly after being admitted to a community palliative care program he phoned 
complaining of severe abdominal pain associated with nausea and vomiting.  He has 
been reluctant to monitor his blood glucose in the past and is reluctant to do it now. 
He does not want to come into hospital, which was suggested by the community 
nurse.  He is drowsy and relatively immobile. 
 
Unstable phase 
Key issues: 
• Exclude hyperglycaemia as a cause of his symptoms. 
• Determine what his current diabetes medicine regimen is and whether he takes 
his medicines.  There could be interactions with his CAM medicines.  Some 
OHA may be contraindicated given his alcohol intake. 
• The long standing alcohol intake may have caused liver disease and nutritional 
deficiencies. 
• His social isolation means that supporting his care requirements or new 
diabetes regimen will be very difficult even with frequent community nursing 
visits. 
• Clinically, he appears to have a sub-acute bowel obstruction.  He is not able to 
take any oral intake.  E thinks he is dying. 
• After explaining that his symptoms might improve with simple non-surgical 
approach he agrees to a hospital admission if his dog can be cared for.  His 
PDN has worsened with recent (weeks) of non-adherence to his adjuvant 
analgesics.  He will need: 
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- IV fluids. 
- Intravenous infusions to deliver analgesics and anti-emetics. 
- He may be prescribed high dose corticosteroids. 
- He may need an insulin infusion and then regular insulin doses while he is 
on glucocorticoids. 
- Medicines to prevent alcohol withdrawal symptoms. 
 
E’s symptoms settle with the regimen described above and after five days he insists 
on returning home on BD insulin after meeting the diabetes team once and the 
diabetes educator once more. 
 
Stable Phase 
Once home he is well supported by the community care team and a further outpatient 
visit to the diabetes educator.  He is able to stop his dexamethasone and his OHAs and 
regular analgesia for PDN are recommenced. He admits the major reason he wants to 
return home is his dog. 
 
Key issues: 
• Careful monitoring during corticosteroid dose titration. 
• Significant education was required when he commenced insulin 
• It is important to explore his wishes in general and that an ACP is started. 
• Social work involvement is important to help address social interventions and 
to discuss t his preferences for his pet’s care into the future. 
• Contingency medications, care plans, and orders need to be in place. 
 
He remains well for three months following an endocrinology review and his cancer is 
relatively indolent, with stable liver disease and no major episodes of obstruction, on 
an oral chemotherapy regimen. 
 
Deteriorating phase 
Over the next few months E complains of increasing abdominal distension and 
becomes jaundiced.  He notes his muscles are wasted.  His nausea increases in 
frequency and his appetite diminishes.  He is re-commenced on Dexamethasone to 
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improve his appetite, wellbeing and nausea.  He is given some nutritional 
supplements.  His alcohol intake reduces dramatically.  He admits he feels depressed.  
He finally agrees to complete his advanced care plan. 
 
Key issues: 
• His weight is unlikely to reflect his muscle mass due to probable ascites. 
• His caloric intake may be dramatically reduced (alcohol and general intake). 
• BGL monitoring is required when he commences glucocorticoids. 
• Insulin may be required when on glucocorticoids but the doses may be lower 
than before due to his weight loss and other factors. 
• Contingency plans that reflect his ACP should be in place. 
• Consider the effects of acute alcohol withdrawal. 
• An appetite stimulating antidepressant (many suppress appetite) may be part 
of a treatment plan for his depression. 
• Discussion regarding his preferences for venue of terminal care should be 
finalised and the timing of when his dog should be moved to the home that 
agreed to adopt it, explored. 
• If the decision is to treat his anorexia/cachexia, the ramifications for his 
diabetes management should be considered. 
• If he is deemed to be clinically depressed this may effect whether his ACP was 
based on informed consent from a competent individual. 
 
Terminal Phase 
A few weeks later E becomes drowsy, bed-bound, confused and is noted to be much 
more jaundiced with obvious hepatic asterixis (liver flap).  He outlined in his ACP (he 
was not thought to be clinically depressed when he made it) that when this occurred 
he wished to be admitted to the local palliative care unit for terminal care and that his 
dog should go to the home that agreed to adopt it.  He confessed he has an estranged 
son and asks to see the priest despite letting his faith lapse. 
 
Key issues: 
• Oral medications should be rationalised and it is likely that most, if not all, 
oral medicines could be stopped. 
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• Routine blood tests may indicate whether this is truly a terminal event and 
exclude reversible causes. 
• Blood glucose monitoring will guide what type of insulin regimen he will 
need, although his ACP stated that in the terminal stages he wanted comfort 
measures only. 
• Regular antipsychotic medicines may help control the symptoms of delirium. 
• He may need higher doses of sedatives to reduce terminal restlessness based 
on his long standing alcohol history. 
• His estranged family should be contacted and supported as needed. 
• His spiritual requests should be respected and the priest contacted. 
• Symptoms of alcohol withdrawal should be monitored and PRN medications 
to reduce the discomfort provided if needed.  
 
E dies 36 hours later in the company of his adult son having required medicines 
through a syringe driver to manage his agitation. 
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THE DRAFT GUIDELINES 
 
The final draft of the Guidelines for managing diabetes at the end of life is presented 
on the following pages.  The document consists of three separate sections:  
• screening for diabetes 
• managing diabetes in the PCOC phases of stable, unstable, deteriorating and 
terminal  
• managing medicine-induced diabetes in patients requiring palliative care.  
 
The draft Guidelines are shown on pages 138 to 144.  They are the result of many 
iterations. Features of the section about managing diabetes in the PCOC phases 
include a consistent format presenting general considerations, information about 
assessing and managing diabetes in separate columns, and include notes highlighting 
the differences in managing type 1 and type 2 diabetes for each PCOC phase rather 
than providing separate guidelines for type 1 and type 2 diabetes for each PCOC 
phase.  However, the section about medicine-induced diabetes does present separate 
information for people with type 1 and type 2 diabetes, based on the recommendation 
of the Advisory Committee.  
 
A succinct version of the accompanying document to the Guidelines was compiled to 
support health professionals to use the Guidelines in clinical practice.  The brief 
accompanying document comprised (see Appendix C): 
• A brief outline of diabetes management. 
• A description of hyperglycaemia and hypoglycaemia. 
• Information about corticosteroid medicines. 
• Details about the Quality Use of Medicines (QUM) Framework and its application 
to managing diabetes at the end of life. The QUM Framework figure in Appendix 
C is an early representation of the Framework. 
• A detailed table presenting the relationship between common palliative care 
symptoms and diabetes. 
• A list of abbreviations and symbols used in the Guidelines. 
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EVALUATING THE GUIDELINES 
Processes utilised to evaluate the Guidelines 
Three processes were utilised to obtain feedback about the draft Guidelines from 
palliative care health professionals during the formative and summative evaluation 
processes: 
• An information and discussion session with palliative care health professionals. 
• A questionnaire distributed to palliative care health professionals working in 
Barwon Health, Geelong. 
• Interviews with palliative care health professionals after the draft Guidelines were 
refined and the health care professionals had the opportunity to use them to plan 
care for people with diabetes at the end of life. 
 
1. Formative Evaluation 
Information and discussion session 
Method 
Twenty-nine health care professionals (HPs) working in palliative care in Barwon 
Health were invited to attend an information and discussion session concerning the 
development of Guidelines for managing people with diabetes requiring palliative care. 
The HPs received a personalised information package containing an explanation of the 
research project, a letter inviting them to information session, a copy of the draft 
Guidelines, the draft information to accompany the Guidelines, and a brief 
questionnaire about the Guidelines.  
 
The information session was held in the McKellar Centre (where the palliative care 
team meeting takes place) immediately after a regular palliative care team meeting on 
November 4th, 2009.  Inpatient and community palliative care teams attend the regular 
meetings.  Fifteen palliative care beds are located in The McKellar Centre.  The 
researchers introduced the research and progress to date prior to guiding an open forum 
discussion about the draft Guidelines.  Two researchers took notes to record the 
discussion. 
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A total of 21 palliative health professionals attended the information session 
comprising: 
− ten nurses  
− two doctors 
− two Department of Health Representatives (these people attended the regular team 
meeting and were invited to stay for the information session.  They did not receive 
information packages prior to the meeting because the researcher’s did not know 
they would be present 
− seven Medical students undertaking clinical placement attended but did not receive 
information packages prior to the meeting because the researchers did not know 
they would be present. 
 
Results 
The discussion was interactive, open and wide ranging and included many aspects of 
palliative care and diabetes management, thus the notes from the discussion were not 
amenable to thematic analysis.  A summary of the discussion is presented as general 
comments and comments specifically about the Guidelines.  
 
General comments about managing diabetes at the end of life: 
• HPs identified two groups of diabetes patient’s requiring palliative care: 
i. Preterminal—in which HPs are ‘more proactive in blood glucose control.’  
ii. End stage or terminal—where HPs stated they became ‘neglectful’ about 
monitoring and treating diabetes.’ 
• HPs indicated it is very complex managing diabetes at the end of life and made 
statements such as should I ‘do BG monitoring … it’s painful’ and ‘manage 
symptoms as we [HPs] perceive them.’ 
• HPs asked ‘does BG control equal better symptom control?’ and questioned the 
need to ‘change established practice.’  However, established practice is possibly ad 
hoc based on the previous experience of the researchers.  
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• HPs acknowledged the significant effect of corticosteroids noting ‘I know it will 
increase blood glucose, therefore, we should test more.’ and ‘it is one of the 
accepted side effects [of the medication].’ 
• HPs recognised the need to ‘find a balance to find the best outcome’ and mentioned 
times such as when ‘the patient may not be eating’ as significant.’  
• Some HPs agreed to ‘go with the best interest of the patient’ but did not say how to 
identify or achieve the ‘best interest of the patient.’   
• HPs noted the complexities of managing diabetes in care settings in which 
palliative care is provided and stated that an inpatient setting has more staff, 
control, and routine as opposed to the home setting where carers are often informal 
and often do not have medical/nursing backgrounds.  
 
Specific comments about the Guidelines included: 
• A senior Community Palliative Care nurse stated: 
The Guidelines are great … [they] identify things that can identify diabetic 
situations at home… sometimes diabetes can be seen as less problematic when 
it might not be … [I] found it [Guidelines] helpful to guide me …[they] seem a 
bit overwhelming but then once it [information] settles … comprehension is 
good. 
• Participants indicated ‘[The Guidelines provide] a sharper focus to identify issues 
that can affect diabetes management at home because diabetes management is seen 
as the least important.’ 
• A community palliative care nurse liked the presentation of the ‘unstable’ type 1 
and 2 management Guidelines, however, she questioned community nurses’ ability 
to test for ketones and thought the explanation about ketone testing in the 
accompanying document could be clearer.   
• HPs agreed the language in the Guidelines was appropriate and ‘made sense.’  
• One senior medical officer asked where the Guidelines will ‘fit’ in other settings:  
Barwon Health versus other facilities… other facilities do not have the 
community resources we have … however, at least the Guidelines may alert 
HPs to the issues surrounding diabetes management.   
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He then commented that, in remote areas ‘[the Guidelines may] help HPs know 
where to refer.’ 
• A senior medical officer asked whether hypercalcemia needed to be included in the 
Guidelines and suggested a clearer explanation about the issue was needed in the 
accompanying document.   
•  HPs agreed that ‘often GPs manage diabetes at the end of life … and the care is 
often ad hoc.’   
• One HP recommended including a podiatrist in the list of HP specialists to refer 
the patient to.  
 
Questionnaires distributed to palliative care health professionals 
Method 
The researchers developed a questionnaire specifically for the study to evaluate the 
Guidelines after HPs comments raised in the discussion group were included.  The 
questions addressed the content, presentation and style of the Guidelines; information 
in the Guidelines that was not useful and information that was missing; and feedback 
based on their use of the Guidelines with at least one patient with diabetes requiring 
palliative care.  The questionnaire is presented in Appendix D.  The questionnaire in 
general performed well.  Missing data were limited, responses to individual questions 
were appropriate suggesting the questions were clear and participants took the time to 
provide detailed responses to the open questions. 
 
The researcher distributed the questionnaire and information package to 22 palliative 
HPs who regularly attended the palliative care team meetings, prior to the information 
session.  The charge nurse of the Palliative Care Unit in the McKellar Centre 
distributed the questionnaire and information package to seven HPs working in the unit.  
Due to an oversight, and unknown to the researchers, these packages did not include 
the brief accompanying information document that provides essential information about 
the Guidelines.  A further four health professionals who commenced working in 
palliative care after the information session was held were provided with the package 
and educated about the Guidelines by the researcher.  
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Results 
At the conclusion of the information and discussion session, 16 completed 
questionnaires were placed in the sealed box provided by the researchers.  An 
additional four questionnaires were returned to the researcher or to the research office.  
Thus, twenty completed questionnaires of the 33 distributed were returned, giving a 
response rate of 61%.   
 
The majority of respondents were nurses (n = 17), two were doctors and one worked in 
allied health.  Three respondents had worked in palliative care for less than one year, 
three for two to five years, nine for six to nine years, four for ten years or more, and 
one respondent did not answer the question.  
 
The first nine questions concerning the Guidelines related to the design, language and 
consistency with palliative care principles. Respondents were asked to rate their 
response according to a Likert scale.  The responses to these nine questions are 
summarised in Table 10 on page 151.  
 
Palliative care HPs were generally positive about the Guidelines.  The majority strongly 
agreed or agreed that the language used in the Guidelines was consistent with palliative 
care language (90%), and 85% strongly agreed or agreed that the Guidelines were 
consistent with palliative care procedures.  Seventy five percent of respondents liked 
the design of the Guidelines, only 25% reported they were difficult to follow in some 
places but most did not provide a reason.  It was some concern that 20% partially 
agreed with the statement ‘I find the language in the Guidelines difficult to understand’ 
but did not explain why. Thus, it was difficult to take these comments into 
consideration when the draft Guidelines were revised. 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
155
 
Table 10.  Responses made by HPs to questions about the design and language of 
the Guidelines and their consistency with palliative care principles (n = 
20).  
 
 
 
 
 
 
 
Strongly 
disagree 
  
 
Freq  
(%)* 
Some-
what 
disagree 
 
Freq 
(%) 
Neither 
agree 
nor 
disagree 
Freq   
(%) 
Some-
what 
agree 
 
Freq 
(%) 
Strongly 
agree 
 
 
Freq 
(%) 
Miss-
ing 
 
 
Freq  
(%) 
I like the design of the Guidelines 
 
0 
 
0 
 
5 
(25%) 
 
9 
(45%) 
 
6 
(30%) 
 
0 
The Guidelines are difficult to 
follow 
 
5 
(25%) 
 
9 
(45%) 
 
1 
(5%) 
 
4 
(20%) 
 
1 
(5%) 
 
0 
The language used in the 
Guidelines is appropriate 
 
0 
 
2 
(10%) 
 
1 
(5%) 
 
9 
(45%) 
 
8 
(40%) 
 
0 
 
The colours used in the 
Guidelines make the information 
easy to read 
 
0 
 
1 
(5%) 
 
4 
(20%) 
 
4 
(20%) 
 
10 
(50%) 
 
1 
(5%) 
I find the design of the 
Guidelines confusing 
 
6 
(30%) 
 
7 
(35%) 
 
4 
(20%) 
 
3 
(15%) 
 
0 
 
0 
The Guidelines are easy to follow 
 
0 
 
4 
(20%) 
 
3 
(15%) 
 
8 
(40%) 
 
5 
(25%) 
 
0 
 
I find the language in the 
Guidelines difficult to 
understand 
 
7 
(35%) 
 
6 
(30%) 
 
3 
(15%) 
 
4 
(20%) 
 
0 
 
0 
The language used in the 
Guidelines is consistent with 
palliative care language 
 
0 
 
0 
 
2 
(10%) 
 
12 
(60%) 
 
6 
(30%) 
 
0 
The Guidelines are consistent 
with palliative care procedures 
 
1 
(5%) 
 
1 
(5%) 
 
1 
(5%) 
 
10 
(50%) 
 
7 
(35%) 
 
0 
 
*  Percentage totals may not sum to 100 due to rounding of decimal places for clarity  
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When asked whether the Guidelines contained any information that is not needed, most 
respondents indicated all the information was relevant (see Table 11).  Thirty per cent 
of respondents suggested some other information that could be included in the 
Guidelines: two people suggested including a glossary of abbreviations, one suggested 
including the frequency of screening patients with diabetes risk factors, one suggested 
including when to discontinue lipid lowering medicines and one suggested including a 
podiatrist on the list of specialist health professionals to refer patients to.  Significantly, 
several respondents suggested discussing what care they want with the patient and 
relatives should be the first priority. 
 
 
Table 11.   Responses HPs made to questions about the Guidelines (n = 20). 
   
 
 NO 
Freq (%*) 
YES 
Freq (%) 
Missing 
Freq (%) 
Q10.  Do the Guidelines contain any 
information that is not needed? 
16 
(80%) 
1 
(5%) 
3 
(15%) 
Q11.  Is there any other information that 
should be included in the Guidelines? 
 
10 
(50%) 
 
6 
(30%) 
 
4 
(20%) 
 
Q12.  Are the Guidelines consistent with the 
PCOC palliative care principles? 
 
 
0 
 
17 
(85%) 
 
3 
(15%) 
Q13.  Do you feel it will be feasible to apply 
the Guidelines in routine clinical practice? 
 
 
2 
(10%) 
 
17 
(85%) 
 
1 
(5%) 
 
* Percentage totals may not sum to 100 due to rounding of decimal places for clarity.  
 
. 
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Most respondents thought the Guidelines were consistent with the PCOC palliative care 
Guidelines and that the Guidelines would be feasible to apply in clinical practice (see 
Table 11 on page 152).  Four respondents commented about the feasibility of applying 
the Guidelines in clinical practice.  Two of these suggested the Guidelines could be 
simplified but did not say how, one suggested doctors would be confused by the 
Guidelines but did not say how or why, and one that HPs needed education about 
managing diabetes. 
 
Respondents were asked to ‘think of a patient with diabetes you have cared for who is 
in one PCOC phase.  Apply the relevant section of the Guidelines and note where the 
Guidelines were useful and how they could be improved’.  Different phases were 
specified on individual questionnaires and randomly allocated to HPs so information 
could be collected about all four PCOC phases.  Responses from the 12 people who 
answered this section of the questionnaire are presented in Table 12 on page 154 on the 
following two pages. 
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Table 12.   Comments HPs made about the Guidelines after applying them to 
patients with diabetes in various end of life phases (n = 12). 
 
PCOC  
Phase 
HP comments after using Guidelines 
Stable Covered all aspects of their care concisely and with good explanations 
and reasons.  
Unstable Guidelines are relevant to the client diabetic group. 
The flowcharts were user friendly.  However, referring to table 1 [in the 
accompanying document] was time consuming because of the wealth of 
information it provided. 
Guidelines very useful, great assessment prompts.  Are tables going to 
be included in draft as references?  Prompts useful in assessment to 
think outside the box in relation to diabetes and other symptoms and 
how they are related.  
Deterior-
ating 
Seems ok.  
If deteriorating likely to enter the terminal phase next.  Why consider 
referral to endocrinologist at this stage? 
Terminal 
 
 
 
 
 
 
 
 
Type 2 diabetes patient the Guidelines were very useful.  Especially so 
that MOs can cease management.  However, some dilemmas re: hypos 
in type 1 diabetes patients.  
After reviewing the Guidelines and applying them to a patient I have 
cared for in the terminal phase of their illness, I found the Guidelines to 
be useful and consistent with the care that was provided for this patient. 
Assessment of patients with diabetes is an ongoing and always 
reportable to the treating team. 
Easy to follow; prompts what to do. 
The main trouble with diabetes management at end of life/pall care is 
h d d l i i d i h lidi
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PCOC  
Phase 
HP comments after using Guidelines 
Terminal 
(Cont.) 
 
 
that doctors don’t always write appropriate orders i.e. they use sliding 
scale insulin orders and the staff do not know how to follow them.  
Education is the key and these Guidelines (while very informative) 
seem to make it harder.  Inpatient care is very different from 
community care.  
I applied the Guidelines on a terminal patient—easy to use the 
Guidelines except patient changed from one phase to the other, 
fluctuating status.  These changes then made the Guidelines difficult to 
use.  
The patient I was considering was in the terminal phase.  The 
Guidelines seemed logical and easy to follow. 
 
 
 
Participants were asked to list three pieces of information they had learned by using the 
Guidelines and attending the information session.  The most frequent types of 
information they listed related to the:  
 
- Need to consider medical conditions other than the primary diagnosis. 
- Impact of corticosteroids and some other medicines on blood glucose levels. 
- How to manage steroid-induced diabetes. 
- Common symptoms that could be diabetes related but are not recognised as such. 
- Risk factors of diabetes. 
- Need to treat the patient as a whole. 
- Side effects of diabetes medicines. 
- Improved understanding of diabetes management at end of life. 
- Importance of the Quality Use of Medicines framework and reviewing medicines. 
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2. Summative Evaluation 
Interviews with palliative care health professionals 
Method 
A total of 34 palliative care health professionals working in Barwon Health were 
invited to use the revised draft Guidelines with patients with diabetes requiring 
palliative care over a period of eight weeks.  After eight weeks, an email was sent these 
HPs inviting them to participate in a brief interview with the researcher to discuss the 
Guidelines.  The interviews were conducted face-to-face at a time and location suitable 
for the health professional using a structured interview schedule (see Appendix E).  The 
researcher wrote notes during each interview. 
 
Results 
Seven palliative care health professionals agreed to be interviewed, giving a response 
rate of 21%.  Most participants were female (n = 6), and most were nurses (n = 6). One 
participant was a doctor.  None of the HPs interviewed utilised the Guidelines in caring 
for a patient with diabetes over the eight week evaluation period.  The HPs, had 
however, spent some time reading and considering the Guidelines. 
 
The Guidelines in general.    All seven participants felt the design of the Guidelines 
was good or very good, five felt the wording was good or very good and two felt the 
document was too long.  Participants commented throughout the interview about the 
Guidelines in general.  Positive comments about the Guidelines included: 
 
I think the Guidelines are great … have been lacking for a long time. (HP 6) 
 
Easy to follow but quite complex. (HP 5) 
 
Flows well, easy to understand, a lot to it, but information is relevant. (HP 4) 
 
One participant made less positive comments about the Guidelines for example: 
 
It read like a medical text book … I would prefer to refer to a text. (HP 3) 
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The preference for using a text presents a difficulty because the information presented 
in the Guidelines is not available in any text book the researchers identified.  It appears 
that the participant was generally not in favour of guidelines: 
 
I don’t find Guidelines in general overly helpful. (HP 3) 
 
However, this participant made other comments about the content of the Guidelines 
that were at odds with these two statements: 
 
This document is almost a good reference document for a registrar but too 
involved for general staff …if you added 3 or 4 pages it could be an advanced 
guide/course for palliative care registrars. (HP 3) 
 
In contrast, another participant asked whether doctors would use the Guidelines: 
 
I don’t think doctors will like them [the Guidelines] … I find it hard to get 
doctors to respond [to new information]. (HP 6) 
 
Further education needed.    The preceding comment and other participants’ comments 
indicate there is a need to educate palliative care HPs about the way diabetes affects 
other health problems and the difficulty determining whether symptoms are related to 
diabetes or to other illnesses, for example: 
 
Too much information … diabetes is not the focus for community palliative care 
… although it is important to manage. … I do agree that we need to care for 
people with diabetes but we have to address palliative symptoms first. (HP 1) 
 
The comment shows the participant did not understand that symptoms could be due to 
diabetes and highlights the need for education about diabetes in palliative care settings.  
 
When asked why they had not used the Guidelines, participants indicated they had time 
constraints, had not cared for an appropriate patient in the evaluation time frame or 
found the Guidelines too long.  Health professionals who were not able to use the 
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Guidelines during the evaluation indicated they would use the Guidelines in the future.  
Some participants suggested they would use the Guidelines if the person had a longer 
term life expectancy or if diabetes symptoms were present, but did not see the point in 
the deteriorating or terminal phases. 
 
For example, participants indicated they would use the Guidelines: 
 
If I had a patient with longer term prognosis or if there was a patient and we 
had ‘ruled out’ ‘normal’ things causing symptoms. (HP 5) 
  
If the patient with diabetes had symptom issues. (HP 4) 
 
These comments illustrate that participants focus on short duration life-limiting 
illnesses and may not consider the different effects of chronic disease on the dying 
process and the likelihood of periods of stability and instability that frequently occur in 
chronic diseases before the deteriorating and terminal phases. 
 
How to improve the Guidelines.    Several participants suggested the Guidelines could 
be reduced or put onto a single poster, which would encourage their use: 
 
Simplified Guidelines … a real simple checklist … not too involved. (HP 1) 
 
Another suggestion was that the Guidelines and the brief accompanying document 
could be more ‘user friendly’: 
 
More user friendly … if there’s too much reading people will shelve it … to put 
into clinical practice it has to be user friendly. (HP 7) 
 
Other participants suggested that, over time, the Guidelines will be incorporated into 
practice, and education about how to use the Guidelines would assist that process, and 
that the Guidelines should be included in the electronic records system to facilitate their 
use. 
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Final comments from participants.   The researcher’s request for any final comments 
elicited some interesting responses.  Two participants mentioned they were more aware 
about the importance of HP collaboration and working with other health professionals 
such as diabetes educators increased after reading the Guidelines.  
 
Summary 
Importantly, the majority of questionnaire respondents found the language in the 
Guidelines consistent with palliative care language and procedures and with the PCOC 
palliative care principles.  Some questionnaire respondents and interview participants 
noted problems with the presentation of the draft Guidelines and wanted them to be 
more user friendly.  The researchers anticipated that these problems would be 
addressed once a graphic designer developed the layout and design of the Guidelines. 
 
Some respondents suggested there was a need to include additional information in the 
Guidelines such as a list of abbreviations and a table presenting information about 
symptoms.  One HP distributed a small number of packages to other HPs and these 
packages did not include the brief accompanying information document that provides 
essential information about the Guidelines.  It is possible that the participants 
requesting additional information did not receive the accompanying document.  These 
respondents’ comments highlighted the value of including the accompanying 
information with the final Guidelines.  Some HPs who were interviewed commented 
that the Guidelines and accompanying document were too long and contained too much 
information.  However, the questionnaire data suggest the information in the Guidelines 
is in fact necessary, and many participants indicated they learnt new facts about 
diabetes after using the Guidelines and accompanying document. 
 
One HP interviewed in the summative evaluation phase commented that the Guidelines 
could almost be an advanced diabetes guide for palliative care registrars, further 
supporting the educational value of the Guidelines. 
 
Some interview participants did not appear to understand the significance of diabetes in 
the context of palliative care and suggested palliative care was their first priority.  
These responses highlight the importance of educating HPs about diabetes management 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
164
in palliative care, particularly about the effect of diabetes on other health problems and 
the difficulty establishing the cause of some symptoms that may be related to diabetes 
or to the other illnesses.  For example, the similarity between the signs of 
hyperglycaemia and the indicators that a patient is entering the terminal PCOC phase 
could be communicated to palliative care HPs. 
 
Interestingly, one HP suggested the Guidelines are too involved for ‘general staff’, 
while another HP commented that it is hard to get doctors to respond to new 
information.  Such comments are contrary to the collaborative approach to palliative 
care that is part of the underlying principles of palliative care and of the Guidelines.  
Strategies to promote interdisciplinary collaboration could be introduced into the 
education provided to HPs when the Guidelines are implemented.  
 
None of the HPs interviewed in the third part of evaluation process utilised the 
Guidelines with a palliative care patient for various reasons.  However, twelve HPs 
who completed the questionnaire in the second part of the evaluation applied the 
Guidelines to at least one patient in a specific PCOC phase.  These participants found 
the Guidelines useful and their comments were generally positive.  In particular, 
respondents indicated the Guidelines were very helpful when managing patients with 
diabetes in the terminal PCOC phase. 
 
A final comment from one of the health professionals interviewed about the Guidelines 
is an appropriate conclusion to this report. 
 
 
 
 
 
 
Guidelines in palliative care … the right answer is, what the patient wants. 
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REFINING THE GUIDELINES 
 
A number of changes were made to the draft Guidelines when the researchers discussed 
the HPs’ comments.  The next step in the Guidelines development process was 
obtaining expert advice on the presentation of the Guidelines from a graphic designer.  
A graphic designer was consulted and designed the content of the draft Guidelines into 
a completely new format and layout.  Throughout the design process the graphic 
designer consulted with the research team and requested some changes to the wording 
in the draft documents.  The researchers made changes where appropriate and 
forwarded the revised Guidelines to the designer for further work. 
 
The final Guidelines and accompanying document are visually appealing, clear and 
easy to follow.  The substantial redesign of the Guidelines should facilitate their use in 
clinical practice.  
 
The key changes to the Guidelines were: 
• A contents page was added to direct the health professional to the section they need. 
• The titles on each page that describe the content of specific pages were clarified. 
• The language within individual sections was revised to ensure it was consistent 
throughout the Guidelines, for example statements in some text boxes were re- 
written as active instructions. 
• Suggested BGL ranges and BGL monitoring frequencies for specific situations 
were included. 
• The final Guidelines document and accompanying document are presented in 
Appendices F and G respectively.   
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PLAN FOR DISSEMINATING THE GUIDELINES 
 
The final Guidelines will be disseminated in the following manner:   
• The Guidelines for Managing Diabetes at the End of Life will be officially launched 
at the Innovations – Updating Professional Practice in Palliative Care Conference 
in Torquay, Victoria in October 2010. Copies of the Guidelines will be available to 
conference attendees. 
• Through the CareSearch website, which attracts 100,000 hits per month. 
• In relevant diabetes and palliative care special interest group meetings. 
• In newsletters of diabetes and palliative care professional associations. 
• At local, state, national and international conferences, some of which have already 
occurred: 
- ADEA Victorian Branch Conference: The hemisphere of Diabetes, 5th June 
2010, Harmonising care of people with diabetes requiring palliative care. 
- Palliative Care Victoria 7th Biennial Conference: Palliative Care—Extending the 
Reach, 23rd July 2010, Diabetes and end of life care—gathering evidence to 
guide care. 
- ADS-ADEA Annual Scientific Meeting: Challenges for the 21st century: the art 
versus science of diabetes care, 1st–3rd September 2010: 1) Managing diabetes at 
the end of life; 2) Engaging people with diabetes and palliative health 
professionals in research. 
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Appendix A: Interview questions for patients 
 
Interview questions – Patients 
What effect does having diabetes have on your health now? 
How is your diabetes monitored? How do you feel about that? 
What type of medicines do you take now? How do you feel about that? 
Who helps you to manage your diabetes now? 
Who would you like to help you manage your diabetes in the future? 
What are your preferences for your diabetes care in the future? For example what do 
you think about having your diabetes monitored in the future? 
What do you think about taking diabetes medicines in the future? 
How do you feel about having some say about how your diabetes is managed in the 
future when you may become very ill? 
How could that be done – how could you be given some say in your diabetes 
management? 
Who would you like to make decisions for you about how your diabetes is managed in 
the future? 
Do you have any questions or comments? 
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Appendix B:  Interview questions for family members/carers 
 
Interview questions for family members/carers 
 
1. Think about the person you care for who has a serious illness and diabetes.  
2. What effect do you think having diabetes has on them?  
3. What effect does their diabetes have on you? 
4. What role have you played in helping them to manage their diabetes in the past? 
5. How do you help them to manage their diabetes now? 
6. How do you feel about doing that? 
7. What effect does it have on your lifestyle? 
8. How would you feel if you were told you did not need to do that any more? 
9. How do you feel about having some say about how their diabetes is managed in 
the future when they may become very ill? 
10. How could that be done—how could you be given some say in their diabetes 
management? 
11. When would you feel it was all right to have diabetes monitoring stopped? 
12. When would you feel it was all right to have diabetes medication stopped? 
13. Do you have any questions or comments? 
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Appendix C:  DRAFT VERSION Brief document to accompany 
guidelines 
  
Brief information to accompany the 
Guidelines for Managing Diabetes at the End of Life 
Outline of diabetes management  
In general diabetes management involves an appropriate diet and activity for both type 
1 and type 2 diabetes even when medicines are needed. Managing diabetes involves: 
• Lifestyle changes particularly for type 2 diabetes. 
• Medicines:   
o Type 1 diabetes—insulin 
o Type 2 diabetes oral hypoglycaemic agents and/or insulin. 
Note beta cell function declines over time and approximately 75% of 
people with type 2 diabetes need insulin. 
• Managing blood glucose, lipids and blood pressure. 
• Regular medicines review. 
• Regular monitoring by health professionals to identify and manage the short and 
long term complications of diabetes. 
• Diabetes education including educating significant others. 
• Self-care by the patient, support from family/carer. 
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Hyperglycaemia and hypoglycaemia 
Two conditions commonly associated with diabetes are hyperglycaemia, a symptom of 
diabetes, and hypoglycaemia, a side effect of glucose lowering medicines, especially 
sulphonylureas and insulin.  
Hyperglycaemia 
Under usual circumstances, many people with type 2 diabetes do not experience the 
symptoms of hyperglycaemia until their blood glucose levels are extremely high.  
Common symptoms of hyperglycaemia include: 
 
• Feeling excessively thirsty 
• Frequently passing large volumes of urine  
• Feeling tired 
• Blurred vision  
• Infections e.g. thrush, cystitis, wound infections 
• Lowered mood 
• Weight loss in the longer term (Diabetes Australia, 2009a). 
 
Hypoglycaemia  
Hypoglycaemia, also called a ‘hypo’, low blood glucose or insulin reaction, occurs 
when the blood glucose level falls below 3.5 mmol/L. Symptoms of hypoglycaemia 
vary from person-to-person, however, common feelings are: 
• Weakness, trembling or shaking 
• Sweating 
• Light headedness 
• Headache 
• Dizziness 
• Difficulty concentrating 
• Tearful/crying 
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• Behaviour change 
• Irritability 
• Hunger 
• Numbness around the lips and fingers (Diabetes Australia, 2009a). 
 
Hypoglycaemia unawareness may be present, especially in people with long-standing 
type 1 diabetes. This means they may not recognise the symptoms of hypoglcycaemia. 
In addition, symptoms may be masked by analgesia, delirium and other cognitive 
changes and cancer-related autonomic neuropathy. Significantly, both people with 
diabetes and their family members/carers are often very fearful of hypoglycaemia and 
its consequences. 
 
Corticosteroid medicines 
Corticosteroid medicines are an essential part of the management of several disease 
processes such as haematological malignancies, inflammatory diseases, allergies and 
shock.  However, long term use and high doses predisposes people to insulin resistance 
(IRS), glucose intolerance (IGT) and steroid-induced diabetes and causes 
hyperglycaemia and the resultant symptoms in people with diagnosed diabetes.  IRS 
and IGT can occur within 48 hours of commencing steroids, especially in at risk 
individuals and those with diabetes. People should be informed they could develop 
diabetes when diabetogenic medicines are prescribed. 
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The Quality Use of Medicines framework 
The Quality Use of Medicines (QUM) Framework (PHARM Committee, 2005) is the 
recommended Australian framework for making medicines-related decisions and is 
used in formulating these guidelines (see Figure 1, next page).  
 
The factors to consider when determining diabetes medicine regimen for people with 
diabetes receiving palliative care, if medicines are indicated are: 
 
• Insulin doses may need to be adjusted frequently. 
• Patients on metformin who develop nausea and vomiting especially the elderly, 
those on diabetogenic medicines, and those with reduced renal function, liver, 
cardiac and respiratory disease, and people who are not eating may be at risk of 
lactic acidosis, a rare but serious adverse event.  Therefore, metformin may not be 
the best choice. 
• Insulin mimetics can induce weight loss and nausea, therefore, they may be 
contraindicated. 
• Thiazolidinediones contribute to weight gain due to flued retention and may be 
contraindicated.  
• Diuretics can exacerbate dehydration and increase blood glucose levels. 
• Corticosteroids, and atypical antipsychotics are frequently used in palliative care 
and other disease processes and increase blood glucose levels. 
• Glucogen used to treat severe hypoglycaemia usually increases blood glucose 
quickly.  A second dose can induce nausea but may be ineffective in emaciated 
people with reduced glucogen stores.  This means if oral glucose treatment of 
hypoglycaemia and IM glucagon are ineffective or contraindicated, IV dextrose 
may be required. 
• Some oral nutrition supplements affect blood glucose levels, often leading to 
hyperglycaemia. 
• The patient may be using complementary medicines (CAM) and other CAM 
therapies.  If so, determine why the person is using CAM, what they are using, and 
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whether CAM is appropriate i.e. the benefits outweigh the risks and there is 
evidence for its use.  
• CAM medicines may interact with conventional medicines.  However, some non-
medicine CAM therapies can relieve symptoms and may be safer than medicines. 
• Opioids and other psychoactive medicines can mask hypoglycaemia. 
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Figure 1: QUM Framework for managing diabetes at the end of life. 
Early identification of 
Diabetes 
Primary prevention 
If the patient is on glucocorticoids or 
other diabetogenic medicines: 
- Conduct risk assessment 
- Review medicines  
-  Provide appropriate medicine 
and/or lifestyle advice 
- Monitor—blood glucose, ketones 
- Check for signs and symptoms of 
diabetes, increased blood glucose 
- Oral health check 
Diabetes present 
as existing 
diagnosis or 
develops during 
palliative care 
process 
See diabetes risk 
assessment tool 
See management of 
the patient on 
steroids and diabet-
ogenic medicines 
- Determine whether there is a need for medicines to manage diabetes 
- Conduct a medicines review encompassing: 
o Type 1–Insulin 
o Type 2–OHA or insulin, depending on the physical assessment: renal, 
liver, respiratory, and gastrointestinal factors that could affect medicine 
pharmacokinetics and pharmacodynamics. 
o For patients on diabetogenic medicines, consider if they can be stopped or 
doses or dose intervals adjusted or an alternative formulation be used? 
- Consider the need for other medicines to manage other conditions including the 
indication for palliative care, which could be diabetes-related e.g. end-stage 
renal disease. 
Is the patient taking any medicines to manage diabetes? 
- Consider self-care potential 
- Determine if oral route 
possible or another route is 
indicated, e.g. insulin 
infusion 
- Consider the complexity of 
regimen. Is insulin simplest 
choice? 
- Provide education 
including ‘sick day care’ 
- Develop medicine 
management plan, a plan 
for monitoring outcomes 
and for stopping medicines 
when indicated 
- Decide alternative 
management strategies 
relevant to PCOC phase 
- Be aware for patients in the 
Terminal phase— 
medicines may be ceased 
but may be needed to 
maintain comfort and 
control symptoms 
- Consider Advanced Care 
Directives 
Refer all patients 
with diabetes to: 
- Diabetes 
specialist 
- Diabetes 
educator 
- Dietitian 
- Other health 
professionals as 
indicated 
  YES     NO 
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Palliative care symptoms and diabetes 
 
Sub-optimal symptom control can be due to the diabetes or the life threatening primary illness 
or both. Distinguishing what is cause and effect can be difficult. Symptoms not caused by 
diabetes can have significant effects on diabetes management. Table 1 (next pages) presents the 
relationships between common palliative care symptoms and diabetes.
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Table 1: The relationship between common palliative care symptoms and diabetes 
Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
Pain 
(acute/chronic) 
 
Increased:  
- somnolence or confusion/cognitive 
impairment due to pain/analgesia 
- risk of hyperventilation 
- hyperglycaemia 
Reduced: 
- intake 
- mobility 
- sleep 
- self-care ability  
- quality of life 
- Peripheral vascular 
disease 
- Amyotrophy 
- Peripheral neuropathy 
- Myocardial Infarction 
(MI) 
- Tissue glycosylation 
(e.g. carpel tunnel 
syndrome) 
- Ketoacidosis 
(abdominal pain) 
 
Depression/ 
anxiety 
 
Increased:  
- fatigue 
- lethargy, change in performance status 
- risk of DKA, HONK 
- social isolation 
Reduced: 
- self-care ability, disinterest increased 
risk of hyperglycaemia 
- confidence 
- inadequate nutrition increased risk of 
hypoglycaemia 
- effects on communication and self-care 
 
 
 
- Associated with 
diabetes especially 
hyperglycaemia 
- Renal disease 
- Corticosteroid 
medicines 
- Hypoglycaemia 
symptoms can be 
mistaken for anxiety 
Oral Pathology 
(oral and 
maxillofacial 
h l )
Increased: 
- pain 
- dry mouth 
- Diabetic ketoacidosis 
(DKA), hyperosmolar 
states (HONK) may 
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Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
pathology)  
Mucositis, 
ulcers, dry 
mouth 
- inadequate nutrition, inappropriate 
weight loss, cachexia, hypoglycaemia 
if on OHA/insulin 
 
Reduced: 
- intake 
- self-care deficits 
- mood 
lead to dry mouth, 
thirst and clinical 
dehydration 
- Risk of dental caries 
and oral pathology 
- Risk of hypoglycaemia 
if on OHAs or insulin 
Nausea/vomiting
 
Increased: 
- confusion 
- lethargy 
- disinterest  
- pain/discomfort 
- inadequate nutrition → weight loss, 
cachexia, hyperglycaemia 
- hypoglycaemia if on OHA/insulin 
- dehydration and electrolyte imbalance 
- risk of ketoacidosis 
Reduced: 
- intake  
- energy, depleted energy stores 
- May be due to gastric 
autonomic neuropathy 
- Renal disease 
- Hyperglycaemia – 
DKA, HONK 
- Medicines: 
- Metformin 
- Byetta 
Delirium 
 
Increased: 
- cognitive impairment 
 
Reduced: 
- ability to communicate and detect 
signs/symptoms of 
hypo/hyperglycaemia  
- self-care ability  
- May be due to many 
factors including hyper 
and hypoglycaemia 
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Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
Sepsis 
 
 - May be silent in 
diabetes (urinary tract 
infection (UTI), MI) 
- May precipitate DKA, 
HONK 
Acute Dyspnoea 
 
Increased: 
- hypoxia contributing to confusion  
Reduced: 
-     self-management capacity 
 
Note: MI often silent in diabetes 
Increased: 
- confusion 
- energy requirements 
- pain 
- difficulty interpreting 
elevated white cell 
count, which could be 
caused by  
hyperglycaemia, 
sepsis, or other factors 
-     bone marrow failure 
Reduced: 
- intake increased  DKA, 
HONK risk 
- quality of life 
- wound healing 
Diabetes 
Emergencies 
Examples: 
- Hypoglycaemia 
- Hyperglycaemia 
- MI 
- Hypoglycaemia 
- DKA, HONK, Lactic 
acidosis 
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Common 
palliative care 
symptoms 
Impact on diabetes management May be diabetes-related 
 
Oncology 
Emergencies 
 
 
Examples: 
- Spinal Cord Compression 
(corticosteroids) and acute immobility 
- Superior vena clava (SVC) obstruction 
(acute dyspnoea and delirium) – high 
dose of corticosteroids 
- Febrile neutropenia 
- Major bronchial obstruction (dyspnoea 
and use of corticosteroids) 
- Hypoglycaemia 
-     DKA, HONK, Lactic 
acidosis 
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List of Abbreviations and symbols 
 
Ĺ  Increased 
Ļ  Decreased 
  Equal to, or greater than 
>  Greater than 
  Equal to, or less than 
<  Less than 
ACD  Advanced care directive 
AM  Morning 
BG  Blood glucose 
CAM  Complementary and alternative medicines 
CCF  Congestive cardiac failure 
DE  Diabetes Educator 
DKA  Diabetic ketoacidosis  
eGFR               estimated Glomerular filtration rate   
GI  Gastrointestinal symptoms 
HONK  Hyperosmolar non-ketotic acidosis  
Hypo  Hypoglycaemia 
ICU  Intensive care unit 
IGT  Impaired glucose tolerance/ glucose intolerance 
IM  Intramuscular 
IRS  Insulin resistance 
IV  Intravenous therapy  
MI  Myocardial Infarction   
OHA  Oral Hypoglycaemic agents 
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Mmol/L millimoles/litre – unit for measuring glucose in blood 
PCOC  Palliative care outcomes collaboration  
PM  Afternoon 
QUM  Quality use of medicines 
SVC  Superior vena clava syndrome/obstruction 
T1  Type 1 Diabetes Mellitus 
T2  Type 2 Diabetes Mellitus 
TZD  Thiazolidinediones 
UTI  Urinary tract infection 
WHO  World Health Organisation 
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Appendix D:  Questionnaire for health care professionals 
 
Brief questionnaire about Managing diabetes at the end of life 
guidelines 
 
Please read the Managing diabetes at the end of life guidelines and then answer the 
following questions. Your answers are anonymous and confidential. We are not 
collecting any information that can identify you. 
 
Please rate the Managing diabetes at the end of life guidelines by circling one number 
on the scale next to the statement that best reflects your point of view.  
The numbers mean: 
 
  1 2 3 4 5 
Strongly disagree Somewhat 
disagree 
Neither agree nor 
disagree 
 
Somewhat agree Strongly 
agree 
 
1. I like the design of the guidelines 
  1      2     3     4     5  
2. The guidelines are difficult to follow 
  1      2     3     4     5  
3. The language used in the guidelines is appropriate 
  1      2     3     4     5 
4. The colours used in the guidelines make the information 
easy to read 
  1      2     3     4     5 
5. I find the design of the guidelines confusing  
  1      2     3     4     5 
6. The guidelines are easy to follow 
  1      2     3     4     5 
7. I find the language in the guidelines difficult to understand 
  1      2     3     4     5 
8. The language used in the guidelines is consistent with 
palliative care language 
  1      2     3     4     5 
9. The guidelines are consistent with palliative care 
procedures 
  1      2     3     4     5 
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10. Do the guidelines contain any information that is not needed?  (Tick one) 
ƑYES                          Ƒ NO 
   
If YES, please tell us what information is not needed:    
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
 
11. Is there any other information that should be included in the guidelines? (Tick 
one) 
ƑYES                          Ƒ NO 
   
If YES, please tell us what other information is needed:    
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
 
12. Are the guidelines consistent with the PCOC palliative care principles? 
ƑYES                          Ƒ NO 
 
If NO, please tell us why not:  
 
_______________________________________________________________ 
 
_______________________________________________________________ 
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13. Do you think it will be feasible to apply the guidelines in routine clinical 
practice? 
ƑYES                          Ƒ NO 
If NO, please tell us why not:  
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
14. Please write any other comments you would like to make about the guidelines. 
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
15. Please think of a patient with diabetes you are caring for or have cared for. 
Determine the PCOC phase (Stable, Unstable, Deteriorating or Terminal). Go to 
the relevant part of the guidelines, and apply the guidelines to that patient’s 
situation. When you apply the guidelines to a specific patient, think about how 
useful the guidelines were, and whether they could be improved. 
   
 Please comment about using the guidelines for the patient you selected, noting 
the PCOC phase of the patient: 
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
_______________________________________________________________ 
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16. Please list three pieces of information you learned by participating in this 
activity. 
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
_______________________________________________________________ 
 
 
17. Have you attended any diabetes education programs in the last two years?  
If YES, please list the name of the program/s. 
 
_______________________________________________________________ 
 
 
18. Please tick your profession.  
Ƒ Nurse            Ƒ Allied Health        Ƒ  Doctor      Ƒ Other 
 
19. How long have you worked in palliative care?  ___________________ 
 
 
20. What age group are you in? 
 
Ƒ20 – 29   Ƒ30 – 39         Ƒ 40 – 49         Ƒ 50 – 59        Ƒ 60+ 
 
 
Thank you for taking the time to complete this questionnaire. We value your 
feedback. 
Please bring your completed questionnaire to the MDT meeting on November 4th 
and place it in the sealed box at the door.  
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Appendix E:   Interview schedule – Health professionals  
 
Managing diabetes at the end of life  
Interview schedule – Health professionals  
Version 1, Dated 22/9/09 
 
1. Are you aware of the Guidelines for Managing Diabetes at the End of Life that we 
developed recently?  (circle one response) 
YES         NO 
2. Have you used the guidelines with any patients receiving palliative care? 
YES         NO 
If YES  ask Questions 3 to Question 13.      If NO, go to Question 14. 
3. With how many patients did you use the guidelines? 
__________________ 
 
4. What Palliative Care Outcomes Collaboration (PCOC) palliative care phase were the 
patients in?  
 
 Phase  Number of patients with whom you used the guidelines 
 Stable   ----- 
 Unstable   ----- 
 Deteriorating  ----- 
 Terminal    ----- 
 
 
5. Were the guidelines helpful?   YES         NO 
6. If so, please tell me how they were helpful. 
_________________________________________________________________ 
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_________________________________________________________________ 
 
7. Did you have problems using the guidelines? If so, what were they? 
_________________________________________________________________ 
_________________________________________________________________ 
 
8. What information was most useful? 
_________________________________________________________________ 
9. What information in the guidelines was least useful? 
_________________________________________________________________ 
 
10. Is there any information that could be omitted? If so, what information? 
_________________________________________________________________ 
 
11. Is there any information that needs to be added? If so, what information? 
_________________________________________________________________ 
 
Please rate the following (circle one response): 
12. The design of the guidelines 
Very Poor / Poor / Good / Very Good / Excellent 
 
 
13. The wording used in the guidelines 
          Very Poor / Poor / Good / Very Good / Excellent 
 
 
14. Ease of use in clinical situations 
    Very Poor / Poor / Good / Very Good / Excellent  Go To Question 17 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
197
 
If NO 
15. If you did not used the guidelines, please say why? 
_________________________________________________________________ 
_________________________________________________________________ 
16. When would you consider using the guidelines? 
_________________________________________________________________ 
 
17. What would make it more likely that you would use the guidelines? 
_________________________________________________________________ 
_________________________________________________________________ 
 
ALL 18. Please suggest any changes that you think would improve the guidelines. 
_________________________________________________________________ 
_________________________________________________________________ 
18. Do the guidelines need to include specific target ranges for BG ranges …..? 
_________________________________________________________________ 
19. Do you have any other comments? 
_________________________________________________________________ 
_________________________________________________________________ 
THANK PARTICIPANT FOR THEIR TIME AND SUPPORT
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Appendix F:   FINAL VERSION Guidelines for managing 
diabetes at the end of life 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
199
 
 
 
 
 
          
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
200
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
201
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
202
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
203
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
204
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
205
     
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
206
 
 
 
 
 
 
 
      
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
207
 
 
 
     
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
208
 
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
209
 
 
    
 
 
 
 
 
      
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
210
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
211
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
212
 
        
   
       
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
213
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
214
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
215
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
216
 
 
     
 
 
       
 
 
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
217
 
 
 
 
 
 
 
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
218
 
 
 
 
 
 
 
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
219
 
 
 
 
 
 
 
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
220
 
 
 
 
 
  
_______________________________________________________________________________ 
Managing Diabetes at the End of Life           Copyright 2010                                                           
 
221
       
 
 
 
 
       
